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The mononuclear phagocyte system (MPS) consists of hematopoietic cells with diverse characteristics, which were originally recognized on the basis of a common lineage derivation and a primary function of endocytosis [1, 2]. In general, cells of the MPS 
originate in the bone marrow (BM) and migrate as monocytes through the blood to peripheral 
tissues, where they develop into mature cells with different features depending on tissue-specific 
environmental conditions. Macrophages (Mf) occur in virtually all organs of the body [2]. 
Moreover, each organ mostly contains multiple, phenotypically different Mf subpopulations. 
For example, the lung hosts at least two different Mf types: alveolar Mf in the alveolar space 
and interstitial Mf integrated in the tissue. Microglia are Mf of the nervous tissue, osteoclasts 
are phagocytes of the bone and Kupffer cells of the liver. All these cells belong to the group 
of resident Mf. Since many of them were identified before their relationship to the MPS was 
established, their names often do not categorize them as Mf. Apart from resident, exudate Mf 
develop at acute inflammation sites [3]. In chronic inflammation, granuloma Mf and epitheloid 
cells are present, which can fuse to form multinucleated giant cells [4, 5].  
Soon after the identification of the dendritic cell (DC), by Steinman and co-workers [6, 7], 
members of this family were considered as candidates for the MPS [2, 8]. However, initially 
this notion has not created a broad audience. The more recent observation that DC as well as 
Mf can be generated in vitro from peripheral blood monocytes has increased the awareness 
that both cell types are closely related and are justly unified in a single system [9-13]. 
A conceptual difficulty, discussed further in this review, is raised by the relatively 
recent findings that DC as well as Mf may originate from either myeloid- or lymphoid-
related progenitors [14, 15]. In addition, some populations of mononuclear phagocytes may 
be maintained in the steady state independently from BM precursors [16], while others 
are strictly BM-dependent. Thus, despite the similarities in morphological and molecular 
phenotype observed in the various MPS populations, a common developmental origin might 
be an incompletely fulfilled property for all cells that belong to the MPS.
Similar to their developmental diversity, the various members of the MPS have widely 
diverse functions and cannot be unified by a single functional characteristic. The most 
common feature of mononuclear phagocytes is their significant ability to endocytose different 
substances, hence their name. However, DC are only strongly endocytic in an immature state 
and downregulate this activity upon final maturation. Furthermore, the functions that DC and 
Mf fulfill by performing endocytosis are different. Macrophages use their endocytic potential 
for the primary function of clearance of pathogens or other unwanted material with least 
consequences for the host. Dendritic cells, however, employ the endocytic process as a mean 
to collect antigens in order to present them to cells of the adaptive immune system. In other 
words, although these two cell types share the capacity to engulf substances of foreign or of 
self-origin, they employ this feature in different manners to perform distinct functions. 
The most well-known functions ascribed to Mf on the one hand - clearance by phagocytosis 
and digestion - and to DC on the other hand - primary activation of the adaptive immune system 
- have long been the leading principle in distinguishing between these cell types. Therefore, 
this convention will be retained in the description below. However, it should be realized that 
this distinction is strongly biased by the initial, historical characterization of these cell types, 
while the biological reality is much more complex. Hence, mononuclear phagocytes should 
be considered as a large family of functionally and/or developmentally related cells that form 
a continuum in which the cells that are recognized as prototypical “Mf” and “DC” are the 
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extremes of a spectrum. 
Given the lack of selection criteria that characterize all cells of the MPS unequivocally, 
we propose that mononuclear phagocytes are leukocytes that lack specific criteria found 
in other leukocytes such as polymorphonuclear morphology, specific granularity or unique 
antigen-specific receptor expression realized by gene rearrangement. Mononuclear phagocytes 
have specialized in certain functions that are shared by large groups in the family, such as 
endocytosis, antigen presentation, and sentinel function to exogenous stimuli. Their functional 
diversity, however, goes far beyond these tasks and justifies the notion that mononuclear 
phagocytes are crucial cells in the maintenance of homeostasis. 
Taken together, the heterogeneity of mononuclear phagocytes can be defined at several 
levels. They are extremely versatile and heterogeneous in function, depending on factors 
such as cell type, tissue localization, maturation or activation status. In conjunction with their 
functional heterogeneity, the phenotype of the different mononuclear phagocytes, reflected 
in morphology, ultrastructural features, and surface and intracellular molecule expression, 
varies significantly. This has enabled the demarcation of a plethora of cell types that belong 
to the MPS. Finally, cells can be segregated based on their developmental relationship and 
hematopoietic origin. In the subsequent parts, these aspects of mononuclear phagocyte 
heterogeneity will be elaborated.
Phenotypic heterogeneity of the mononuclear phagocyte system
 
The difficulty to develop uniform criteria to define mononuclear phagocytes stems from 
their extreme phenotypic heterogeneity in different tissues. This relates to the morphology of the 
cells at light microscopic and electron microscopic level, as well as to molecular features of the 
cells visualized by cytochemical and immunocytochemical methods. Nonetheless, a number of 
morphological generalizations at the subcellular level can be made for mononuclear phagocytes. 
In addition to this, subtypes may show distinctive morphological features, such as the racket-
shaped Birbeck granules that characterize the Langerhans cells [17]. In the last decades, the 
hybridoma technology provided a wealth of monoclonal antibodies against molecules on the 
surface or in the cytoplasm. Tagging these antibodies with fluorescent dyes or other detecting 
agents in conjunction with advanced flow cytometric and immunohistological technology made 
immunophenotypic labeling of mononuclear phagocytes the most commonly used method 
for identification. Any of the methods used revealed not more than a static view of the MPS 
as they only allowed taking a snap-shot picture in time, preventing the follow-up during cell 
development, migration or activation. Therefore, it is important to realize that, due to the lack 
of a dynamic dimension, our notion of the developmental and functional relationship between 
the different mononuclear phagocytes is still limited. Despite this restriction, morphological 
and (immuno)phenotypic identification have brought important insights into the heterogeneity 
of mononuclear phagocytes, which is depicted in the following parts.
Phenotypic heterogeneity of macrophages
The extensive diversity of Mf is illustrated by the lack of a universal, common Mf 
marker, despite the vast amount of monoclonal antibodies that has been generated against 
Chapter 114 Introduction 15
these cells. In the mouse, F4/80 was introduced as a prototypical Mf marker [18, 19] but 
this monoclonal antibody fails to recognize some subpopulations such as Mf of the lung and 
lymphoid organs. Similarly, CD14 and CD68 are widely expressed on human Mf, but cannot 
be considered as truly universal markers. Expression of the receptor for M-CSF, the essential 
growth factor for Mf recognized by CD115 antibodies, has been proposed as a common 
marker for the MPS [13, 20]. Indeed, mice deficient in CSF-1 or the CSF-1R show a deficit 
in several Mf subpopulations including monocytes, peritoneal Mf and osteoclasts [21, 22]. 
However, the Mf deficiency is not complete in these mice, implying that also CD115 is not 
a universal marker for all Mf.
The array of markers that has become available for phenotypic labeling allowed a detailed 
analysis of Mf in steady state as well as in inflammatory conditions. For instance, the study 
of Mf in the steady-state spleen in human and mouse has revealed a significant number of 
subpopulations differing in phenotype and anatomical location [23, 24]. Such initial studies 
have increased our conscience of Mf heterogeneity considerably, but left many questions 
about the functional implications. Approaching these questions has resulted more recently in a 
better understanding of the phenotype - function-link of Mf. Multiple ways of activation have 
been identified that are all characterized by a distinct marker profile [25-27]. However, much 
remains to be learned in this respect. Current developments in molecular profiling by array 
technology undoubtedly will contribute significantly to this field in the near future [28].
Phenotypic heterogeneity of dendritic cells
The highly increased awareness of the role of DC in the steering of the immune system and 
their possible clinical applications has resulted in a wealth of information about the phenotypic 
heterogeneity of DC. However, unequivocal interpretation of these findings in developmental 
and functional terms has proven to be difficult, especially because of the high turn-over of 
DC, their significant mobility between peripheral and immune organs, and the phenotypic 
volatility of these cells in response to environmental conditions. Thus, the application of the 
static phenotypic labeling created confusion by definition of many “new” DC types in different 
organs, without a clear view on the possible developmental relationships between these and 
already known DC types. Given these restricting considerations, different classifications can 
be made of phenotypically defined DC types. Figure 1 provides an exemplary overview of 
only some of the DC populations identified in lymphoid and non-lymphoid tissues.
To illustrate the complexity of the DC field: in human thymus, three distinct DC 
populations were found [29], up to five populations in lymph nodes [30] and tonsils [31] and 
at least three populations in blood [32]. The situation is similarly complex in mice, since up 
to six different DC types were found in mouse lymph nodes and spleen [33]. The generation 
of an overview of lymph node DC is complicated by the fact that, apart from resident DC, the 
lymph node hosts varying populations of DC that migrate from the periphery upon triggering. 
Depending on the tissue drained by the different lymph nodes, different subtypes of DC have 
been observed, such as in mesenteric and subcutaneous lymph node DC [34]. This points to 
tissue-specific differences between DC in peripheral organs, as has been observed for Mf 
before.
Dendritic cells in non-lymphoid organs represent a sizeable cell population of immature 
cells. For example, in the skin, Langerhans cells are located in the epidermis in close proximity 
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to the basal membrane. Upon antigenic or irritant triggering, they migrate to the skin-draining 
lymph nodes and present accumulated antigens to T cells. A unique feature of Langerhans 
cells is the possession of cytoplasmic Birbeck granules that makes them distinguishable 
from other cells at the subcellular level. Related to this, Langerhans cells can be uniquely 
identified by their expression of Langerin, a C-type lectin that is functionally involved with 
the induction of Birbeck granules [35]. Next to the Langerhans cells, which are primarily 
located in the epidermis, a distinct population of skin DC has been identified in the dermis. 
In humans, these cells are characterized by the expression of factor XIIIa and DC-SIGN [36, 
37]. Likewise, virtually all other non-lymphoid tissues contain at least one DC population in 
the steady state.
Recent studies on phenotypic variability of DC have revealed considerable promiscuity 
of DC to express molecules previously considered characteristic for other hematopoietic 
lineages. Typical examples are the expression of CD4, CD8 and B220 (CD45R) molecules by 
particular mouse DC subpopulations. Conversely, phenotypic features thought to characterize 
DC uniformly had to be reconsidered. While classic DC in the mouse all have a high level 
expression of CD11c, the recently discovered plasmacytoid DC (PDC) express only low levels, 
in combination with the previous B-cell marker B220 [38, 39] and, in some mouse strains, the 
granulocyte marker Gr-1 [40]. Realization of this phenotypic promiscuity and flexibility led to 
identification of additional DC subtypes, such as the new “tolerogenic” DC [41]. These cells 
could be generated in vitro by using GM-CSF with IL-10 and were also found in the spleen 
expressing a CD11b+ CD11clow CD45RB+ phenotype. Time will tell whether this is yet another 
new DC type or an unrecognized developmental stage of already known DC or Mf.
Figure 1. Exemplary classification of main DC subtypes in lymphoid and non-lymphoid organs. The phenotypic 
distinction of DC according to their expression of CD4 and CD8 markers is based on studies in the mouse. Depending 
on the marker combinations used, different, and often more, subtypes can be distinguished in both mouse and human 
tissues (see text for details).
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Functional heterogeneity of macrophages and dendritic cells
The functional diversity of the mononuclear phagocytes is reflected in the wide-ranging 
actions in the innate immune response, for the support of the adaptive immune system, but 
also for the organogenesis, hematopoiesis, wound-healing; maintenance of homeostasis in 
general. Mf and DC have long been considered separate cell types, specialized in particle 
uptake and degradation on the one hand, and antigen presentation and immune activation on 
the other. However, the dichotomy between Mf and DC regarding these primary functions 
has proven to be unrealistic: DC may phagocytose as good as Mf, while Mf may also activate 
the immune system. Moreover, Mf and DC perform many more homeostatic functions (Table 
1). In general, these can be separated into functions related to endocytosis and digestion, and 
those related to tissue regulation. The production of cytokines and other mediators plays an 
important role in these regulatory functions.
function cell type (example)
endocytosis and digestion
effete cells splenic red pulp Mf
bone and cartilage degradation osteoclasts
killing and degradation of microorganisms1 monocytes / inflammatory Mf
tissue regulation
regulation of inflammation resident tissue Mf
regulation of immune responses mature DC in the lymph node
regulation of hematopoiesis hematopoietic island Mf in bone marrow
regulation of endocrine function folliculo-stellate cells in pituitary
tissue remodeling embryonic Mf
wound healing and tissue regeneration histiocytes (connective tissue Mf)
killing or support of tumor cells Mf and DC in the tumor
Endocytosis  
The common characteristic of Mf and DC is their extensive ability to endocytose 
particulate and soluble substances. Based on the nature of the endocytosed substance and the 
mechanism of uptake, endocytosis has been subdivided into pinocytosis and phagocytosis 
(reviewed in [42]). Phagocytosis starts with recognition of the material via receptors that are 
present on the surface of phagocytes. These receptors facilitate the full enclosure of the particle 
by the phagocyte membrane in a zipper-like fashion. Though mononuclear phagocytes lack 
antigen-specific receptors as expressed by T- and B-lymphocytes, they display an impressive 
array of less selective receptors that enable them to sample their environment continuously. 
These receptors are involved in endocytosis, but also lend the cells their sentinel function, 
depending on the signaling cascade triggered by occupation of the receptor. Phagocyte receptors 
can be segregated into several groups depending on their ligands, their overall molecular 
structure, the structure of the recognition site or a common function that phagocytes performs 
Table 1. Overview of mononuclear phagocyte functions
1 depending on the activation stage of mononuclear phagocytes, they will also support microbial growth.
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by employing them (reviewed in [43]). 
Different lectin-like receptors recognize carbohydrate structures and play an important 
role in host defense [44, 45]. They include distinct families of receptors, which enable complex 
interactions with pathogens as well as (modified) self molecules. The most extensive family 
comprises the C-type lectins that require calcium ions for carbohydrate recognition. A number 
of these C-type lectins, such as CD205 (DEC-205), CD207 (Langerin) and CD209 (DC-
SIGN) are expressed more specifically on DC and are used as markers for these cells [46]. 
The versatility of these lectins is well illustrated by the variety of functions identified for 
CD209 (DC-SIGN). This lectin is involved in the recognition of a variety of microorganisms, 
including HIV and mycobacteria, but also in transendothelial migration of DC precursors as 
well as in interaction with T cells [47].
The Toll-like receptors (TLRs) represent another family of structurally homologous 
receptors that mediate the recognition of primarily microbial structures (reviewed in [48]). The 
most thoroughly studied is TLR4 that is essential in binding of LPS and initiating the subsequent 
signaling cascade. TLRs are also present on DC and provide a means for diversification of 
different DC types as they express specific sets of TLRs differentially [48, 49]. Interestingly, 
this differential expression of TLRs by different mononuclear phagocytes thus implies that 
different cell types respond depending on the nature of the infective agent.
Additional mononuclear phagocyte receptors that are involved in recognition of potentially 
hazardous substances are Fc receptors which bind immunoglobulin-opsonized particles [50, 
51], complement receptors [52] or scavenger receptors, which recognize a wide variety 
of mostly poly-anionic molecules [53]. Together with a phosphatidylserine receptor, these 
receptors also mediate phagocytosis of apoptotic cells [54]. This homeostatic clearance function 
is probably the primary role of these receptors. Uptake of apoptotic cells does not activate 
mononuclear phagocytes, unless they are simultaneously triggered by a danger signal, such 
as those delivered by TLRs. In addition to the role in clearance, engagement of some of the 
endocytic receptors is important for anti-tumor activity of mononuclear phagocytes, which 
could be further exploited in anti-tumor therapy [55].
The fate of the endocytosed substance depends highly on its nature, as well as on the 
mononuclear phagocyte type that engulfs it. While prototypical scavenger Mf have extensive 
lysosomal machinery that mostly facilitates elimination, DC have different subcellular features. 
These allow DC to contain many microbes, such as mycobacteria, in a live but inactive stage 
and extend their ability to process microbial molecules for presentation to the adaptive immune 
system [56].
Regulation of homeostasis
As prime cells of the innate immune system, mononuclear phagocytes take part in all 
phases of the acute and chronic inflammatory responses. Resident Mf and DC act as sentinel 
cells in peripheral tissues on the basis of their versatile receptor expression (see above) and 
become activated upon encountering danger. In short time they produce and release large 
amounts of proinflammatory cytokines, such as TNF-a and IL-1, and chemokines, such as 
IL-8 and CCL2/MCP-1, and other mediators that will attract inflammatory cells of the innate 
immune system [57, 58]. However, depending on the tissue site of inflammation and the 
eliciting agent, the type of infiltrating mononuclear phagocyte may differ significantly. For 
instance, at mucosal sites, myeloid DC are rapidly recruited in response to bacterial challenge 
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[59]. Furthermore, in viral infection a specific role has been identified for PDC, as these 
cells are major producers of IFN-a upon activation [60, 61]. Finally, at a certain point in the 
inflammation process, mononuclear phagocytes that develop at the site of inflammation will 
start producing more IL-10 and suppressor molecules that induce apoptosis of cells in the 
inflammatory infiltrate [25, 57]. Thus, these cells initiate the resolution of inflammation before 
too much damage occurs at the affected site.
Since inflammation takes place primarily in connective tissues, it is not surprising that 
mononuclear phagocytes have a close relationship to connective tissue and its components. 
These cells are involved in maintaining homeostasis by their sentinel function and production 
and degradation of extracellular matrix components. Together with their impressive ability to 
recognize and engulf apoptotic cells, this makes mononuclear phagocytes, such as connective 
tissue histiocytes, lung Mf and osteoclasts, to prime cells in tissue remodeling in steady state, 
during wound healing and in embryonic development [62-65]. 
Tissue regulation by mononuclear phagocytes is most prominently illustrated by their 
interaction with the endocrine and hematopoietic systems. Both male and female gametogenesis 
are crucially dependent on the proper function of Mf and DC [66-68]. Not only do they 
have a role in clearance and endocrine tissue remodeling, but they also modulate hormonal 
secretion by endocrine cells, primarily by production of cytokines such as IL-1 and IL-6. In 
essence, all endocrine organs contain populations of mononuclear phagocytes, which appear 
intimately involved with regulation of endocrine function [66, 69, 70]. Also in hemato- and 
lymphopoiesis, mononuclear phagocytes play important roles as integral constituents of the 
hematopoietic stroma in BM and thymus. They are central to erythro- and myelopoiesis in the 
BM as well as to selection of developing T cells in the thymus [71, 72].
Antigen presentation
The support of the adaptive immune response essentially involves presentation of an 
antigen. DC and Mf share, together with B cells, the function of antigen presentation that 
leads to the activation or the suppression of T cells. In general, DC are claimed to be unique 
in their capacity to activate naïve T cells, while Mf and B cells primarily stimulate memory 
responses [73]. This view is supported by findings in in vivo models in which DC were depleted 
experimentally, leading to a significant decrease in immune activation [74, 75]. However, this 
generalization should be valued with caution, since multiple studies show that also cells with 
the unequivocal features of Mf may activate naïve T cells [76, 77].
Activation of T cells requires that at least two signals are transferred by the antigen- 
presenting cells: (1) antigen in the form of peptide bound to MHC molecules (reviewed in 
[78]), (2) costimulation, especially provided by molecules of the B7 and TNF-receptor families 
[79, 80]. Virtually all cells express on their surface MHC class I molecules in which peptides 
of cytoplasmic, endogenous molecules are incorporated. In contrast, MHC class II molecules 
primarily contain peptides from exogenously obtained antigens. To enable activation of naïve 
MHC class I-restricted cytotoxic T cells, DC are specialized in so-called cross presentation of 
exogenous antigens on MHC class I molecules (see [81] for a review). CD1 family members, 
which are expressed by Langerhans cells and some other leukocyte types, may be considered 
alternative antigen-presentation molecules as they present (glyco-) lipids to (NK)T cells with 
a restricted T cell receptor repertoire [82]. Cellular adhesion molecules and cytokines support 
activation of T cells that have made a productive interaction with antigen-presenting- and co-
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stimulatory molecules. For instance, DC produce IL-2 upon microbial stimulation, which is 
thought to play an important role in activation of naïve T cells [83].
In addition to the well-characterized antigenic and costimulation signals, antigen-
presenting cells (APC) convey additional signals that imprint the developing T cells. A third 
signal relates to the skewing of T cells into a polarized phenotype, such as T helper-1 (Th1) or T 
helper-2 (Th2) [84]. Cytokines produced by APCs, such as IL-12 or IL-4, mediate this process 
in which transcription factors GATA-3 and Stat6 versus Stat1 and T-bet promote the Th2 versus 
Th1 differentiation, respectively [85-88]. In addition, T cell skewing was recently also ascribed 
to Notch ligands, Delta and Jagged, which separately induce Th1 or Th2 differentiation and 
are present on DC [89]. Furthermore, depending on the tissue of origin of the APC, stimulated 
T cells may be endowed with corresponding tissue-specific homing capacities [90, 91]. This 
can be considered a fourth signal delivered by APC to T cells.
Together, the quantity and quality of the distinct signals delivered by APC determine 
the outcome of the ensuing T cell response [92]. This may lead to a strong effector cell 
response, activating T helper or cytotoxic T cell subsets that are polarized in certain directions. 
Alternatively, APC also are crucial in the downregulation and tolerization of the adaptive 
immune system. It is now more appreciated that the primary function that APC perform is the 
induction and maintenance of immune tolerance rather than activation of effector responses 
[93]. 
Tolerance induction - regulation of the adaptive immunity 
Mononuclear phagocytes play central roles in the regulation of the adaptive immune system 
by virtue of stimulation, but also by specific silencing and constant tolerization. Tolerance is 
defined as lack of an effector immune response against a particular antigen. Depending on 
the origin of the antigen, we can differentiate tolerance for self-antigens and tolerance for 
antigens that originate in the environment. In addition, induced tolerance for alloantigens 
after transplantation is the goal for the transplantation immunology. Brake of tolerance leads 
to pathology in all cases. Reaction of the acquired immunity against alloantigen leads to the 
transplant rejection; against foreign antigens that are normally tolerized to allergy while the 
immune response against self-originating antigen is identified as the autoimmunity.
There are different mechanisms by which immune tolerance can be achieved: by 
mechanisms that ensure removal of T cells with unwanted specificity, by inducing a balance 
between Th1 and Th2 types of immunity or by action of specific T cells (regulatory T cells 
- T
reg
) that can induce tolerance. With regard to the control of the immune response directed 
against self-antigens, the available knowledge does not clarify whether all mechanisms 
contribute equally to tolerance or different antigens preferentially employ a particular 
tolerogenic process. 
A superior ability of DC to interact with naïve and experienced T cells makes them the 
most likely candidates for tolerance induction; they contribute to all mechanisms of immune 
tolerance. DC are involved in the deletion of potentially dangerous autoreactive T cells in 
the thymus, as a part of the central tolerance. Furthermore, in the periphery they prevent the 
destructive action of self-reactive T cells, that had escaped the selection in the thymus, by 
mechanisms of peripheral tolerance (reviewed in [93]). Stimulation of Th1 and/or Th2-type 
of the immune response, which is hypothesized to balance the immunity, is also critically 
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dependent on action of DC [89, 94, 95]. Finally, a cross-talk between DC and T
reg
 is active. 
Induction and maintenance of T
reg
 depends on DC while T
reg
, in addition to the influence on 
effector T cells, employ their regulatory action also through direct interaction with DC [96-
99]. All these tolerogenic mechanisms essentially employ the antigen-presenting function of 
DC. 
Heterogeneity of tolerance-inducing dendritic cells: Do tolerogenic dendritic cells 
represent a distinct subset?
In general, two schools of thinking have arisen in the past decade; one that proposes 
tolerogenicity to be a functional property of DC at a particular, immature stage in development 
and another that hypothesizes that a specific tolerogenic DC lineage exists.
In favour of the first proposal, immature DC were able to induce anergic T cells, T cells 
with regulatory properties as well as T cells that secrete immunomodulatory cytokines [100, 
101]. However, it may be questioned whether this holds true in vivo, i.e. whether DC in the 
lymph nodes that originate from the immature DC in the periphery are still able to perform such 
tolerogenic function. Internal signals that induce DC migration towards the draining lymph node 
simultaneously induce their maturation [102], which according to the hypothesis, would lead 
to the loss of their tolerogenic capacity. Therefore, the initial hypothesis has been somewhat 
modified and an additional maturation stage of “semi-mature” DC has been introduced [103]. 
These DC would represent the steady state DC that carry self antigens and differ in maturation 
state from the DC that migrate from the periphery in case of inflammation. Semi-mature DC are 
characterized by a mature cell surface marker phenotype, but lack high level pro-inflammatory 
cytokine production, in contrast to fully mature DC. Cells with a semi-mature phenotype 
could be generated in vitro and their repetitive injection prevents autoimmunity in a mouse 
model of experimental autoimmune encephalomyelitis [104]. The spontaneous ability of DC 
to induce tolerance in an immature (or a semi-mature) state explains tolerance in steady-state 
conditions. Infections or other inflammatory signals, in general induce maturation of DC. 
Therefore, a special DC would be needed to preserve a non-destructive autoimmunity in the 
settings of an activated immune system.
The hypothesis about a specific lineage of DC that induces tolerance has been widely 
accepted as well (reviewed in [105]). The first likely candidates for the tolerogenic DC lineage 
was the CD8a+ DC population. Thymic DC in the mouse were almost exclusively CD8a+ 
and were shown to originate from lymphoid precursors. These cells were involved in the 
negative selection of T cells in the thymus [72]. Also in the periphery, CD8a+ DC were found 
to be involved in induction of tolerance [108], so they were a logical candidate for a special 
tolerogenic DC lineage. CD8a+ and CD8a– DC have been implicated in the regulation of 
immunity also by their ability to stimulate Th1 vs. Th2 responses, differentially [109, 110]. 
However, it has been shown that the potential of DC to stimulate a particular type of helper 
T cells depends on the type of the stimulatory signal they encounter and is not related to the 
expression of CD8a [111, 112]. The discovery that CD8a+ and CD8a– DC may share the 
origin and that DC express CD8a at a specific stage in maturation (see later), made them less 
attractive as candidates for a separate tolerogenic DC lineage. Still, their capacity to mediate 
tolerance has not been discarded.
The title of the tolerogenic DC in the mouse was next attributed to the mouse PDC, 
shortly after their discovery [113]. Recently, it has been demonstrated that PDC also control 
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the allergic inflammation in the periphery [114], showing indeed their significant role in the 
down-regulation of the immune system. Yet, PDC are also able to stimulate both Th1 and Th2 
immunity as well as CD8+ T cell responses, indicating therefore that they can perform distinct 
functions depending on the sum of factors that had influenced the maturation and activation 
of PDC [115, 116]. 
Interestingly, PDC as found in the blood, BM or other peripheral organs represent the 
immature stage of this cell type. This speaks in favor of the notion that “immature” DC 
(plasmacytoid or myeloid) are able to downregulate immunity until they encounter an activation 
stimulus and become immunostimulatory APC. This again strengthens the view that all DC 
are in principle tolerogenic in a steady state situation, unless triggered by a “danger signal” 
in the inflammatory context.
In summary, DC that mediate tolerance induction exist without any doubt. The question 
which DC do what in vivo is still incompletely answered. Immune tolerance can be achieved 
through different mechanisms, so there are probably several DC types involved in tolerance 
induction. Moreover, induction of tolerance by one mechanism, for instance by stimulation 
of naïve regulatory T cells, might well be performed by other DC than those maintaining the 
tolerant state. Whether DC able to mediate a particular mechanism belong to a separate lineage 
or represent a particular maturation stage is a matter of semantics. Most likely, this issue will 
be solved once the development of the DC system is understood and we are able to track DC 
throughout their life without influencing their functionality. 
Criteria to distinguish dendritic cells from macrophages: is this distinction real?
The vast majority of studies published on DC and Mf might leave the impression that 
both cell types are separate entities that can be well distinguished on the basis of phenotypic 
and functional criteria. This partition primarily stems from the early characterization of DC 
as the professional APC, restricted to thymus and secondary lymphoid organs. These cells 
are indeed easily distinguished from the Mf, located in peripheral tissues, and defined as 
professional phagocytes that eliminate debris and microorganisms. A more extensive list of 
criteria that separate these prototypical Mf and DC is provided in Table 2.
Before DC were better understood, all phagocytic cells in the periphery were designated 
Mf. But, were they all Mf? We know now that immature DC reside as phagocytic cells in the 
periphery and would be characterized as Mf by many accepted criteria [118, 119]. Thus, in 
many instances the distinction between Mf and DC appears to become a matter of definition 
and semantics, rather than a biological reality.
Multiple surface markers are shared between DC and Mf and even a combination of several 
markers does not provide sufficient indication for a clear separation. Both Mf and myeloid DC 
in the mouse may express CD11b, both can express CD11c, F4/80, MHC class II, costimulatory 
molecules, etc. It was thought that especially markers related to antigen presentation are 
expressed constitutively on DC and only upon activation on Mf. However, this difference 
was mostly based on a restricted definition of DC as resident cells in secondary lymphoid 
organs. Furthermore, this criterion is difficult to use in practice, applying mostly non-dynamic 
phenotypic characterization. The notion that both cell types are sensitive to environmental 
conditions and change their phenotype extensively during maturation and activation, makes 
a general phenotypic distinction between DC and Mf a treacherous enterprise. 
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Mf DC
phagocytosis ++ –/±
adhesion + –/±
acid phosphatase ++ ± (spot)
non-specific esterase + –
killing of microbes ++ –
MHC class II expression inducible constitutive
costimulation ± ++
APC for 1o response – ++
APC for 2o response + ++
At the level of function, DC can phagocytose significantly in vitro as well as in vivo [120]. 
They also share with Mf the potential to produce several cytokines and other soluble factors, 
which provide them with the potential to perform similar regulatory functions. Conversely, 
as argued before, some Mf may activate naïve T cells, at least in in vitro assays. Thus, also in 
these prime functions, no clear-cut difference between DC and Mf can be made.
The in vitro generation of DC and Mf has been a similar source of confusion. For example, 
the same cytokine, granulocyte-macrophage colony stimulating factor (GM-CSF) has been used 
for the generation of cells that were either designated DC or Mf, depending on the definition 
and characterization [11, 121-123]. In general, GM-CSF has now been accepted as a growth 
factor of choice to generate myeloid DC in both mouse and human, but this may be related to 
a wider appreciation of the DC-entity. 
Taken together, there are no solid criteria to distinguish between DC and Mf in general. 
Nevertheless, multiple subtypes of cells can be recognized as either DC or Mf, based on the 
expression of prototypical features and historic conventions. Given the resulting Babylonic 
confusion, it is no surprise that a number of studies have reported the conversion from Mf into 
DC and vice versa, depending on experimental conditions [124-126]. We do not expect that 
unequivocal separating features between DC and Mf will be found in the future, based on the 
extensive phenotypic and functional overlap between the cells. Developmental relationship 
between cell types could have been an alternative and more definitive criterion for distinction. 
However, in the next section, the comparably heterogeneous and confusing developmental 
origin of DC and Mf will be elaborated.
Table 2. Phenotypic and functional criteria used to distinguish between prototypical 
Mf and DC, based on early characterization of the cell types.
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Heterogeneity in the origins of dendritic cells and macrophages
 
In the original concept of the MPS, the members are all considered to have a myeloid nature 
and originate from a common progenitor in the BM [1]. According to this view, the shared 
direct precursor of Mf in the periphery is a circulating monocyte that, upon passage through 
the endothelium of the blood vessel, undergoes final differentiation into a macrophage [1, 127, 
128]. The wealth of more recent studies that have shown that monocytes also can develop 
into DC [11, 129-131] support inclusion of DC in the MPS. Moreover, several studies have 
demonstrated that DC originate from the BM and can be derived from BM precursors in 
vitro using different myeloid-related growth factors [40, 105, 132-134]. However, the view 
that all Mf and DC are myeloid in origin and continuously depend on replenishment by BM 
precursors may be too simplistic.
Studies on early development of DC in both mouse and human suggest that subsets of DC 
may be developmentally closer related to lymphocytes than to the myeloid lineage [135, 136]. 
In particular, thymus-derived common T/NK/DC precursors appear to mature into distinctive 
DC, independent of myeloid development. Human lymphoid-related DC were found to be 
identical to the enigmatic plasmacytoid cells, the major IFN-a producers upon viral stimulation 
[60, 137]. Identification of a mouse equivalent of PDC underlined the evolutionary importance 
of this cell type [38, 39, 138]. The lack of the myeloid marker CD11b on their surface, their 
morphology and other features resembling human PDC, point towards their lymphoid origin. 
However, mouse PDC, unlike human PDC, can develop independently of T cells [139]. 
This study did not exclude the possibility that, in the mouse, PDC may be more related to B 
cells, and recently a lymphoid heritage for PDC has been demonstrated by the presence of 
immunoglobulin heavy chain gene rearrangements, CD3 chain mRNA expression, and pre-Ta 
mRNA expression [140]. 
Interestingly, similar lymphoid-related molecular markers were observed in thymic CD8a+ 
DC, but not in DC from peripheral organs, indicating a closer lymphoid relationship of thymic 
DC [140]. Previously, CD8a expression was proposed as a marker for lymphoid-related DC 
[107], but this concept was left after finding induction of CD8a on myeloid-related DC when 
stimulated under different conditions [132, 141-143]. These findings, together with specific 
localization of CD8a+ DC in the T cell zone of the spleen or the lymph nodes, imply that the 
expression of CD8a on DC probably marks their functional state rather than origin.
The recent characterization of DC precursors has indicated an impressive plasticity of 
hematopoietic progenitors to generate different DC types. For example, both lymphoid- and 
myeloid-committed progenitors isolated from mice have the ability to generate similar DC 
types: both develop into CD8a+ and CD8a– DC in vitro or in vivo [144, 145]. The frequency 
of DC that originate from myeloid or lymphoid progenitors varies per organ, with general 
predominance of a myeloid derivation. 
In contrast to the proposed dual lymphoid and myeloid origin of DC, Ardavin and 
collaborators proposed distinct lineage derivation for DC [146]. They have isolated a precursor 
population that can give rise to CD8a+ DC, CD8a– DC as well as PDC. Similarly, it has been 
shown that the CD31+Ly-6C+ population in mouse BM can develop into all three types of DC 
[147]. Both studies, however, lack the formal proof that this is possible at single cell level. In 
fact, further analyses of the respective DC precursor populations revealed heterogeneity and, 
thus, possible contamination with other progenitors [148, 149].
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An alternative explanation for the confusing lineage derivation of DC has been offered 
by Canque and Gluckman [150]. According to their model, hematopoietic progenitors might 
retain the potential to develop into DC for an extended period during their development, 
depending on environmental signals. Thus, DC might be generated by a lineage-independent 
developmental program that has evolved relatively recently and, once switched on, elicits the 
rapid transformation of distinct leukocytes into professional APCs (namely DC). Recent studies 
lend support to such a view as they suggest that common lymphoid progenitors are flexible 
cells that can be reprogrammed to develop into myeloid cells, including DC, depending on 
specific cytokine signals [151, 152]. Even pro-B cells might develop into DC, when triggered 
appropriately [153].
In a similar manner, Mf might arise from progenitors that have a lymphoid past, in 
contrast to the usual myeloid origin of Mf. Reprogramming of developing B cells into Mf 
was shown by the lack of Pax-5 or enforced expression of transcription factors of the C/EBP 
family [154, 155]. It could be argued that such genetically manipulated systems bear little 
resemblance to normal in vivo situations. However, bipotential cells capable of developing 
into B-cells and Mf have also been demonstrated in unmanipulated mice [15, 156]. In fact, the 
human Hodgkin’s lymphoma cells might represent similar transitional stages, as they derive 
from germinal center B cells and carry immunoglobulin gene rearrangements, but lack most 
classic B-cell markers, and express some myeloid features instead [157]. Interestingly, more 
than a decade ago Brown and colleagues proposed an alternative model for hematopoietic 
development in which the Mf pathway would represent a default choice in case developing 
cells failed to fulfill other pathways [158].
In addition to a fixed myeloid origin of Mf and DC, also the obligatory replacement of 
mature cells by precursors derived from the BM has been under scrutiny. During embryonic 
development, the first CSF-1R expressing cells appear in the yolk sac and spread through 
the developing embryo. These are primitive Mf that play an important role in phagocytosis 
of dying cells, and therefore in tissue remodeling and organogenesis. Embryonic Mf do not 
originate from hematopoietic islands, they do not pass through the monocyte stage, lack F4/80 
expression and seem to be independent of PU.1, a key transcriptional regulator in adult Mf 
development [65, 160]. It has been argued before that they might remain in the adult as BM-
independent populations, but this has not yet been resolved definitively (discussed in [24]). 
A problem in these studies is that adequate monitoring of the fate of transplanted genetically 
marked BM cells requires conditioning of the host, and thus disturbance of the steady state, 
including putative local precursors. However, even in this potentially biased setting, lung and 
liver Mf would remain mostly of host origin even after one year and microglia were even less 
likely to be donor-derived [161, 162]. 
Taken together, the ground plan of the MPS has been profoundly confirmed and completed 
since its establishment. However, a large number of studies have urged to revise the concept 
of a single lineage of cells that is continuously replenished from BM precursors. The view is 
emerging that plasticity at the precursor level may allow immature cells from different origins 
to adopt a developmental program that leads to the generation of mononuclear phagocytes with 
indistinguishable phenotypes and functions. A good example of this putative multiple origin 
is provided by the development of Langerhans cells, residing in epithelial tissue (Fig. 2).
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In man, Langerhans cells have been derived in vitro from a distinct myeloid CD34+ 
precursor population characterized by expression of the skin-homing molecule CLA [163, 164]. 
Alternatively, Langerhans cells may develop from monocytes under the influence of GM-CSF 
and TGF-b [165]. In vivo studies in mice have suggested that Langerhans cells may have a 
lymphoid rather than a myeloid origin [166]. Last but not least, experiments using parabiotic 
mice have shown that Langerhans cells in the steady state are maintained independently from 
the BM [16], possibly by local precursors residing in the skin [167]. Only when depleted 
collectively by an inflammatory trigger, BM-derived cells will reoccupy the niche and develop 
into Langerhans cells. Thus, while the former studies show the potential of different precursor 
cells to develop into Langerhans cells, the latter experiments represent the best indication that 
Langerhans cells are essentially a BM-independent population of mononuclear phagocytes.
Figure 2.  Proposed origins for Langerhans cells. In different experimental settings, Langerhans cells were 
shown to derive from a subset of myeloid progenitors, lymphoid progenitors, circulating monocytes or local 
precursors (see text for details). CLA = cutaneous lymphocyte antigen, a homing molecule for the skin.
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Concluding remarks
Mononuclear phagocytes are characterized by their functional and phenotypic 
heterogeneity. As outlined above, Mf and DC have crucial functions in multiple homeostatic 
processes. This is reflected in their phenotypic characteristics, which are so diverse that no 
clear-cut phenotypic definition of mononuclear phagocytes can be given. The heterogeneity 
may originate from different developmental processes. 
First, mononuclear phagocytes can have different precursors. The vast majority of 
mononuclear phagocytes probably stems from the myeloid hematopoietic lineage, but also 
lymphoid progenitors may give rise to mature DC and Mf that may either be indistinguishable 
from their myeloid counterparts (e.g. Langerhans cells) or constitute a specific subset of 
cells (e.g. PDC). Even mesenchymal cells may be direct progenitors of adult mononuclear 
phagocytes, if, as some studies suggest, fetal Mf may persist throughout adult life.
Second, environmental factors crucially influence the generation of diversity among 
mononuclear phagocytes throughout the different phases of their development. At the precursor 
level, cells will commit to a certain lineage under the influence of local developmental factors. 
Subsequently, numerous exogenous factors influence the maturation of precursor cells to 
peripheral Mf and DC, with obvious functional consequences. Finally, the nature of Mf and 
DC as peripheral sentinel cells makes them sensitive to their environment par excellence. 
These cells carry peripheral messages not only to the immune system, but also to other, such 
as the hematopoietic and neurendocrine systems.
Since the adaptive immune system is vital to host defense and strongly depends on the 
proper function of the MPS, it is no wonder that the observed heterogeneity and redundancy 
exists. Complete absence of Mf and DC has, to our knowledge, never been reported in humans 
or in experimental settings, and is probably incompatible with life.
Here, we propose the MPS as a large continuum of cell types of different functions, 
different phenotypes and even different origins. The flexibility and limits in developmental 
heterogeneity of the MPS is just now starting to be explored. This research is boosted by the 
awareness that modulation of the function of the MPS, in either a stimulating or inhibiting 
manner, may have great clinical potential in a wide variety of diseases. However, the study of 
various functions of mononuclear phagocytes has remained underdeveloped, primarily because 
of the pre-occupation of viewing DC as cells only specialized in immune interaction and Mf 
only as scavengers and destroyers of invaders. Given the recent interest in the mononuclear 
phagocytes, and DC especially, it may be anticipated that before too long more light will be 
shed on these “dark spots” of the mononuclear phagocyte system.
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Immune reaction directed against self-antigens is called autoimmunity. Eliciting factors of autoimmunity lead to a malfunction of immune regulation and brake of tolerance. Au-toimmune destruction of insulin-producing b-cells in the pancreas causes type 1 diabetes 
(T1D), an organ-specific autoimmune disease clinically detected by insulin insufficiency. 
After Banting and Best had discovered insulin, and this hormone was applied as a treatment 
of diabetic patients, their life could be significantly prolonged, however, not without adverse 
consequences. Several complications would develop, like damage to the circulatory and nervous 
system, which lead to an increased risk of heart attacks, strokes, blindness, kidney failure and 
foot and leg amputations. These complications usually begin to occur approximately 10 years 
after the diagnosis of T1D, unless the person’s blood glucose has been well controlled.
The causes of T1D are multiple. Both environmental and genetic factors contribute 
to type 1 diabetes [1-6]. Genetic susceptibility has been related mostly to the genes of the 
major histocompatibility complex (MHC) [7, 8] but many other non-MHC-associated genes 
contribute to the propensity for the disease. Environmental factors like infections, stress, 
diet and hygienic circumstances contribute to the autoimmunity by increasing the risk for 
developing the autoimmune disorder [9-13]. Neither genetic susceptibility nor environment 
alone will lead to the disease. Combined, however, genetically determined susceptibility creates 
the playground at which the environmental factors determine the course of the autoimmune 
response. It has been shown that at early ages, genetic factors contribute to the diabetes more 
critically than later in life, while in adults, environmental factors contribute more actively to 
the susceptibility [14, 15].
T1D is clinically recognized only when more than 80% of the islet mass is destroyed. 
At that point, the self-directed immune response is already full-blown and it is impossible to 
trace the preceding steps and factors. Therefore, animal models play an important role in the 
investigation of the pathogenesis of diabetes.
 
Animal models for type 1 diabetes
Several animal models for T1D exist [16]. In the animal models, the disease develops either 
spontaneously (the BB rat and the NOD mouse model) or is induced (by cyclophosphamide 
or via transgenes e.g. the RIP-LCMV mice). Animal models provide means to follow the 
initiation and progress of the disease prior to onset. Furthermore, they enable research of 
potential treatments that can be applied at early stages of the autoimmune process. Also, 
recent progress in NOD mice shows that animal models are very helpful for the development 
of prognostic tools [17, 18].
 Inbred mice and rats used as animal models for T1D are genetically identical. A lack 
of genetic variability may be considered a disadvantage of the inbred animal models when 
the findings need to be extrapolated to a human situation (for a larger group of patients). 
Furthermore, experimental animals are bred in specific pathogen free conditions, in which 
the environmental factors play a minor role, so the research mainly focuses on the genetic 
determinants of the disease. This might be an important drawback considering that T1D is 
both genetically or environmentally driven.
From the point of view of basic investigations, the fact that inbred animals are genetically 
identical is an advantage for it provides reliable studies in an properly controlled setting. The 
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lack of variability when using a single inbred mouse strain as a disease model can be improved 
by using different transgenic animals, which may enlarge the animal pool of different genetic 
backgrounds and/or with different etiologies of the same disease. Yet, generation of new 
transgenic animals is time consuming and not widely available. 
Much of the knowledge about the course of the pancreatic b-cell destruction in T1D has 
been obtained in the past two decades from two spontaneous animal models: the non-obese 
diabetic (NOD) mouse and the BioBreeding (BB) rat.
Bio-breeding (BB) rat
The BB rat strain has been derived from an outbred Wistar strain in Canada [19, 20]. 
After a few generations of inbreeding, two lines have been selected, a diabetes-resistant (BB-
DR) rat and a diabetes-prone (BB-DP) rat. In the diabetes-resistant rat colony less than 1% 
animals develop the disease while 50-80% of BB-DP rats become diabetic with the mean age 
of onset of about 14 weeks. Similar to humans, there is no difference in diabetes incidence 
between males and females in the BB-DP rat. In addition, similar to the human and the mouse, 
an important genetic determinant that greatly contributes to susceptibility is the MHC locus 
[21]. However, BB-DP rats differ from human diabetics since they are severely lymphopenic 
due to the inheritance of the lymphopenia (Lyp) gene [22]. Although both MHC and Lyp genes 
are important for diabetes development, these two are not sufficient to produce susceptibility 
[23-25]. In addition, the pre-clinical period between the evident initiation of insulitis and the 
clinical onset is relatively short [20]. This points to a fast progression of the autoimmune 
process. 
Since the actual autoimmune process cannot be followed in patients, it is hard to establish 
with certainty the course the autoimmune process has taken in a patient with overt diabetes. 
Given that the variety of factors and mechanisms can lead to T1D, the rapid disease onset in 
the BB-DP rat might reflect one of many possible routes.
Non-obese diabetic (NOD) mouse
The similarities between a presumed scenario for the pathogenesis of human T1D and 
the observed islet inflammation in the NOD mouse made this model one of the earliest and 
most extensive models studied. 
The NOD mouse has been generated in Japan by selection from a mixture of outbred mice 
prone to develop cataract (a complication of diabetes) [26]. Interestingly, the NOD mouse 
was derived as a “by-product” of a selective breeding for an obese mouse: a model for type 
II diabetes [27]. So, the researchers were looking for a fat mouse that would develop diabetes 
and they ended up with a slim mouse, which would spontaneously develop insulin dependent 
diabetes. At first, this mouse was exclusively kept in Japan, but later several colonies around 
the world have been started. Although all NOD mice come from the same original source, 
years of isolated breeding have led to varying levels of diabetes incidence and possibly other 
differences with regard to some cellular defects as well [28, 29]. Importantly, while the diabetic 
phenotype appears with different incidence among colonies, virtually all NOD mice develop 
insulitis [29]. 
Similar to the human, environmental factors such as diet, infections or the temperature 
contribute to diabetes development in NOD mice [30-32]. Different breeding conditions 
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influence the diabetes incidence. NOD mice bred in a microbiologically “clean” environment 
have in general a higher diabetes incidence. Remarkably, even in the same animal facility, 
different caging of mice will influence the incidence, demonstrating a multifactorial contribution 
to the outcome of the autoimmune process.
NOD mice are not only used as a model for autoimmune diabetes but also as a model 
for other autoimmune diseases. Besides chronic inflammation in the pancreas that leads to 
autoimmune diabetes, these mice develop autoimmunity of the salivary glands (Sjogren’s 
syndrome) [33, 34] and thyroid autoimmunity in a specific setting i.e. when kept on a high 
iodine diet and with the appropriate MHC class II genes [35, 36]. NOD mice also develop 
hemolytic anemia and anti-nuclear antibodies, indicating that they suffer from systemic 
autoimmunity as well [37]. Around 12 weeks of age, NOD mice start to develop a spontaneous 
hearing loss, which also might be autoimmune-related [38]. The NOD mice are susceptible 
to induced autoimmune models like experimental allergic encephalomyelitis (EAE) [39, 40] 
and have been used for studies on some features of systemic lupus (SLE) [41, 42]. They can 
develop an extremely strong Th2 allergic response against OVA, therefore are susceptible for 
experimentally induced asthma as well [43]. Remarkably, however, NOD mice are resistant 
to collagen-induced arthritis (CIA), a model for reumathoid arthritis (RA) [44].
Taken together, a susceptibility to different types of autoimmune disease coexists in the 
NOD mice. Since the genetic factors play a greater role in the specific-pathogen free conditions, 
under which they develop these diseases, NOD mice are a good model to study genetic factors 
and gene clusters that are shared between T1D  and other autoimmune disorders.
Genetic control of diabetes in NOD mice 
Investigation of genetic traits can help significantly to understand genetic defects that 
increase the susceptibility to an autoimmune disease as well as to determine which molecules 
are essential for the pathological mechanisms. Identifying polymorphisms that enlarge the 
propensity to autoimmunity in general or to a particular autoimmune disease can help in 
prognostic analysis. However, this knowledge does not provide direct means to fight the 
disease. 
Studies in which NOD mice were crossed with diabetes-resistant mouse strains have 
unveiled several loci contributing to insulitis or diabetes. These loci are termed Idd’s (for 
insulin-dependent diabetes) and they are regions in the mouse genome which provide a partial 
or a full protection from diabetes, when replaced by the same region from the diabetes-resistant 
mouse. Up to now, 24 Idd loci distributed across 14 chromosomes in the genome have been 
found to be associated with the insulin-dependent diabetes (IDDM) [45-47]. Overview of 
the Idd loci, their location and contribution to the autoimmune diabetes in the NOD mouse 
is given in Table 1. 
It is not yet clear for all Idd loci by which means they contribute to diabetes. Of them, 
Idd1 located on chromosome 17, which contains the NOD-specific MHC genes, is the major 
locus associated with IDDM. Replacement of this locus fully protects NOD mice from 
diabetes development [48]. Together with the MHC, the Idd3 locus on chromosome 3 has the 
strongest control of the autoimmune diabetes in the mouse [49, 50]. Interestingly, replacement 
of some Idd loci in the NOD mouse shows minor contribution to protection from diabetes, yet 
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combination of them provides a strongly increased resistance. This underlines the complexity 
of the defects in the immune system in which several small faults, that on their own would not 
be able to do much harm, combined in the NOD mouse lead to an inevitable and irreparable 
destruction of b-cells and disease. 
The genes encoded by the different Idd loci are not all known yet. Despite the uncertainties, 
the congruence and the candidate-gene approach have taught us that besides the MHC-locus, 
genetic predisposition is closely linked to the genes that encode the costimulatory molecules 
CD28 and CTLA-4 on chromosome 1, genes encoding molecules from the TNF family on 
chromosome 4, and possibly the IL-2 gene on chromosome 3 [51-53]. Thus, it seems that genes 
correlated to the diabetes susceptibility that have been identified thus far are often associated 
with immune regulation and with molecules expressed in APC in particular. 
Genetic loci that contribute to other autoimmune diseases in the NOD mouse have been 
traced as well [45]. Some of them are shared by several disorders and probably influence the 
common aspects of autoimmunity, like inflammatory effects. However, many remain specific 
for a particular disease, indicating that each disease is controlled by a unique set of disease-
promoting genes. The genetic control of autoimmune disorders might be more distinct in the 
NOD mouse than previously suggested [54, 55]. In the NOD mouse, the various spontaneous 
diseases use different pathogenic pathways, which also importantly depend on the initial 
trigger, microbiological status, stress etc.
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Table 1. Currently available information regarding Idd loci, their contribution to insulitis or diabetes 
and candidate genes found in these loci
Locus Chromosome Role of NOD allele in Disease Phenotype Candidate Genes at Locus
Idd1 17 Diabetes: required but not sufficient diabetes MHC class II genes (IA
g7, IE)
Idd2 9 Diabetes: confers susceptibility; Insulitis: no linkage undefined
Idd3 3 Diabetes and insulitis:   confers susceptibility 
Il-2 (Interleukin-2), Fgf2 (fibroblast 
growth factor-2)
Idd4 11 Diabetes: confers susceptibility; Insulitis: no linkage undefined
Idd5.1 1 Diabetes: confers susceptibility Casp8, Cd152 (CTLA4), Cflar (FLIP), Cd28 
Idd5.2 1 Diabetes: confers susceptibility Nramp1, Cmkar2 (CXCR2, IL-8 receptor a )
Idd6 6 Diabetes: confers susceptibility;Insulitis: no linkage undefined
Idd7 7 Diabetes: partially protective; Insulitis: no linkage undefined
Idd8 14 Diabetes: partially protective; Insulitis: no linkage undefined
Idd9.1 4 Diabetes: confers susceptibility; Insulitis: no linkage
may co-localize with Idd11, Lck is 
a candidate gene
Idd9.2 4 Diabetes: confers susceptibility; Insulitis: no linkage
Tnrf2, Cd30 (receptors for tumor 
necrosis factor family)
Idd9.3 4 Diabetes: confers susceptibility; Insulitis: no linkage
Cd137 (receptor for tumor 
necrosis factor family)
Idd10 3 Diabetes and insulitis:   confers susceptibility
region includes Csfm, Cd53, 
Kcna3, Nras, Rap1a 
Idd11 4 Diabetes: confers susceptibility may co-localize is a candidate with Idd9.1; Lck gene
Idd12 14 Diabetes: confers susceptibility undefined
Idd13 2 Diabetes: confers susceptibility; Insulitis: no linkage beta 2 microglobulin gene
Idd14 13 Diabetes: confers susceptibility; Insulitis: no linkage undefined
Idd15 5 Diabetes: confers susceptibility undefined
Idd16 17 Diabetes and insulitis:      confers susceptibility MHC Class I K gene
Idd17 3 Diabetes: confers susceptibility undefined 
Idd18 3 Diabetes: confers susceptibility region includes Csfm, Cd53, Kcna3, Nras, Rap1a 
Idd19 6 Protective against diabetes undefined
Idd20 6 Diabetes: confers susceptibility undefined
Idd21 18 Diabetes: confers susceptibility undefined
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Which cells are the players in the diabetes pathogenesis? 
All types of immune cells seem to be implicated in the self-directed inflammation in the 
pancreas. However, some contribute to the initiation while others play a predominant role in 
the progression phase or the final precipitation of the disease. 
In essence, diabetes pathogenesis in NOD mice can be divided into two phases. In the 
first phase, a gradual accumulation of leukocytes in the close proximity of islets of Langerhans 
takes place. This phase is called the insulitis-phase. The second phase involves the actual 
destruction of the b-cells in the pancreas leading to overt diabetes (schematic overview of the 
diabetogenic process is given in the Figure 1).
Congenic NOD mice, in which a part or a complete Idd locus has been replaced, have 
provided much insight concerning the genes that are involved in these different disease phases. 
Some congenic strains are protected from both insulitis and diabetes, while others are protected 
from diabetes only but still develop insulitis (a complete overview of congenic NOD mice is 
provided in [56]). In addition, gene expression profiles using cDNA microarray analysis of 
spleen cells has enabled defining an immunological checkpoint at 5 weeks of age in the NOD 
mouse, at which a switch of the expression profiles of about 70 genes (among them seven genes 
map to the diabetes susceptibility regions) are consistent with increased antibody production, 
Figure 1. Two phases of the diabetogenic process. A. The earliest event related to the initiation of the autoimmunity 
in the NOD mouse is the accumulation of DC and Mf in the close proximity of Langerhans islets. B. Many cells of the 
immune response are present in the insulitic infiltrate: Mf, DC, effector CD8+ and CD4+ T cells, B cells, NK cells, regulatory 
T cells. Arrows demonstrate the changes in the cell composition during the progression from the non-invasive towards 
the invasive insulitis. This process is marked by the infiltration of Mf and CD8+ T cell into the islet and the departure of 
NK cells and regulatory T cells from the islets or loss of their function.
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antigen presentation, and cell proliferation associated with an active autoimmune response 
[57]. The functional studies will reveal whether these genes contribute to the progression 
towards insulitis and diabetes.
The first signals of the insulitis-phase involve the increased presence of DC and Mf around 
the islets.  Already in neonatal NOD mice a slightly raised number of DC and Mf is found 
in the target organ [58]. However, it is not known whether at this point in time the cells are 
involved in the developmental changes of the pancreas or already in initiating autoimmunity, 
probably in both [59]. An additional accumulation of DC and Mf around the islets at 4-5 weeks 
of age precedes the peri-insular infiltration of lymphocytes [60, 61]. Subsequently, DC and Mf 
in the NOD pancreas probably are involved in the production of the chemokines necessary 
for the formation of the high-endothelial venules and the lymphocyte attraction. Activated 
pancreatic endothelium enables the extravasation of lymphocytes into via integrins [62, 63]. 
At this stage, lymphocytes create large non-destructive peri-insular infiltrates.
An important checkpoint in the initiation of autoimmunity is the propagation of 
autoreactive T cells in the pancreatic lymph nodes (PLN). This occurs in the first three to four 
weeks after weaning, as the removal of PLN at this time significantly prevented diabetes [64]. 
This demonstrated the essential role of PLN in the stimulation of autoreactive lymphocytes. 
However, the antigens that elicit the autoimmune response might not be delivered solely by 
the pancreas via pancreatic DC that traffic to PLN. The initial priming of diabetogenic T cells 
is suggested to take place in the gut-associated lymph nodes and the PLN would serve for the 
amplification of the autoimmune response [65]. It is predictable that DC mediate the priming 
of diabetogenic T cells but no direct evidence exists that DC originating from pancreas present 
antigen in the PLN. Peripheral DC continuously migrate from the periphery to the draining 
lymph nodes, where they present antigen [66, 67]. This notion is highly probable for pancreatic 
DC as well. A transmigration of DC in the pancreas through the lymphatic endothelium has 
been demonstrated, although at later stages of the pathogenic process [68].
Activated autoreactive T cells migrate to the pancreas where they accumulate and form 
infiltrates located in the near proximity of the islets (peri-islet accumulation). Infiltrates contain 
DC, Mf, CD4+ and CD8+ lymphocytes and are initially benign [60]. CD4+ T cells are at this stage 
of both Th1 and Th2 type. The b-cell destruction is mediated mostly by CD8+ lymphocytes and 
Mf, which relocate into the islets [60, 61]. So far it is incompletely understood which event(s) 
trigger the progression of a non-destructive towards the destructive form of insulitis. Several 
events take place at this point. Progression from insulitis to diabetes could be due to the shift 
toward Th1 type inflammation [69, 70], which can be traced as a downregulation of IL-10 and 
an increase of IL-12 in serum [71]. A candidate cytokine that could drive this Th1-shift could 
be IL-15. An acceleration of insulitis progression by cyclophosphamide downregulates the 
expression of prostaglandin H synthase 2 and arginase (an antagonist enzyme of the inducible 
NO synthase) and induces a strong concomitant upregulation of IL-15 that precedes lymphocyte 
invasion of islets and a rise of IFN-g mRNA levels [72]. B cells have also been implicated in 
overcoming the checkpoint towards destructive insulitis since mice in which I-Ag7 was replaced 
specifically in B cells did not spontaneously convert a non-invasive into destructive insulitis 
[73]. Conversely, regulatory T cells and NK cells might provide the necessary keys that hold 
the insulitis under control, and loss of these cells or loss of their function enables other cells 
to start the destruction [74-76]. 
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Which cellular defects lead to autoimmunity?
The knowledge of the biology and physiology of cells involved in insulitis is still 
insufficient to enable a straightforward translation of the scarce genetic polymorphisms found 
in diabetes-related loci into functional defects. Therefore in parallel with the research of the 
NOD mouse genetics, many groups have focused on investigations of aberrant function of 
different cells involved in the diabetogenic process. The goal of this research is to find intrinsic 
defects in b-cells or in cells of the innate or the adaptive immune system, which could contribute 
to the dysregulation of the immune system, leading to the initiation and progression of the 
autoimmune response and finally causing diabetes. 
Defects in the target organ
Abnormalities in the pancreas could contribute to the sensitivity for an autoimmune attack 
or even to an elicitation of an autoimmune response. Indeed, aberrant islets and b-cells have been 
found in the NOD mice. Malformations in the development of the pancreas have been traced 
[59]. These probably find their origin already at the fetal stage. In the perinatal pancreas, Fas+ 
nerves are present, which concomitantly express IP-10, a chemokine that attracts leukocytes 
[77]. Indeed, others have suggested that not only b-cells but also neuronal elements might be 
the targets in the NOD pancreas [78]. In addition, b-cells in the NOD mouse are hypersensitive 
to oxidative stress [79, 80]. All the architectural aberrancies and/or the hypersensitivity to 
oxidative stress might induce “danger” signals that stimulate local cells of the innate immune 
system to start and perpetuate the autoimmune response. 
Defects in the cells of the adaptive immune system 
Effector T cells recognizing auto-antigens – In all mouse models as well as in human 
diabetes, disease onset critically depend on the existence of auto-reactive effector T cells. 
Lymphocyte-deficient NOD mice (NOD-scid or NOD-Rag knock-out mice) are protected from 
insulitis and diabetes. The reconstitution of these mice with the T cell pool from diabetic NOD 
mice will in short time lead to diabetes [81, 82]. Both CD4+ and CD8+ autoreactive T cells exist 
in the NOD mouse. Unlike CD4+ T cells that mediate their destructive activity by cytokines, 
CD8+ T cells are themselves actively cytoxic cells that enter the islet and destroy b-cells.
Reconstitution experiments demonstrate the important role of T cells in the diabetes 
pathology but do not imply that these cells have possible functional defects. The existence of 
autoreactive T cells is considered to reflect a defect in the negative selection in the thymus 
[83]. Faulty negative selection might originate in an intrinsic defect of the thymocyte itself or 
in the cells that mediate negative selection, in particular the thymic DC. An intrinsic defect of 
NOD lymphocytes relevant to defective negative selection could be their hyporesponsivness to 
normal TCR stimulation [84, 85]. However, such poor reactivity could not explain the expansion 
of autoreactive T cells in the periphery. Later studies demonstrated that a reduced apoptosis 
might be the defect in NOD thymocytes by which autoreactive T cells escape negative selection 
[83, 86-89]. However, Villunger et al have challenged this view as they could induce a proper 
apoptosis in NOD thymocytes [90]. Also for circulating T cells, an incomplete activation 
induced cell death (AICD) or a prolonged proliferation due to a low apoptosis in vitro has 
been demonstrated [91, 92]. However, from the latter two studies it cannot be clearly deduced 
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whether the defective apoptosis comes from an abnormality in the lymphocyte or from the 
APC that does not stimulate the T cell sufficiently to go into apoptosis. Interestingly, it has 
been reported that some CD8+ T cells from the NOD mouse are able to re-activate the VDJ-
recombination machinery in the periphery [93]. This might explain why some high-avidity 
autoreactive lymphocytes can develop again in the peripheral pool of selected CD8+ T cells 
in the NOD mouse [94].
Regulatory T cells – An important cell type that contributes to the prevention of 
autoimmune disease is the regulatory T cell [95]. Cells that can execute regulatory activity 
are a heterogeneous group (reviewed in [96, 97]). There are in principle two types of T cells 
that propagate suppressive activity: T cells that produce the suppressive cytokines IL-10 or 
TGF-b (called Tr1 or Th3 cells) and so called regulatory T cells (T
reg
) that also work via cell-cell 
interaction. Cells of the T-regulatory system express a diverse TCR repertoire and recognize 
foreign as well as self-antigen. They also have a different development: T
reg
 are generated 
and selected in the thymus while Tr1/Th3 derive from the naïve peripheral T cell pool that is 
specifically stimulated in the lymphoid organs in an active immune response [96, 97]. 
The precise phenotype of T
reg
 cells has not been revealed completely and nowadays they 
are primarily defined on the basis of their functionality. Most of the T
reg
 cells are CD4+CD25+, 
but this phenotype is not an exclusive characteristic of T
reg
 cells. Activated CD4+ T cells also 
express CD25 (the IL-2-receptor a chain). Additional markers expressed by T
reg 
have been 
reported recently: CD44, CD62L, GITR, CD134 and Foxp3 (reviewed in [98, 99]). 
The important role of T
reg
 in the maintenance of tolerance is well accepted. A plethora of 
studies have demonstrated that depletion of these cells leads to autoimmunity [98, 100] or that 
the selective supplementation or in vivo expansion of these cells prevents autoimmunity [101-
103]. The number of CD4+CD25+ T cells is reduced in NOD mice and these cells have been 
shown to be functionally deficient as well [102]. The decrease in the suppressive activity of 
these cells in NOD mice has been reported to be age-dependent [70]. Interestingly, a defect in 
STAT-1 has been shown to lead to an impaired development and function of regulatory T cells, 
which renders STAT-1 deficient mice susceptible to autoimmune disease [104]. Potentially, 
defective function of STAT-1 might contribute to the regulatory T cell deficiency in the NOD 
mouse as well. 
Balance between the effector and regulatory T cells - Autoreactive T cells have been 
found in healthy individuals [105], which do not necessarily have a higher risk to develop 
autoimmunity. Furthermore, some self-reacting T cells might work as regulators and ensure 
tolerance, unless imbalanced by inflammatory conditions. High frequency of autoreactive T 
cells may exist without causing autoimmune disease due to a proper equilibrium between 
effector and regulator cells [60, 74, 106]. Too many effectors or too few regulators might 
become dangerous when an altered function of one of them disturbs the balance. 
 The altered response of T cells to apoptotic signals and/or defects in the inhibitory 
signaling pathways of the NOD T cells contribute to the dysbalance and autoimmunity 
(reviewed in [107]). However, the balance can be disturbed by an altered function of other 
players in the immune response as well. Likely candidates are APC, which may allow for the 
propagation of a dangerous self-reactive immune response either by an unnecessary activation 
of effectors or by a deficient support of the suppressive forces. 
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B cells – The contribution of B cells to autoimmunity was previously attributed exclusivelly 
to the production of auto-antibodies. However, islet-specific antibodies are of little importance 
for the initiation of autoimmunity. T cells transferred without B cells to NODscid mice were 
able to induce diabetes, implying that B cells are not essential in the effector response. New 
attention to B cells has been drawn by studies indicating that they may play a role as antigen- 
presenting cells in the autoimmune diabetogenic process. B cell-deficient NOD mice did 
not develop diabetes and a depletion of B cells also abrogated the disease [108, 109]. The 
antigen-presenting function of B lymphocytes is important in later phases of the autoimmune 
process, at the switch from a non-destructive to a destructive insulitis [73]. Recently, a defective 
deletion of B cells that recognize some soluble antigens has been described, which could be 
an important intrinsic defect leading to a high frequency of B cells reactive to auto-antigens 
in the NOD mouse [110, 111]. In addition, an expanded pool of B cells has been found in 
NOD mice that express a high level of CR1/CR2 complement receptors and have a high CR3 
binding activity. Prevention of the emergence of these cells conferred resistance to autoimmune 
diabetes in NOD mice [112]. 
Defects in the cells of the innate immune system 
NK and NK T cells - The function of NK cells is mainly killing of recognized tumor 
targets. Interaction of NK cells with self-MHC class I molecules provides inhibitory signals 
that keep NK cells in an inactive state. If MHC class I molecules start presenting antigens 
other than self (e.g. derived from viruses), NK cells will sense that “self is missing” and start 
producing proinflammatory cytokines, which are able to activate DC and in that way stimulate 
an adaptive immune response [113-115]. NK T cells represent a subset of T lymphocytes that 
also express the NK-specific molecule (NK1.1). These cells have a very limited TCR repertoire 
and the majority of them recognize glyco-lipid antigens presented by the MHC class I-like 
molecule (CD1d) [116]. 
A reduced number and function of NK and NK T cells in NOD mice has been reported 
soon after the initiation of the analysis of cellular defects in this mouse strain [117, 118]. 
Further investigation was hindered by the fact that NOD mice lack the NK1.1 molecule, the 
only available marker that separates NK cells from other leukocytes in mice. Generation of 
transgenic NOD mice that express NK1.1 facilitated cytometric and functional analysis of these 
cells [119]. In these mice, NK and NKT cells were reduced in the number in the periphery and 
increased in the BM, suggesting a defect in NK cell export from the BM. Furthermore, they 
produced less IL-4 upon stimulation when compared to normal NK cells. 
A severe but partially restorable killing defect in the NK cells of NOD mice has been 
reported recently [120]. Additionally, NOD NK cells to fail to modulate the activating receptor 
NKG2D, which implied an unwanted killing activity [121], and the blockade of this molecule 
prevented autoimmunity in NOD mice [122].
NK T cells are normally present in pancreatic islets of both female and male NOD mice. 
Their number starts to decline specifically in female mice at the time of diabetes progression, 
therefore they might be important in the regulation of autoimmune diabetes [123]. Modulation 
of the NK T cell pool by adoptive transfer, endogenous recovery or stimulation with aGalCer 
prevented spontaneous diabetes development in NOD mice [124-126]. Stimulation of NK 
T cells with aGalCer induced their accumulation in the pancreas and PLN, supporting their 
putative regulatory role. 
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Macrophages – At least two subsets of Mf can be found in the pancreas, ER-MP23+ and 
BM8+ Mf. ER-MP23+ are resident Mf, normally present in the pancreas while BM8+ Mf are 
often associated with inflammation and are critically involved in the destruction of b-cells 
[60]. Several defects of Mf have been identified in NOD mice. Abnormal Mf development and 
underlying intracellular defects have been found in the BM cells [127]. Furthermore, isolated 
NOD Mf show a reduced phagocytosis of apoptotic cells and a reduced cytokine production in 
response to apoptotic cells [128, 129]. In general, phagocytosis of apoptotic cells is a mechanism 
to sustain tolerance and this defect could abnormally promote inflammation in NOD mice 
[130, 131]. The molecular defect underlying the increased ability to mediate proinflammatory 
response might be a hyperactivation of NF-kB, the transcriptional activator of many cytokines 
[132, 133]. Indeed, NOD Mf produce increased levels of IL-12 when stimulated with LPS 
or Hsp60 [134, 135]. In addition, NOD Mf also produce high amounts of nitric oxide (NO), 
which contribute to the destructive phase of the insulitis process [136, 137]. 
Taken together, defects found in NOD Mf point to a preferential and elevated 
proinflammatory response when stimulated. Potentially, this could have detrimental 
consequences for the pancreas in which resident Mf could “misunderstand” the signals from 
the environment and induce inflammation there where it normally should not be induced.
Dendritic cells – Together with Mf, DC are the first leukocytes that accumulate in the 
pancreas during the islet inflammatory response. They are present in the pancreas throughout 
the course of the autoimmune destruction of b-cells. Because of their important role in the 
acquisition and maintenance of tolerance as well as in induction of immunity, it is likely that 
a faulty function of DC will contribute to the development of autoimmune diabetes (Figure 2). 
Therefore, the search for defects in DC has been a focus of investigation for many groups.
The interplay between DC and T cells is essential for the initiation, propagation and 
regulation of the T cell function. The defects in T cells were not evident indisputably, so 
investigations of problems with their partners (DC) were performed as well. A candidate 
explanation for the faulty selection of T cells was a defective function of DC in the thymus 
or in the peripheral lymphoid organs (the spleen or the lymph nodes). 
At first, a defect in the function of DC in NOD mice was associated with MHC molecules. 
It has been shown that a unique I-Ag7 allele, specifically expressed in NOD mice, shows a 
poor binding to certain peptides [138-142]. According to the hypothesis, due to an instable 
MHC-peptide complex, the duration of the DC-thymocyte contact would be inefficient and 
auto-reactive cells would escape negative selection [139, 140]. Also in the periphery, where 
a strong interaction with DC enables the AICD of T cells, the short interaction with the NOD 
DC would disable proper deletion of auto-reactive effectors. However, auto-reactive cells 
also need a good interaction with peripheral DC to be activated and an instable MHC-peptide 
complex could not explain the propagation of these cells in the periphery (reviewed in [143]). 
Furthermore, the contribution of the MHC defect to autoimmunity does not necessarily involve 
DC, since other cells (e.g. B cells, Mf, endothelial cells) also express MHC II molecules. The 
role of the MHC molecules in providing susceptibility to diabetes is certain [48, 142, 144], 
yet whether it implicates the functional defect in DC is not clear.
Problems in antigen presentation by DC might also involve the non-MHC-linked genes 
that contribute to the failure to delete the high avidity autoreactive cells in the NOD thymus 
[87]. Defects in Tap1 and Tap2 molecules important for antigen presentation through MHC 
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class I molecules to CD8+ T cells could enable faulty selection of potentially auto-reactive 
cytotoxic clones [143]. However, this also does not necessarily need to be a DC problem.
Modest conclusive data exist on the actual defects of DC in NOD mice. In vitro generation 
of DC from the NOD BM appears to be defective [145-149]. When stimulated with GM-
CSF, BM cells from the NOD mouse yield low numbers of DC, which are also poor cytokine 
producers and poor stimulators of T cells. Unlike cells from other mouse strains, BM cells 
from the NOD mouse need to be stimulated with GM-CSF together with IL-4 in order to fully 
mature into capable antigen presentign cells. However, when sufficiently stimulated, the NOD 
BM cells tend to show an increased DC generation and an elevated Th1 skewing capacity of 
the cells generated in vitro [150, 151]. 
Many of these defects could not be clearly traced in vivo. In a congenic NOD mouse 
strain, an imbalance in the in vivo development leading to an over-representation of CD8a– DC 
in the spleen has been demonstrated [152]. However, DC isolated from the spleen and lymph 
nodes of the genuine NOD mouse did not reveal major phenotypic nor functional defects [92, 
149]. Of note is also that the functional studies focused on the ability of ex vivo isolated DC to 
stimulate, not to silence T cells, so the hypothesis that the NOD DC fail to silence autoreactive 
T cells is neither rejected nor confirmed. Furthermore, the possibility that peripheral DC fail 
to maintain T
reg
 also remains. 
A central role of a DC dysfunction in the development of autoimmunity is expected. 
However, a specific aberrant function of NOD DC has not been traced. Moreover, opposite 
conclusions drawn from different studies make it difficult to reach a definite conclusion on 
whether a particular deviation in the NOD DC exists.
Figure 2. Checkpoints at 
which DC could be involved 
in the faulty tolerance regu-
lation. A “healthy” scenario is 
represented with white arrows 
while grey arrows point to the 
autoimmunity-related sce-
nario. To preserve tolerance, 
in the thymus or in the lymph 
node, autoreactive effector T 
cells are deleted (or silenced) 
and regulatory T cells gener-
ated (or activated). Both faulty 
removal of autoreactive ef-
fector T cells and deficient 
propagation of regulatory T 
cells contribute to the break 
of tolerance. Importantly, 
DC critically regulate both 
processes
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Aims of this thesis:
The great heterogeneity of the DC and Mf with regard to their phenotype, active functional 
communication with other cells of the immune system and the functions as APC and regulators 
of the immune homeostasis assure the central place for DC and Mf in the immune response. 
Fine-tuning of DC and Mf in central and peripheral lymphoid organs is of essential importance 
in determining the type of immune response that will be induced. 
Dysfunction of DC may also be central to development of autoimmunity. A role of DC in 
the induction and maintenance of tolerance, early presence of DC and Mf in the NOD mouse 
pancreas and functional aberrancies of the in vitro generated DC from the NOD mouse BM, 
underscore the importance of further studies of DC in the autoimmune diabetes.
Therefore, given the suggested aberrations in the development of DC in the NOD mouse 
and the uncertainties about their reality, the putative role of DC and Mf in the initiation, 
propagation, faulty regulation of the autoimmune response and the final b-cell destruction 
leading to diabetes and given the heterogeneity but a close developmental relationship of the 
DC/Mf system, we aimed: 
-    to establish relationships between Mf, DC and lymphocytes in the pancreas of NOD 
mice and investigate the modulation of the phagocytic cell compartment and the effects 
on insulitis and diabetes development in the NOD mouse; 
-    to characterize the in vivo developmental stages of DC and Mf in mice;
-   and to try to clarify inconsistent findings about the faulty in vitro development and 
investigate potential aberrations in the in vivo DC differentiation in NOD mice.
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Dendritic cells (DC) and macrophages (Mf) are present in higher numbers in the pancreas 
of the NOD mouse during the diabetogenic process from very early stages onwards. In this 
study we used clodronate-loaded liposomes to mediate the temporary systemic depletion 
of these phagocytic cells and monocytic precursors in order to modulate the pancreatic 
inflammation. Two intra-peritoneal injections given with a 2-day interval to 8-week old 
NOD mice depleted monocytes from the circulation and monocytes, DC and Mf from 
the spleen within the first days after the injections. Monocytes, DC and Mf re-appeared 
in the circulation and the spleen within one week and had an unchanged phenotype and 
antigen presenting function. Interestingly, this treatment caused a delayed, long lasting 
disappearance (7–21 day post-injection) of DC and Mf from the endocrine pancreas at 
a time when monocytes, DC and Mf had already repopulated the circulation and spleen. 
The depletion of DC and Mf from the endocrine pancreas was accompanied by a total 
disappearance of lymphocytes from the pancreas. DC, Mf and lymphocytes re-appeared 
in the pancreatic inflammatory infiltrates in treated mice from 28 days post depletion 
onwards. Importantly, the treatment significantly postponed the onset of diabetes, leading 
to a strongly decreased incidence by 35 weeks of age.
Taken together, our data show an essential role of phagocytic cells, i.e. DC and Mf, in 
the recruitment of lymphocytes to the pancreatic islets in NOD mice. 
Type I diabetes is an auatoimmune disease in which a self-destructive immune process against the pancreatic b-cells 
leads to insulin deficiency. In the non-obese 
diabetic (NOD) mouse, a widely used animal 
model for autoimmune diabetes, dendritic cells 
(DC) and macrophages (Mf) have been proposed 
to be important for the initiation, progression and 
final destruction of the b-cells [1]. Histological 
studies show slightly raised numbers of DC and 
Mf already in the pancreas of neonatal NOD 
mice [2]. A further accumulation of DC and Mf 
around islets at 4-5 weeks of age precedes the peri-
insular infiltration of lymphocytes. A relocation of 
lymphocytes and Mf into the islets characterizes 
the initiation of the final b-cell destruction [3, 4]. 
The continuous presence of elevated numbers 
of DC and Mf in the NOD pancreas from birth 
onwards strongly suggests an important role of 
these cells in the diabetogenic process. Yet, these 
histological studies are descriptive and therefore 
inherently inconclusive regarding the functional 
role of these cells. 
Functional approaches have involved the blocking 
of the intra-islet infiltration of inflammatory cells 
by an intervention of leukocyte-adhesion to the 
pancreas endothelium [5-7] or by inducing a long-
term depletion of phagocytic cells [8-10]. These 
methods protected mice from diabetes, further 
strengthening the concept of an essential role of 
Mf and DC in the development of autoimmune 
diabetes in the NOD mouse. However, previous 
studies mainly focused on the depletion of Mf 
and did not consider the effects of DC depletion. 
We have previously demonstrated that clodronate-
loaded liposomes (lip-CL
2
MDP) not only deplete 
Mf, but also DC in liposome targeted-tissues 
[11]. 
We here report an investigation on the intra-
pancreatic and peripheral changes in the 
monocyte, DC and Mf compartment after a 
short-term lip-CL
2
MDP treatment of NOD mice. 
We show that two intra-peritoneal (i.p.) injections 
of lip-CL
2
MDP given with a 2-day interval in 8-
week-old pre-diabetic NOD mice significantly 
delayed diabetes onset for more than 20 weeks 
in the majority of treated mice. Considering the 
short-term disappearance of monocytes, Mf and 
DC from the circulation and the spleen, and the 
rapidly regenerated normal function of the newly 
recruited spleen DC, the beneficial effects could 
not be attributed to a modulation of cells from 
this compartment. However, the same treatment 
induced a delayed and prolonged disappearance 
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of DC and Mf from the endocrine pancreas. The 
absence of DC and Mf directly influenced the 
presence of lymphocytes and lymphocytic (peri-) 
insulitis resolved completely. Our observations 
point to an essential role of DC and Mf in the 
continued persistence of lymphocytic infiltrates the 
pancreas and subsequent b-cell destruction.
Material andMethods
Animals
Female NOD/Ltj and C3HeB/FeJ mice were bred at 
the animal facility of the ErasmusMC, Rotterdam, The 
Netherlands. C57BL/6j, BALB/c and NOR female mice 
were obtained from Harlan (Horst, The Netherlands). All 
strains were kept under specific pathogen-free conditions 
and fed ad libitum. By 30wks of age, the incidence of 
diabetes in our NOD colony is 90% for females and 60% 
for males. For all experiments, mice were sacrificed at 
postnatal ages of 7-12wks or at 35wks of age. Glycosuria 
was tested with the Gluketur test (Roche Diagnostics 
GmbH, Mannheim, Germany). A minimum of 3 animals 
per age/strain/time point was used for all studies. Animal 
handling followed the ethical rules of the European 
Union and was approved by the Erasmus University 
Animal Welfare Committee.
Liposome preparation and in vivo application
Multilamellar liposomes containing clodronate 
(dichloromethylene bisphosphonate, a gift from Roche 
Diagnostics GmbH) (lip-CL
2
MDP) in the aqueous 
phase were prepared as described previously [12, 
13]. Liposomes consisted of phosphatidyl choline 
and cholesterol in 6:1 molar ratio. After washing, the 
liposomes were resuspended in PBS. A volume of 0.2ml, 
containing about 2mg of liposome-entrapped clodronate 
was injected twice intraperitoneally (i.p.) with a two-day 
interval between two consecutive injections into 8-week 
old mice (in a stage of well advanced peri-insulitis). 
This approach was chosen in order to obtain a complete 
depletion of phagocytic cells in the spleen. Mice were 
sacrificed (by CO
2
 exposure) at various time points 
after the second injection (days 2, 4, 7, 14, 21, 28) and 
indicated organs were removed for analysis.
Diabetes incidence after treatment with clodronate-
loaded liposomes
Mice were followed until 35wks of age and the presence 
of glucose and ketones in the urine was measured weekly. 
A group of non-injected mice of the same age were used 
as control. At 35wks of age, mice were sacrificed and 
organs removed. Insulitis was characterized by analyzing 
the composition of islets with respect to the presence 
of insulin- and glucagon positive cells, T cells, DC or 
Mf in histological examination of sequential sections 
stained for each cell type, according to the staging 
established previously [3]. In addition, a numerical 
score was ascribed to the four stages as follows: stage 
0 (unaffected islets)–score 0, stage I+II (early para-
insular accumulation of DC and Mf, no T cells present, 
insulin+)–score 1, stage III+IV (para- and peri-insular 
accumulation of DC, Mf and T cells, insulin+)–score 2, 
stage V (infiltration of T cells into islets, insulin+)–score 
3, stage VI (end stage, insulin-)–score 4. In the latter case, 
islet remnants were identified by glucagon-labeling. A 
score was assigned to each counted islet and an average 
of all scores per 100 counted islets was calculated. 
Preparation of single cell suspension of circulating 
leukocytes and spleen
Blood was obtained by heart puncture after exposing the 
organ, and collected in heparin-coated tubes or in syringes 
containing 1ml PBS with 8mM EDTA. Erythrocytes were 
eliminated using lysing solution (BD Biosciences, San 
Diego, CA, USA) and leukocytes were washed twice by 
centrifugation at 400g in phosphate-buffered saline (PBS) 
supplemented with 0.5% BSA and 20nM NaN
3
 (further 
referred to as the FACS buffer). 
The spleen was cut into two parts. The larger part 
was used for histological analysis. The smaller part 
of the spleen was cut into small pieces and incubated 
for 1h at 37°C with collagenase-D (Roche Diagnostics 
GmbH; 0.27 U/mg) at a final concentration of 1mg/ml 
in RPMI-1640 medium supplemented with 60mg/ml 
penicillin and 100mg/ml streptomycin. The resulting 
digested tissue suspension was pushed through a 100mm 
cell strainer using a rubber-end of a 5ml syringe plunger 
and centrifuged. Subsequently, the cell suspension was 
washed with RPMI-1640 medium supplemented with 
antibiotics and 10% fetal calf serum (FCS). 
Spleen DC isolation by MACS procedure
DC were sorted from the spleen cell suspension by 
magnetic enrichment using auto-MACS. Cells were 
centrifuged, resuspended to obtain a concentration of 
108 cells in 400ml MACS buffer (PBS supplemented 
with 1% FCS and 2mM EDTA) and incubated with 
100ml CD11c microbeads (Miltenyi Biotec GmbH, 
Germany) for 30min on ice. Subsequently, cells were 
washed twice and then resuspended in MACS buffer 
to obtain a concentration of 108 cells/ml. The program 
for high purity of cells with low frequency was used on 
the autoMACS machine (Miltenyi Biotec GmbH) and a 
positive fraction was collected. In all experiments, the 
purity was higher than 95% as determined by subsequent 
flowcytometric analysis.
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Phenotypic analysis
The list of antibodies used in this study is given in the 
Table 1. Aliquots of 2x106 cells were incubated with the 
prepared mix of monoclonal antibodies. Each incubation 
step was performed at room temperature for 10min. All 
biotinylated antibodies were detected by streptavidin-
APC (BD Biosciences). Anti-CD71 was detected by 
R-PE labeled goat-anti-rat IgG (mouse-absorbed; 
GaRa-PE) purchased from Caltag Laboratories, San 
Francisco, CA.
marker
monoclonal 
antibody
conjugate origin
Ly-6G 1A8 PE BD Biosciencesa
Ly-6C ER-MP20 FITC own laboratory
CD11b / 
Mac-1 M1/70 PerCP BD Biosciences
CD11c N418; HL3 Æ
b;   
FITC, PE 
own laboratory;
BD Biosciences
CD43 S7 FITC, PE BD Biosciences
CD8a 53-6.7 FITC, APC BD Biosciences
F4/80 F4/80 FITC Caltag Lab, SanFrancisco, CA, USA
CD31 ER-MP12 bio own laboratory
CD45RB 16A FITC BD Biosciences
MHC class 
II (I-Ab) ER-TR3 bio
BMA Biomedicals AG,
Switzerland
MHC class 
II (I-Ag7) 10.2.16 bio own laboratory
CD80 16-10A1 PE BD Biosciences
CD86 GL1 FITC BD Biosciences
CD4 RM4-5 APC BD Biosciences
insulin Æb DAKO,Carpinteria, USA
glucagon Æb DAKO,Carpinteria, USA
CD3 KT3 Æb own laboratory
ER-MP23 ER-MP23 Æb own laboratory
BM8 BM8 Æb BMA Biomedicals AG,Switzerland
CD71 ER-MP21 Æb own laboratory
Mixed leukocyte reaction
The capacity of sorted spleen DC to activate allogeneic 
lymph node (LN) cells was measured as previously 
described [14]. Briefly, responder T cells, isolated 
from LN of C3H mice, and stimulator cells (DC) were 
resuspended in RPMI-1640 (with Hepes), 10% FCS 
(heat inactivated; 0.2 mm filtered), 60 mg/ml penicillin, 
100 mg/ml streptomycin, 20 mg/l sodium pyruvate and 
50 mM 2-ME (further referred to as MLR medium). T 
cells were resuspended at a concentration of 106/ml. The 
concentration of stimulator cells varied depending on 
the desired stimulator: responder cell ratio. The cells 
(100ml of each cell suspension) were incubated in 
round-bottom 96-well plates for 4 days at 37°C in 7% 
CO
2
. Stimulator and responder cells, incubated separately 
in MLR medium, were used as negative controls. 
Mitogenic stimulation of T cells by concanavalin A 
(final concentration 1.25 mg/ml) (Sigma Chemical Co., 
St. Louis, MO, USA) was used as a positive control for 
cell proliferation.
After 4 days of co-culture, cells were harvested 
and analyzed by flow cytometry. Triple labeling of cells 
with antibodies against CD4, CD8 and CD71 (anti-
transferrin receptor) was performed and 1.5 x 104 events 
were acquired within the live cell gate. Data analysis 
was performed using Cell Quest Pro analysis software. 
The percentage of CD71-positive T cells, as a measure 
of proliferating cells, was determined within the CD4+ 
and CD8+ population.
Immunohistochemistry
Pancreases were embedded in Tissue-Tek (Miles, 
Elkart, IN, USA) and frozen in liquid nitrogen. 
Cryostat sections (5mm thick) were cut at 100 or 
200mm intervals. Series of 5 or 6 pancreas sections 
cut at different levels were fixed for 10min in acetone 
containing 0.03% hydroxyperoxide to block endogenous 
peroxidases. PBS with 0.05% Tween-20 was used for 
the washing steps. Unconjugated primary antibodies 
specific for insulin, glucagon, T-cells (CD3), dendritic 
cells (CD11c) or subsets of Mf (ER-MP23 or BM8 
[15]) were subsequently detected with appropriate 
peroxidase-coupled- (DAKO, Glosstrup, Denmark) 
secondary antibodies in the presence of 1.5% normal 
mouse serum. The 3-amino-9-ethylcarbazole substrate 
(Sigma Co., St.Quentin Fallavier, France) dissolved in 
50mM sodium acetate/0.02% hydroxyperoxide was used 
to detect peroxidase activity. The resulting labeling was 
examined by light microscopy.
Results
Phagocyte depletion with lip-CL
2
MDP in 8 
week-old pre-diabetic NOD mice, significantly 
delays the onset of diabetes. 
To investigate the modulating effects of temporary 
phagocyte depletion on pancreatic inflammation 
and diabetogenesis, we treated NOD mice with 
two i.p. injections of lip-CL
2
MDP. This treatment 
Table 1. Monoclonal antibodies used in this study
aSan Diego, CA, USA; bunconjugated
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caused a significantly delayed onset of diabetes 
(p<0.01) (Fig. 1A). At the endpoint of our studies 
(35 weeks of age) the majority of treated NOD 
mice (73%) was still normo-glycemic. However, 
immunohistological examination of the pancreases 
of these mice showed that none of the mice had 
been permanently protected from insulitis. 
Leukocyte accumulations in the endocrine pancreas 
were present in all treated mice at 35 weeks of age. 
The infiltrates comprised DC, Mf and T cells and 
the infiltrates composition varied per individual 
islet, depending on the stage of the destructive 
process, as has been described before for non-
treated mice [3]. The insulitis severity score (Fig. 
1B) of the non-diabetic 35wk old treated NOD 
mice was comparable either to that of non-treated 
pre-diabetic (11wks old) or to the diabetic NOD 
mice. Hence, a two-fold injection of lip-CL
2
MDP 
strongly reduced the progression of the destructive 
process and significantly delayed the diabetes onset 
in majority of treated mice for 18-24 weeks. 
Monocytes, DC and Mf return rapidly to the 
spleen of NOD mice after the depletion.
We examined the effects of lip-CL
2
MDP on the 
disappearance of monocytes, DC and Mf from the 
circulation and the spleen of NOD mice as well as 
the kinetics of their repopulation and compared 
these parameters to those of identically treated 
C57BL mice. 
Blood monocytes were quantified using 
a recently established analysis [16] in which 
monocytes are gated as SSCloCD11bhi cells. Blood 
monocytes consist of an immature pool (Ly-6Chigh), 
readily recruited into inflammations, and mature 
monocytes (Ly-6Clow), a resident DC and Mf 
precursor pool [17]. For the quantification of DC 
and Mf in the spleen by a flow cytometric analysis, 
monoclonal antibodies against CD11c, CD8a, 
CD11b and F4/80 were applied simultaneously. 
This enabled definition of four distinct cell 
populations (Fig 2A). CD11c+ cells (gate: R1) were 
subdivided into CD11c+CD11bhiCD8a– (myeloid 
DC) and CD11c+CD11bloCD8a+ cells (CD8a+ 
DC). A third population, CD11c–CD11bhiF4/80+ 
(gate: R2), represent the red pulp Mf as verified 
by immunohistochemistry. The F4/80-negative 
fraction in the gate R2 were granulocytes. Finally, 
the CD11clowCD11bhi cells (gate: R3) formed a 
fourth population; these cells were F4/80low, Ly-
6Clow/med, CD43+, CD31+ and correspond to the 
mature blood monocytes as we have recently 
defined [16]. 
Treatment with lip-CL
2
MDP (i.v.) causes 
the virtually complete depletion of circulating 
monocytes during the first hours, followed by a 
rapid return [16]. Starting from the day 2 after the 
i.p. treatment, the pool of Ly-6Chigh monocytes did 
not change. In contrast, the Ly-6Clow monocyte 
population was almost completely depleted at 
Figure 1. A short-term treatment of 8-week-old NOD mice with lip-CL2MDP induced a significant delay of diabetes 
onset, resulting in strongly reduced incidence at 35 weeks of age. A. Kaplan-Meier analysis of the diabetes incidence 
in treated and untreated mice. The Log Rank statistical test was performed to compare the Kaplan-Meier curves (p<0.01). 
B. Insulitis score of control untreated C57BL mice (empty triangles), untreated NOD mice at age 11 weeks and 17 weeks 
(diabetic) (empty squares) and treated NOD mice at 35 weeks of age (filled squares). Symbols represent the values of 
the insulitis score of mice, individually. For a description of scoring, see the Material and Methods section
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Figure 2. Normal maturation kinetics of the NOD DC and Mf compartment after lip-CL2MDP in the spleen. A. Phe-
notypic definition of spleen DC and Mf populations according to CD11b and CD11c expression. Histograms represent the 
expression profile for a given marker of cells that belong to the indicated gate. CD11chi cells (Gate:R1) can be divided into 
CD8+ DC and myeloid DC (CD8–). The F4/80+ population within CD11c–CD11bhi cells (Gate:R2) represent the red pulp Mf 
(verified by immunohistochemistry). The CD11cloCD11bhi (gate: R3) cells correspond to mature blood monocytes and are 
F4/80lo, Ly-6Clo/med, CD43+, CD31+ and CD45RB+. The vertical line represents a negative control limit. B. Time course of 
the depletion and repopulation of the myeloid cells in the spleen as defined by phenotype in A. Each bar represents an 
average value of a minimum of 3 mice per mouse strain per time point. P-values indicated graphs represent the statistical 
significance (Student’s t-test) of the indicated time point vs. the point 0 in a given mouse strain.
A
B
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day 2 and significantly reduced until the end of 
the observation period (day 28) (Table 2). Similar 
kinetics were found for the C57BL control mice 
(not shown).
Time 
point 
(days) All monocytes
Inflammatory      
Ly-6Chi            
monocytes
Mature          
Ly-6Clo          
monocytes
0 13.03 ± 1.36 a 4.47 ± 0.33 8.56 ± 1.05
2 5.83 ± 0.57* 5.28 ± 0.61 0.55 ± 1.07**
4 9.74 ± 0.81 5.87 ± 1.72 3.87 ± 0.04*
7 10.87 ± 1.49 5.97 ± 1.04 4.90 ± 0.74*
14 14.04 ± 3.51 9.73 ± 2.68 4.31 ± 0.93*
28 12.26 ± 1.59 7.37 ± 1.57 4.89 ± 0.83*
second injection, the red pulp was devoid of viable 
F4/80 or CD11c positive cells (Fig. 3C and 3D). 
The remaining F4/80 and CD11c positive labeling 
in the white pulp at day-2 resembled non-viable 
pycnotic cells that lacked a typical membrane 
staining as present in the spleen of non-treated 
control mice (Fig. 3A and 3B).
F4/80+ cells started to return to the red pulp 
from day 4 post-injection onwards (Fig. 3F) and 
at day 7 (Fig. 3H) the number and the distribution 
of the F4/80 positive population were comparable 
to non-depleted control mice. The repopulation of 
the spleen by CD11c+ cells also started at day 4 
(Fig. 3E) and at day 7 CD11c+ cells in NOD mice 
had regained their normal staining pattern as 
compared to the non-treated controls (Fig. 3G). In 
addition, other Mf populations like metalophillic 
(MOMA-1+) and marginal zone (ER-TR9+) Mf 
were depleted in NOD mice by lip-CL
2
MDP in the 
same fashion as has been reported for other mouse 
strains [18]. These cells, however, only reappeared 
several weeks after depletion (data not shown). 
Taken together, the kinetics of depletion and 
repopulation by different populations of splenic 
DC and Mf in NOD mice is fully comparable with 
the repopulation in C57BL mice.
A normal phenotype and function of re-
populated spleen DC in NOD mice after the 
depletion
Despite the rapid return, we argued that the 
treatment with lip-CL
2
MDP may have caused 
a modulation of the function of the returning 
phagocytes, contributing to an altered role in 
diabetogenesis. Therefore, we compared the 
phenotype and the function of spleen CD11c+ 
cells, isolated by an autoMACS procedure, from 
treated (day 7 post-injection) and from non-treated 
NOD and C57BL mice. Although we utilized a 
high purity separation program, both CD11chigh 
and CD11clow cells were isolated, based on the 
phenotypic analysis (Fig. 4A). We found no 
difference in the cell yield between NOD and 
C57BL mice from both untreated and treated 
mice. Also, the isolated CD11c+ cells from treated 
mice displayed the same expression of MHC class 
II and of the co-stimulatory molecules CD80 and 
CD86 in comparison to such cells isolated from 
non-treated mice (Fig. 4A). In addition, the T-cell 
Table 2. Kinetics of the blood monocytes repopulation in 
NOD mice after lip-CL2MDP treatment
Mature monocytes, DC and Mf in the spleen 
were clearly depleted at day 2 after the last injection 
of lip-CL
2
MDP (Fig 2B). All four investigated cell 
groups were present in the spleen of the treated 
mice, starting from day 4 in both mouse strains. 
Myeloid DC reached steady state levels in the 
second week post-treatment, while CD8a+ DC 
needed more than two weeks to normalize (Fig. 
2B - upper row). Similar kinetics were found for 
the NOD and C57BL mice. Red pulp Mf were 
restored almost instantly: despite a short initial 
drop, the rate of NOD red pulp Mf remained stable 
at the steady state level with even a slight increase 
at day 11. However, in C57BL mice, the frequency 
of red pulp Mf remained significantly higher till 
the end of the observation period. Splenic mature 
monocytes were also depleted at day 2, but returned 
to normal levels shortly thereafter and remained 
stable from day 4 onwards in both mouse strains 
(Fig. 2B - lower row). 
Observations in flow cytometric analysis are 
confirmed by the immunohistological analysis 
Immunohistological analysis of CD11c+ (myeloid 
DC and CD8+ DC) and F4/80+ cells (mature 
monocytes and Mf) in the spleen indicated the 
same kinetics as the flow cytometric analysis. As 
shown in Figure 3, treatment with lip-CL
2
MDP 
induced a complete depletion of both Mf and DC 
from the spleen of NOD mice: 2 days after the 
a data represent mean ± SEM 
 *p<0.05; **p<0.01 vs. 0 time point
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stimulating capacity of the isolated DC co-cultured 
with allogeneic LN cells was similar before and 
after the treatment, in both mouse strains (Fig. 4B). 
Similar proportions of allogeneic CD4+ or CD8+ T 
cells had up-regulated CD71 (transferrin-receptor), 
irrespective of the fact that the cells isolated from 
treated mice had a higher proportion of mature 
monocytes than before treatment. 
Lip-CL
2
MDP treatment leads to a late 
disappearance of DC and Mf from the NOD 
pancreas
To examine the effect of lip-CL
2
MDP treatment 
on the target organ inflammation, pancreases were 
removed before and after the injections (at days 0, 
2, 4, 7, 14 and 28 post-treatment), and the presence 
of the different cell populations was examined by 
immunohistochemical staining. 
Untreated (8wk old) NOD mice had a 
considerable lymphocytic peri- and intra-islet 
infiltration. BM8+ and ER-MP23+ Mf (Fig. 5) 
were found scattered throughout the pancreas and 
most likely represent resident Mf. Unlike Mf, DC 
(CD11c+) were localized only in close proximity 
Figure 3.  
Immunohistochemical analysis of the 
distribution of CD11c+ and F4/80+ cells 
in the NOD spleen at different time 
points after lip-CL2MDP treatment. 
A-B. Distribution of cells before the 
treatment. C-D. At day 2 after injection 
DC and Mf were completely depleted 
from the spleen red pulp. E-F. The return 
of F4/80+ cells in particular, is evident 
already at day 4 after injection. G-H. 
Normal distribution of CD11c+ and F4/80+ 
cells was observed from days 14 and 7 
after the depletion, respectively. 
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to the islets and not in the intra- and interlobular 
septa of the exocrine pancreas (Fig. 7A).
The treatment with lip-CL
2
MDP had no 
immediate effect on pancreas Mf and DC, unlike 
hitherto observed in the spleen and the circulation. 
However, starting from day 4 after the treatment, 
we observed reduced numbers of BM8+ and 
ER-MP23+ Mf in both exocrine and endocrine 
pancreas. The decline in the Mf number further 
continued and many islets were clear from Mf 
(Fig. 5C and 5D). Quantification of Mf-containing 
islet-inflammations at day-7 post-treatment showed 
that about 95% of islets were free of Mf (Fig. 
6A) and the frequency of islets that contained 
Mf was almost as low as in C57BL mice of the 
same age. Additionally, at day 14 after injection, 
many islets and exocrine lobes were devoid of 
Mf (Fig. 5E, 5F and 6A). The distribution of the 
few remaining Mf had also drastically changed as 
they were found only in confined areas such as the 
inter-lobular connective tissue, but not associated 
with endocrine or exocrine cells. At 28 days after 
treatment Mf had reappeared again at the islet 
periphery (Fig. 5G and 5H). 
Similar to Mf, the number of pancreatic DC 
declined from day 4 after treatment onwards (Fig. 
6B). At days 7 and 14, the short-term injection 
of lip-CL
2
MDP had almost completely depleted 
DC from NOD pancreases. When quantified, the 
number of DC-free islets was similar to the number 
of Mf-free islets (Fig. 6B). Also like Mf, DC were 
again present in islets at day 28 after lip-CL
2
MDP 
Figure 4. Phenotype and T cell stimulatory capacity of DC isolated from spleens from treated or untreated NOD 
and C57BL mice. A. Isolated CD11c+ cells from the spleens of treated or untreated NOD and C57BL mice showed a 
normal mature DC phenotype. Histograms display the marker expression in the autoMACS-isolated population. The gray 
line represents the negative isotype control, the thin-black line the marker expression by cells isolated from untreated 
mice and the thick-black line the expression pattern of cells isolated from treated mice at day 7 after treatment. B. The 
stimulation capacity of isolated DC was the same in NOD and C57BL mice irrespective of whether DC were derived from 
treated or untreated mice. Stimulation of CD4+ and CD8+ cells was measured as a percentage of cells that have upregulated 
expression of transferrin-receptor (CD71) on their surface. Representative histograms (in A.) and average values ± SEM 
(in B.) of three separate pools from two independent experiments for each group are shown in the figure. 
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injection (Fig. 7).
The loss of Mf and DC from NOD pancreas 
leads to a prolonged disappearance of 
lymphocytes 
In parallel with the loss of Mf and DC, we 
observed a disappearance of lymphocytes from the 
pancreases of treated mice (Fig. 6B). The decline in 
DC and Mf numbers at day 4 already led to the loss 
of lymphocytes from the pancreatic infiltrates (not 
shown). This phenomenon was more prominent 
at days 7 and 14 after treatment and observed in 
parallel with the absence of DC (Fig. 7 C-F). At 
day-28, when a substantial number of DC and 
Mf had returned to the pancreas, T cells also re-
appeared. B cells demonstrated a similar kinetics 
as T cells. At day-4, the numbers of B cells started 
to decline and the cells had completely disappeared 
by day 7. Interestingly, B cells seemed to require 
other conditions to infiltrate the pancreas again, as 
they did not reappear by day-28 but returned to the 
pancreas much later, i.e. at day-49 post-treatment 
(data not shown).
Figure 5. 
Prolonged disappearance of Mf from 
the pancreas of NOD mice after lip-
CL2MDP treatment. A-B Peri- and intra-
islet infiltrates from untreated 8wk old 
NOD mice contain BM8+ and ER-MP23+ 
Mf. Both subsets of Mf were also found 
scattered throughout the connective 
tissue of the exocrine pancreas. C-D. 
From day 7 after lip-CL2MDP treatment 
a considerable amount of resident Mf 
had disappeared from the endocrine 
pancreas. E-F. At day 14, the pancreas 
is found similarly devoid of Mf as at day 
7. G-H. Mf were again detectable at day 
28 after the lip-CL2MDP treatment and 
present in the close proximity of pan-
creatic islets. 
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Discussion
In this study we bring to light three important 
findings related to the role of dendritic cells (DC) 
and macrophages (Mf) in the development of 
insulitis and diabetes in the NOD mouse model. 
First, a short-term treatment with lip-CL
2
MDP 
given in the stage of a progressing peri-insulitis (8 
weeks of age) was sufficient to induce a significant 
decline in the number of Mf and DC in the islet 
vicinity for a period of at least three weeks in 
NOD mice. Second, the lasting loss of DC and 
Mf from the pancreas revealed an essential role of 
these cells in the local recruitment and retention of 
lymphocytes. Lymphocyte infiltrations dissolved 
completely when the DC/Mf pool was absent 
and reappeared only upon return of DC and 
Mf in close proximity to the endocrine tissue. 
Third, the depletion of the DC and Mf did not 
happen concomitantly in the pancreas and in 
the circulatory compartment. Monocytes, DC 
and Mf were depleted and rapidly returned to 
the circulation and the spleen within one week 
with similar kinetics in NOD and control mice, 
whereas in the pancreas their disappearance 
started at the end of the first week. Furthermore, 
in line with the observed changes in the pancreas, 
Figure 6. Differential analysis of the islets with inflammatory infiltrations before and after lip-CL2MDP treatment. 
The treatment significantly decreased the frequency of islets infiltrated with Mf and DC, which directly correlated to the 
disappearance of lymphocytes from the pancreas. A. Correlation of the Mf presence with islet infiltration, at different time 
points. Light-grey bars represent the percentage of infiltrated islets, determined by morphological examination of glucagon-
positive islets. Dark-grey bars show the frequency of islets associated with ER-MP23+ Mf and black bars represent values 
for the BM8+ Mf; before the treatment, at different post-treatment time points and in untreated C57BL mice. B. Correlation 
of a DC loss with the departure of T cells, in the pancreas of treated mice. Black bars represent the percentage of islets 
that contained CD11c+ DC and light-grey bars the percentage of islets that contained T cells in NOD mice, like in A. All 
bars show the average value (±SEM) calculated from 3 or 4 mice per group for each strain and each time point.
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the diabetes onset and incidence were strongly 
delayed and decreased, respectively, after short-
term lip-CL
2
MDP-treatment of NOD mice at 8 
weeks of age.
It is well known that an i.p. injection of lip-
CL
2
MDP depletes Mf from the spleen, peritoneal 
cavity and the omentum [19], but the pancreas 
has not been included in such previous depletion 
studies. Our study shows that i.p. injections of 
lip-CL
2
MDP also influence the accumulation 
of monocytes, Mf and DC in the pancreas. 
Remarkably, however, when we compared the 
effects of depletion in the pancreas with that of the 
spleen/circulation, we observed different kinetics 
of disappearance and return of the phagocytes: DC 
and Mf took a week longer to disappear from the 
pancreas. Unfortunately, we cannot readily explain 
these differential disappearance patterns. 
The return of mature monocytes to the 
circulation and the spleen, preceded the return of 
DC and Mf. This supports the view that spleen 
APC originate from blood monocytes. Treatment 
with lip-CL
2
MDP ineffectively deplete phagocytes 
in the connective tissue [20]. Indeed, the delayed 
disappearance of pancreatic DC and Mf upon 
treatment strongly suggests that liposomes do 
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not reach these phagocytes directly. Instead, it is 
more likely that the natural turnover of the cells, 
under conditions when the precursors might 
be lacking, causes their decline. It is however 
difficult to understand why monocytes did not 
rapidly replenish DC and Mf in the pancreas, 
like they do in other target organs such as spleen 
and liver, since the disappearance of pancreas DC 
and Mf started when monocytes were back in the 
circulation.
One possible explanation is that pancreas DC 
and Mf might originate from other precursors 
than those found in the circulation. The origin 
of pancreas resident Mf and DC is not known. 
They might develop from intra-organ precursors, 
like in the skin [21], or from precursors that 
reside in the vicinity of the pancreas. In this 
context it is noteworthy that i.p. application of 
lip-CL
2
MDP to rats induced a depletion of Mf in 
the peritoneum and omentum within two days, but 
the repopulation of the omental Mf was not seen 
within the next 23 days [22]. This “postponed” 
pattern of re-appearance overlaps with the here 
described slow pattern of re-appearance of Mf 
and DC in the pancreas and this might either 
point to the omentum as a source of precursors 
Figure 7. 
The presence of T cells correlated 
directly with the DC in the pancreas 
of NOD mice. A-B. Before the 
treatment with lip-CL2MDP, DC were 
found in the close proximity of T cells 
as judged by the immunohistochemical 
analysis of serial sections of the NOD 
mouse pancreas. C-D. At day 7 after 
the treatment, DC had disappeared 
from the pancreas and T cells as well. 
E-F. Islets that were free of DC were 
also free of lymphocytic accumulations 
in the pancreas, at day 14 after the 
treatment. G-H. At 28 days after the 
treatment, return of DC was found in 
a few islets, paralleled by the return 
of T cells.
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for pancreas DC and Mf, or to a shared precursor 
of omental and pancreas DC and Mf. Further 
investigation is needed to evaluate whether such 
peripheral precursors might be affected by the 
i.p. lip-CL
2
MDP treatment more extensively than 
the circulating monocytes. Alternatively, the lip-
CL
2
MDP treatment does interrupt the continuous 
influx of monocytes into the pancreas for several 
days and thereby also the production of appropriate 
chemoattractants for other inflammatory cells [23, 
24]. In this case, the dynamic inflammatory process 
might be transiently interrupted and subsequently 
slowly restored, similarly to what has been 
demonstrated previously [25].
A role for DC in the NOD lymphocyte 
accumulation has been suggested previously. 
The administration of streptozotocin (STZ) to 
C57BL/6 mice, an induced diabetes model, led to 
an accumulation of DC in the pancreas, followed 
by an enhanced expression of adhesion molecules 
on the pancreatic endothelium and an increased 
adherence and infiltration of lymphocytes [26]. 
Furthermore, lymphocyte adhesion and infiltration 
decreased upon silica-mediated depletion of the 
Mf additionally suggesting that the Mf were 
involved in the recruitment of lymphocytes [27, 
28]. The DC and Mf possibly act by inducing the 
addressins VCAM-1, MAdCAM-1 and ICAM-1 
on the pancreatic endothelium [5, 29, 30]. The 
dependence of lymphocyte infiltration on Mf 
and DC has also been shown in other situations. 
Elimination of phagocytic cells by lip-CL
2
MDP 
reduced the lymphocytic infiltration of transplanted 
fetal pig pancreas xenografts in NOD mice [31]. In 
addition, the loss of marginal zone Mf as the result 
of chronic Leishmania infection severely abrogated 
normal trafficking of lymphocytes into the white 
pulp of the spleen [32]. 
The responsible Mf or DC-derived factor 
that initiates the infiltration and maintenance 
of lymphocytes in the pancreas has not been 
identified thus far. Several chemokines like IP-
10, MCP-1 and RANTES have been implicated 
in the attraction of monocytes and Th1-cells 
to the pancreatic islets during the progression 
of autoimmune diabetes [33-36]. Although the 
expression of some of these chemokines was 
found to be islet-specific, DC and Mf are also able 
to make other suitable chemokines that possibly 
attract and retain lymphocytes to the pancreas. 
In conclusion, a depletion of DC and Mf via a 
regimen of two injections of lip-CL
2
MDP in the 
stage of a progressing peri-insulitis (at 8 weeks 
of age) was sufficient to clear DC and Mf almost 
completely from the pancreas, and to delay the 
re-appearance of these cells considerably. The 
presence of DC and Mf in the pancreas dictated 
the presence of lymphocytes, which should be 
taken in account for developing possible new 
treatments for diabetes.
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The lineage relationship of dendritic cells (DC) with other hematopoietic cell types has 
been studied extensively, resulting in the identification of different bone marrow (BM) 
progenitors that give rise to distinct DC types. However, the identity of the different 
maturation stages of DC precursors in the BM remains unclear. In this study we define 
the in vivo developmental steps of the myeloid DC lineage in mouse BM. To this end, BM 
cells were separated according to their expression of CD31 (ER-MP12), Ly-6C (ER-MP20) 
and ER-MP58 antigens, and stimulated to developinto myeloid DC, using granulocyte 
macrophage colony stimulating factor as a specific growth factor. DC developed from 
three BM subpopulations: ER-MP12high/20- (early blast cells), ER-MP12+/20+ (myeloid 
blasts) and ER-MP12-/20high (monocytes). The kinetic and phenotypic features of DC 
developing in vitro indicate that the three populations represent successive maturation 
stages of myeloid DC precursors. Within the earliest ER-MP12high/20- population, DC 
precursors exclusively occurred in the myeloid-restricted ER-MP58high subset. By using 
switch cultures, we show that these BM precursor subpopulations, when stimulated to 
develop into macrophages using macrophage colony stimulating factor, retain the ability 
to develop into myeloid DC until advanced stages of maturation. Together, these findings 
support a common ER-MP12/20-defined differentiation pathway for both macrophages 
and myeloid DC throughout their BM development.
Dendritic cells (DC) are bone marrow (BM)-derived cells that have the unique capacity to initiate a primary immune response by 
efficient antigen presentation to naive T cells. The 
DC system is widely distributed throughout the 
body, and comprises Langerhans cells in epithelial 
locations, veiled cells in lymph, interdigitating 
cells in lymphoid organs and interstitial DC 
in connective tissue of non-lymphoid organs 
[1]. Many studies in the past few years have 
addressed the lineage relationships of DC with 
other hematopoietic lineages. Mainly, DC of two 
possible origins, lymphoid and myeloid, have 
been identified in human and mouse. Both types 
have been shown to originate from the BM from 
which they can be derived in vitro by stimulation 
with different growth factors [2-4]. Myeloid DC 
have been generated in vitro from early common 
myeloid progenitors in BM and from monocytes 
in peripheral blood using granulocyte macrophage 
colony stimulating factor (GM-CSF) as a growth 
stimulus. In contrast, using Flt-3 ligand (Flt-3L), 
both myeloid and lymphoid DC can be generated 
in vitro from BM [5-7]. A progenitor population 
for human lymphoid DC, which also can give rise 
to lymphoid cells, has been identified in BM and 
thymus [3]. However, data about this DC lineage 
in the mouse are inconclusive since the identity 
of the mature lymphoid DC has been unclear. An 
earlier study on mouse thymic DC precursors has 
suggested CD8a as a marker of the lymphoid-
related DC lineage [8]. More recent reports, 
however, show that CD8a is not a reliable marker 
for lymphoid DC since it can be expressed also on 
myeloid DC [9] and that CD8a+ DC can be derived 
from myeloid progenitors [10]. A new candidate 
for the lymphoidrelated DC in the mouse has been 
proposed [11-13] which shows characteristics 
equivalent to those of human plasmacytoid DC 
(PDC).
The developmental plasticity inherent to the DC 
system has been demonstrated in different studies, 
showing that both common lymphoid and common 
myeloid progenitors are able to differentiate into 
different types of DC [14-16]. The studies by Manz 
et al. and Mebius et al. indicated that both types of 
progenitors give rise to both CD8a+ and CD8a– DC 
in vitro and in vivo [14,15], while Izon et al. showed 
a previously unrecognized link between early B 
cell and DC ontogeny [16]. Furthermore, recent 
experimental evidence suggests the existence of a 
common DC precursor in the BM [17] as well as 
in the peripheral blood [18] for CD8a+, CD8a– and 
presumed PDC.
The studies cited above were mainly directed 
to define the origins of the different DC types and 
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to identify their precursors in the BM. However, 
the identification of the different developmental 
stages of DC precursors in the BM still remains 
unclear. In this study, we have investigated in 
mouse BM the in vivo differentiation pathway of 
myeloid DC progenitors identified by differential 
ER-MP12/CD31 and ER-MP20/Ly-6C expression. 
In addition, we addressed the developmental 
relationship of myeloid DC precursors with 
macrophage precursors.
Material and Methods
required. Prior to phenotypic analysis, cultured cells 
were washed with PBS supplemented with 0.5% (v/v) 
BSA (Organon Teknika, Boxtel, The Netherlands) and 
20 mM sodium azide. 
Cell sorting and flow cytometric analysis
For cell sorting, BM cells were labeled with two (ER-
MP12 and ER-MP20) or three (ER-MP12, ER-MP20, 
and ER-MP58) mAb as described previously (20,21). 
Prior to sorting (FACS Vantage; Becton Dickinson, 
Amsterdam, The Netherlands), cell suspensions were 
Æltered over a 30-mm sieve (Polymon PES; Kabel, 
Amsterdam, The Netherlands) to avoid clogging of the 
nozzle. After sorting, the purity of the cell suspensions 
was checked by re-running sorted samples. Purity was 
>95%, unless stated otherwise. Suspensions were kept at 
4°C throughout the staining and sorting procedure. Sorted 
cells were counted in a Bürker hemocytometer.
For flow cytometric analysis, samples of cultured cells 
(> 2x104 cells) were aliquoted into 96-microwell plates 
(round bottom; Nunc, Roskilde, Denmark) and labeled 
with antibodies as described before [21]. Samples were 
analyzed on a FACSCalibur flow cytometer using 
CellQuest analysis software (Becton Dickinson).
Immunocytochemistry on poly-L-lysine-coated 
slides
For immunocytochemical analysis, aliquots of cultured 
cells were placed at 37°C, 7% CO
2
 in complete medium 
for 1 h to adhere to poly-L-lysine-coated microwell 
slides (Nutacon, Schiphol-Oost, The Netherlands). 
Next, cell preparations were gently washed once with 
PBS (37°C), fixed in 1% paraformaldehyde in PBS for 
10 min at room temperature, and washed with PBS and 
with PBS supplemented with 0.5% BSA. Cells were 
incubated with primary mAb, followed by rabbit anti-rat 
IgG conjugated to horseradish peroxidase (HRP; Jackson 
ImmunoResearch, West Grove, PA) (both incubations 
30 min at room temperature). Diaminobenzidine (DAB; 
Sigma, St Louis, MO) was used as substrate. Between 
incubations, cell preparations were washed in PBS 
supplemented with 0.5% (v/v) Tween 20. After the DAB 
reaction was completed (3-5 min at room temperature), 
the cell preparations were dehydrated and coverslipped 
using Entallan (Merck, Darmstadt, Germany). Antibody 
reactivity was determined under a light microscope. 
Culture supernatant of the Y3 myeloma followed by the 
second stage antibody was used as negative control.
Growth factors
Conditioned medium of LADMAC cells was used as a 
source of mouse macrophage colony stimulating factor 
(M-CSF) [23]. Conditioned medium was prepared as 
described elsewhere (19). Recombinant mouse GM-CSF 
Mice
Female C57BL6/J and C57BL6/Ly-5.1-Pep mice 
between 11 and 13 weeks of age were used in this 
study. Female C3HeB/Fej mice were used as a source 
of allogeneic responder T cells. Animals were specific 
pathogen free, and kept with free access to food and 
water in the animal care facility at the Erasmus University 
Rotterdam under the institutional guidelines for usage of 
experimental animals.
mAb and conjugates
mAb used for cell sorting, flow cytometric analysis, 
immunocytochemistry and read out of T cell activation 
in the mixed leukocyte reaction (MLR) were either 
generated in ourlaboratory or obtained from BD 
PharMingen (Alphen aan de Rijn, The Netherlands). 
These were: biotinylated ER-MP12 (anti-CD31); 
FITC-ER-MP20 (anti-Ly6C); undiluted hybridoma 
culture supernatants ER-MP58 (19,20), ER-MP21 
(anti-CD71/transferrin R) and M5/114 (anti-MHC class 
II), obtained in our laboratory; and 53-6.7-FITC (anti-
CD8a), RM4-5-PE (anti-CD4) and HL3-phycoerythrin 
(PE) (anti-CD11c) purchased from BD PharMingen. 
Biotinylated ER-TR3 (anti-MHC class II) antibody 
was kindly provided by BMA Biomedicals (Augst, 
Switzerland). PE-streptavidin, TriColor-streptavidin 
and PE-goat anti-rat IgG (mouse absorbed) were used 
as conjugates (Caltag, San Francisco, CA). 
Cell suspensions
Single-cell suspensions of BM, isolated from femora 
and tibiae, were prepared as described previously 
[20,21]. Similarly, single-cell suspensions of spleen 
and lymph nodes were prepared and used for T cell 
isolation as described [22]. Cultured BM-derived DC 
were isolated from Teflon culture bags or from culture 
plates. Cells were washed in PBS supplemented with 
5% FCS (heat inactivated), 60 mg/ml penicillin and 
100 mg/ml streptomycin when sterile suspensions were 
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(rGM-CSF) was purchased from Biosource International 
(Camarillo, CA).
rGM-CSF- and M-CSF-stimulated BM cultures
DC were generated by culturing total BM or isolated 
subsets in Teflon culture bags [24] or 24-well plates 
(Nunc) in RPMI-1640 (no HEPES; Biowhittaker, 
Verviers, Belgium) supplemented 516 Myeloid DC 
development in mouse BM with 10% FCS (heat 
inactivated; 0.2 mm filtered), 60 mg/ml penicillin, 100 
mg/ml streptomycin and 20 ng/ml rGM-CSF. Cells were 
cultured at 37°C, 7% CO
2
 for various periods of time, as 
indicated, for up to 14 days. Differentiation of isolated 
BM subsets, to macrophages, was induced by culturing 
in Teflon culture bags (24) in IMDM (with glutamax 
I; Gibco, Invitrogen BV, Breda, The Netherlands) 
supplemented with 20% FCS (heat inactivated; 0.2 
mm filtered), 15% LADMACconditioned medium as a 
source of M-CSF, 100 mM 2-mercaptoethanol, 60 mg/
ml penicillin and 100 mg/ml streptomycin. Cells were 
cultured for 4 or 5 days at 37°C, 7% CO2 as indicated.
MLR
In vitro generated DC (stimulator cells) and T cells 
(responder cells) isolated from the spleen and lymph 
nodes were resuspended in RPMI 1640 supplemented 
with 25 mM HEPES, 10% FCS (heat inactivated; 
0.2 mm filtered), 60 mg/ml penicillin, 100 mg/ml 
streptomycin, 20 mg/l sodium pyruvate and 50 mM 2-
mercaptoethanol (further referred to as MLR medium). 
T cells were resuspended at a concentration of 2 x 
106/ml and the concentration of DC varied depending 
on the desired ratio of DC:T cells. The cells (100 ml of 
each cell suspension) were incubated in round-bottom 
96-well plates for 4 days at 37°C, 7% CO
2
. DC and T 
cells, incubated separately in MLR medium, were used 
as negative controls. Mitogenic stimulation of T cells by 
concanavalin A (final concentration 1.25 mg/ml) (Sigma) 
was used as a positive control. 
After 4 days of co-culture, cells were harvested and 
analyzed by flow cytometry. Triple labeling of cells 
with anti-CD4, anti-CD8 and ER-MP21 antibodies 
was performed, and 15,000 events within the living 
gate was acquired. Analysis was performed using 
CellQuest analysis software. The percentage of ER-
MP21 (CD71/transferrin R) positive cells, as a measure 
of proliferating cells, was determined within the 
CD4+ and CD8+ population. This method of analysis 
provides comparable results to those obtained with 
the [3H]thymidine incorporation method (unpublished 
results) and in addition allows us to analyze, in more 
detail, the characteristics of the responding T cell 
population.
Results
Distinct DC precursors in the BM can be 
identified by ER-MP12/20 labeling 
Based on ER-MP12/CD31 and ER-MP20/Ly-
6C expression, we can fractionate BM into six 
separate, morphologically and phenotypically 
distinct subsets (Fig. 1) as we showed previously 
[25,26]. We also demonstrated that in this way 
the different hematopoietic lineages (lymphoid, 
erythroid, granulocytic and monocytic) and three 
different stages of macrophage precursors could 
be distinguished [21,26]. To examine in which of 
the cell populations DC precursors were present, 
BM subsets were sorted and cultured with GM-
CSF. At day 10 of culture, the development of 
DC was evaluated by examining the cultures 
under an inverted light microscope (Table 1). DC 
were clearly visible in cultures derived from ER-
MP12high20–, ER-MP12+20+ and ER-MP12–20high 
subsets. No DC or other cell types could be grown 
from the ER-MP12med20–, ER-MP12–20– and ER-
MP12–20med subsets by GM-CSF stimulation. The 
latter BM subsets consisted of morphologically 
identifiable cells of the lymphoid, erythroid and 
granulocytic lineage respectively [21,26].
Figure 1. Flow cytometric dot-plot of ER-MP12/20-
labeled BM cells. Upon double labeling of BM cells with 
these mAb, six distinct subsets can be discerned. Gates 
used for cell sorting are shown. Percentages are the mean 
of five experiments.
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The presence of DC in cultures was also 
examined by assessing MHC class II expression 
in immunocytochemistry (Fig. 2). DC derived 
from different precursor populations showed the 
same typical DC morphology with MHC class II 
molecules present preferentially on the cell surface. 
However, the frequency of MHC class IIhi DC at 
day 6 (Table 1) in the ER-MP12high20– culture 
was lower than that in the ER-MP12+20+ and ER-
MP12–20high cultures (an average of 6 versus 33 and 
25% respectively), suggesting that precursors from 
the ER-MP12high20– population needed more time 
to develop into DC. This was in agreement with the 
results from visual examination of the cultures. By 
day 10, the frequency of DC had increased in the 
cultures derived from the ER-MP12high20– subset 
(on average 12%), but was still lower than that in 
the ER-MP12+20+ (16%) and ER-MP12–20high (on 
average 37%) subsets. In conclusion, on the basis 
of differential ER-MP12 and ER-MP20 expression, 
we can distinguish three subsets in mouse BM from 
which DC can be derived with GM-CSF.
DC derived from different ER-MP12/20 
populations develop into fully mature cells
Immature and mature DC differ in the level of 
MHC class II molecule expression on their surface. 
To determine the maturation state of DC derived 
with GM-CSF from different BM subpopulations, 
we double-stained cells at the end of culture with 
CD11c and anti-MHC class II antibodies. On 
the gated CD11c+ population, we measured the 
expression of MHC class II molecules (Fig. 3A): 
30, 76, 76 and 91% CD11c+MHC class IIhi mature 
DC were present in cultures derived from ER-
MP12high20–, ER-MP12+20+, ER-MP12-20high and 
TBM respectively. In addition, all cultures contained 
a relatively low percentage of CD11c+MHC class 
IIlow immature DC, except for the culture derived 
from the ER-MP12high20– DC precursors in which 
a significant amount of DC was still immature 
(50%). These immature cells responded very 
well to overnight lipopolysaccharide (LPS) 
stimulation as this induced a significant increase 
of the percentage of mature CD11c+MHC class IIhi 
cells (Fig. 3B). All cultures contained also some 
CD11c–MHC class II– cells (not shown), which 
are mainly granulocytes also developing in vitro 
with GM-CSF.
To investigate the functionality of DC derived 
from different precursor subpopulations, we 
assessed their antigen-presenting capacity by 
co-culturing GM-CSF derived cells with purified 
T cells (Fig. 3C). DC derived from all three BM 
subpopulations were good activators of T cells. The 
MLR stimulatory capacity was enhanced after LPS 
stimulation, particularly in the culture derived from 
the ER-MP12high20– subpopulation when tested at 
lower DC:T cell ratios.
Three ER-MP12/20-defined subpopulations 
represent successive maturation stages of DC 
precursors in the BM
Morphological and functional analysis of DC 
cultures showed that different BM subpopulations 
develop with different kinetics into similar DC, 
aDuring entire culture.
bResults are for Experiments I and II as they were identical.
ND, not enough cells present on the poly-L-lysine-coated slides to determine percentage MHC class II+ cells.
Table 1. DC-like cells generated from ER-MP12/20 bone marrow subsets
BM subset
Overall 
cell 
growtha)
DC-like cells visible in 
cultureb)
% of MHC II++ cells with DC morphology 
(immunocytochemistry)
day 6 day 10 day 6 day 10
Exp.  I II I II
ER-MP12hi20– + ± + 6 ND 15 9
ER-MP12med20– – – – – – – –
ER-MP12–20– – – – – – – –
ER-MP12+20+ + + + 20 43 16 ND
ER-MP12–20med – – – – – – –
ER-MP12–20hi + + + 23 26 40 33
TBM + + + 19 ND 23 ND
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which suggests that precursors in these populations 
might be in a different maturation stage at the time 
of isolation. To investigate this, we sorted the ER-
MP12high20–, ER-MP12+20+ and ER-MP12–20high 
subpopulations from the BM, stimulated them with 
GM-CSF in vitro, and analyzed the expression of 
ER-MP12 and ER-MP20 by cultured cells at 
various time points (Fig. 4).
At day 2 of culture, cells from the ER-MP12high 
20– subpopulation had up-regulated ER-MP20 on 
their surface and about a half of them were double 
positive for both markers. By day 5 all cells derived 
from this population were ER-MP20+ while 
most of them showed no ER-MP12 expression 
anymore. By day 8, the culture contained ER-
MP12/20 double-negative cells and those that 
expressed medium levels of ER-MP20. The ER-
MP12+20+ population followed a similar pathway 
of development. At day 2, most of the cells had 
down-regulated ER-MP12 expression and were 
ER-MP12–20+. At day 5 of culture, some cells 
also down-regulated ER-MP20 and were double 
negative. By day 8 almost all cells had lost both 
markers on their surface and were ER-MP12–20–. 
Finally, the ER-MP12–20high -derived cells also 
down-regulated ER-MP20 on majority of the 
cells by day 5 of culture. By day 8 most of the 
cells in this culture had died (they probably were 
fully differentiated already before day 8) so no 
phenotypical analysis could be performed at this 
time point. Importantly, in all investigated cultures 
cells successively pass through the ER-MP12+20+ 
and ER-MP12–20high stages and finally become 
ER-MP12–20–.
 In the same cultures we followed the 
development of DC by using the DC marker 
CD11c. A common pattern of in vitro DC 
development was observed in cultures from 
all three fractions: first CD11c expression was 
induced followed by a prompt down-regulation 
of ER-MP20 (Fig. 5). CD11c+ cells were present 
already at day 2 in the culture derived from the 
ER-MP12–20high subpopulation. CD11c+ cells were 
also present at day 2 in cultures derived from the 
ER-MP12+20+ subpopulation, but at much lower 
frequency. The percentage of CD11c+ cells was 
increased in both cultures at day 5 and continued 
to rise in cultures derived from the ER-MP12+20+ 
subpopulation to reach 91% at day 8 of culture. 
In contrast, in cultures derived from the ER-
MP12high20– precursors, CD11c+ cells were present 
only from day 5 (10%) and reached 45% at day 8 
ofculture, implying that these precursors are indeed 
the earliest precursors able to differentiate into DC 
when stimulated with GM-CSF.
The maturation sequence of BM DC precursors, 
indicated by these phenotypic studies, is consistent 
with the decreasing proliferative capacity of the 
cells with increasing maturity. GMCSF-stimulated 
culture of the distinct subsets in semi-solid medium 
demonstrated that the ER-MP12high20– subset 
generated predominantly large colonies (>50 cells), 
the ER-MP12+20+ subset predominantly clusters 
(<50 cells) and some smaller colonies, while the 
ER-MP12–20high subset gave rise primarily to small 
clusters. Liquid culture recoveries were in line with 
these findings. In a representative experiment, 
1x105 cells from the ER-MP12high20– population 
produced 4x106 cells after 7 days of culture, thus 
multiplying their starting number 40 times. From 
Figure 2. Immunocytochemical 
MHC class II staining on cells from 
day 6 GM-CSF-stimulated cultures. 
DC (identified as MHC class IIhi and 
typical dendritic morphology) from 
cultures grown from (A) ER-MP12hi20–, 
(B) ER-MP12+20+ and (C) ER-MP12–
20hi BM cells are shown. Mfs were 
also present in the cultures (arrow) 
and differed from DC in morphology 
and MHC class II expression (lower 
levels). Original magnification x590.
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4x105 ER-MP12+20+ cells, 3.6 x 106 progeny 
cells (9-fold) were generated, while 4x105 ER-
MP12–20high cells gave rise to only 2.8 x 105 cells 
after culture (0.7-fold).
The earliest ER-MP12high20- DC precursors have 
the phenotype of myeloid-committed cells
Previously, we showed that the same ER-MP12/
20-defined subpopulations in the BM contain 
macrophage precursors as we found now for DC 
precursors [21]. In addition, we also showed that 
within the ER-MP12high20– subpopulation, early 
myeloid-committed cells could be purified from the 
other hematopoietic differentiation capacities on 
the basis of differentialexpression of a third marker, 
ER-MP58 [20]. Since we found that DC could also 
be generated from the ER-MP12high20– BM subset, 
we asked whether the earliest DC precursors 
also have a myeloid-committed phenotype by 
examining their ER-MP58 expression. For 
this purpose, ER-MP12high20– BM cells were 
fractionated according to their level of ER-MP58 
expression (Fig. 6) and cultured in the presence of 
GM-CSF. Cultures were examined microscopically 
for the presence of DC at different time points. 
Starting from day 7 (Table 2), morphologically 
mature DC could only be detected in cultures of 
the ER-MP58hi subset within the ER-MP12high20– 
population. This onset of DC appearing in culture 
was similar to what was observed when the total 
ER-MP12high20– subset was cultured (see above). 
No DC-like cells could be grown from the ER-
MP58med and ER-MP58–/low subsets under these 
culture conditions. Together, these data show that, 
like macrophage precursors, GM-CSF-responsive 
DC precursors present in the ER-MP12high20– BM 
subset are characterized by a high level Fig. 3. 
Flow cytometric and functional analysis of DC 
generated from BM precursors. (A) Cells derived 
from the total BM and three different precursor 
populations are double stained with MHC class II 
and CD11c antibodies. Histograms show the MHC 
class II expression by CD11c+-gated cells. (B) 
DC derived from the ER-MP12high20– population 
matured upon 24 h LPS stimulation as measured 
by enhancement of MHC class II expression. The 
profile indicated by a solid line only represents 
the expression before LPS stimulation; the filled 
surface is after 24 h LPS stimulation. The dotted 
line marks the isotype control and numbers 
represent the percentage of MHC class IIhi cells. 
(C) Potential of DC, either or not treated with LPS, 
Figure 3. Flow cytometric and functional analysis of DC generated from BM precursors. (A) Cells derived from the 
total BM and three different precursor populations are double stained with MHC class II and CD11c antibodies. Histograms 
show the MHC class II expression by CD11c+- gated cells. (B) DC derived from the ER-MP12hi20– population matured 
upon 24h LPS stimulation as measured by enhancement of MHC class II expression. The profile indicated by a solid line 
only represents the expression before LPS stimulation; the filled surface is after 24 h LPS stimulation. The dotted line 
marks the isotype control and numbers represent the percentage of MHC class IIhi cells. (C) Potential of DC, either or not 
treated with LPS, derived from different BM precursors to stimulate T cells in the MLR. T cell activation is measured by 
expression of transferrin R (ER-MP21) on their surface.
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derived from different BM precursors to stimulate 
T cells in the MLR. T cell activation is measured 
by expression of transferrin R (ER-MP21) on their 
surface. Myeloid DC development in mouse BM 
of ER-MP58 expression and thus have a myeloid-
committed phenotype.
BM progenitors maturing along the macrophage 
lineage in vitro maintain the capacity to generate 
DC
To approach the question whether macrophages 
and DC share progenitors throughout their BM 
development, we cultured BM subsets sequentially 
with M-CSF (‘primary culture’) and GM-CSF 
(‘secondary culture’). ER-MP12high20–58high 
(early myeloid precursors) and ER-MP12+20+ 
(myeloid blasts) were induced first to develop 
along the macrophage lineage in vitro (21). 
M-CSF was then replaced by GM-CSF and the 
potential of macrophage precursors to form DC 
was measured.
After 4 days in M-CSF-stimulated culture of 
the ER-MP12high20–58high subset, ~90% of the 
cultured cells expressed the ER-MP20 antigen at 
a high level (Fig. 7A), representing BM monocytes 
as previously shown [21]. Changing the growth 
stimulus to GM-CSF at this point resulted in the 
appearance of DC only 1 day later as determined 
by morphological inspection. The more mature 
ER-MP12+20+ subset developed further along the 
macrophage pathway in vitro, since after 5 days 
of M-CSF-stimulated culture approximately half 
of the cells still expressed the ER-MP20 antigen, 
whereas the other cells in the culture had lost their 
ER-MP20 expression (Fig. 7B). When these cells 
were further stimulated by GM-CSF, similarly to 
ER-MP12high20–58high-derived cultures, DC were 
visible after only 1 day of secondary culture and 
Figure 4. Successive expression of ER-MP12 and ER-MP20 during the in vitro culture of BM precursor populations. 
Sorted populations were cultured with GM-CSF, and at various time points double-labeled with ER-MP12 and ER-MP20. 
Starting from the earliest precursor population, ER-MP12hi20–, all cells show the same pattern of ER-MP12/20 expression, 
indicating that they follow the same ER-MP12hi20– →ER-MP12+20+ → ER-MP12–20hi developmental pathway.
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in increased numbers after 3 days of culture. 
Apart from DC, macrophages (ER-MP20–) also 
developed in cultures from both precursor fractions 
as indicated by the presence of cells with (i) high 
forward and perpendicular light scatter (data not 
shown), indicative of a complex cell type like the 
mature macrophage with its numerous vacuoles, 
etc., and (ii) a high autofluorescence level, also 
characteristic of mature macrophages. After 9 days 
of GM-CSF-stimulated secondary culture, 28 and 
71% DC developed from ER-MP12high20–58high 
and ER-MP12+20+ derived cultures respectively. 
These cells expressed MHC class II molecules 
at a high level and had typical DC morphology, 
as determined in immunocytochemistry (Fig. 7C 
and D). Thus, myeloid precursors from the BM 
developing for 4 or 5 days along the macrophage 
lineage in M-CSF-stimulated culture still have the 
potential to generate DC.
Discussion
In the past few years a significant amount of data 
has been generated about different DC types and 
their relationship to other hematopoietic lineages. 
Figure 5. Kinetics of the in vitro DC development from different BM precursors. Subpopulations were sorted from 
the BM and cultured for 8 days in the presence of GM-CSF. At different time points cells were labeled with ER-MP20 and 
CD11c. The DC development is marked by upregulation of CD11c on the cell surface.
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Recently, it has been shown that both common 
myeloid and common lymphoid precursors can 
give rise to different DC types both in vitro and in 
vivo [14-16]. Mature myeloid and lymphoid DC 
have been identified phenotypically in human 
and also in mouse [3,4]. However, the exact 
maturation pathways of either of the types have 
remained unclear. 
In this study we have examined the different 
stages of BM DC precursor development in vivo, 
as defined by the expression of  ER-MP12/CD31, 
ER-MP20/Ly-6C and ER-MP58 antigens. DC 
are derived in vitro with GM-CSF only from 
the ER-MP12high20– (early blasts), ER-MP12+20+ 
(myeloid blasts) and ER-MP12–20high (BM 
monocytes) [21] subpopulations, while no cell 
growth could be detected from the other three 
sorted populations, ER-MP12med20–, ER-MP12–
20– and ER-MP12–20med. These populations 
represent subsets containing morphologically 
identifiable precursors and mature cells of the 
other hematopoietic lineages (lymphoid, erythroid 
and granulocytic respectively). Our results show 
that GM-CSFresponsive DC precursors reside in 
the same ER-MP12/20-defined BM subsets as M-
CSF-responsive macrophage precursors [19-21]. 
Earlier reports show that mature DC develop 
from the BM within 8 days in GM-CSF-stimulated 
culture [27]. In agreement with this we observe 
that the majority of DC derived from any of the 
BM subpopulations express significant amounts 
of MHC class II molecules, which, together with 
their good potential to stimulate allogeneic naive 
T cells in vitro, indicates that mature DC develop 
in these cultures. However, in cultures derived 
from the ER-MP12high20– cells, immature DC, 
expressing medium levels of MHC class II, were 
also present in significant numbers after 7 days of 
culture. These cells mature upon LPS stimulation, 
suggesting that they need an extended period of 
time to develop into mature DC since they develop 
from early precursors.
This delay in reaching a mature state is in 
agreement with the observation that during the 
in vitro development, a difference in time of 
appearance of CD11c+ cells exists in cultures 
grown from the ER-MP12high20– versus the ER-
MP12+20+ and ER-MP12–20high BM subsets (day 
5 versus 2 respectively). This further implies that 
ER-MP12high20– DC precursors are less mature 
than the other two subsets, and need more time 
to develop into DC than ER-MP12+20+ and ER-
MP12–20high cells. In addition, the percentage of 
CD11c+ DC derived from the GM-CSF-stimulated 
ER-MP12+20+ cells is 2-fold higher than that found 
with the ER-MP12high20– BM subset as a starting 
population (90 versus 45%). Probably the higher 
proliferative capacity of the ER-MP12high20–
population contributes to the observed difference 
in maturation kinetics. Both the size and extent of 
colony/cluster formation and culture recoveries 
indicate that ER-MP12high20– cells have the highest 
potential to proliferate, which then decreases to be 
the lowest among ER-MP12–20high cells. The high 
recoveries obtained from the ER-MP12high20– and 
ER-MP12+20+ fractions make it highly unlikely 
that contaminating populations (<5%) in the 
sorted fractions account for the observed results. 
Together, these findings reinforce the notion that 
ER-MP12high20–, ER-MP12+20+ and ER-MP12–
20high populations represent different stages of 
DC development, since they show a reciprocal 
relationship between the ability to proliferate and 
the ability to develop into mature DC in a short 
Figure 6. ER-MP58 expression within the ER-MP12hi 
20– gate. Cells were triple labeled with ER-MP12, ER-
MP20 and ER-MP58. ER-MP12hi20– cells were gated (A) 
and sorted on the basis of their ER-MP58 expression as 
indicated (B).
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Table 2. DC generated from ER-MP12hi20- bone marrow 
subsets
BM subset
Overall 
cell 
growtha)
DC visible in culture
day 5 day 7 day 14
ER-MP12hi20–58hi + – + +
ER-MP12hi20–58med b) ± – – –
ER-MP12hi20–58–/lo – – – –
a) During entire culture
b) From this subset only macrophagess and immature cells were 
generated
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period of time.
The successive expression of ER-MP12 and 
ER-MP20 antigens during the in vitro culture 
with GM-CSF strongly suggests that the three 
DC precursor populations, which we defined in 
the BM, differentiate along the pathway with the 
order ER-MP12high20– → ER-MP12+20+ → ER-
MP12–20high. Furthermore, this same sequence was 
previously shown for the macrophage precursors 
[21] suggesting that GM-CSF-responsive myeloid 
DC and macrophage precursors follow a similar 
ER-MP12/20-defined developmental pathway.
The population that contains the earliest DC 
precursors in the BM, ER-MP12high20–, can be 
further divided into three subpopulations based 
on the expression of the early myeloid marker 
ER-MP58 [20]. Of these three subsets, only ER-
MP12high20–58high BM cells are able to differentiate 
into DC in rGM-CSF-stimulated cultures. Since 
high level expression of ER-MP58 within the 
ER-MP12high20– BM population has been shown 
to mark the earliest myeloid committed precursors, 
able to give rise to macrophages with M-CSF [20], 
we conclude that macrophages and myeloid DC 
most probably originate from the same precursors 
in the BM. Recently, Akashi et al. have described 
the existence of a common myeloid progenitor in 
mouse BM that gives rise to all myeloid lineages 
[10]. The comparison of its colony forming ability 
and further characteristics with those of the ER-
MP12high20–58high population strongly suggests 
that the latter represents a similar, if not identical, 
multipotent myeloid precursor population. 
In a recently published paper [7], Gilliet et al. 
show that the mouse PDC (CD11c+CD11b–B220+) 
can be generated in vitro from the total BM, when 
Figure 7. DC development from precursor populations stimulated previously along the macrophage pathway. 
Bone marrow subsets ER-MP12hi20–58hi (A) and ER-MP12+20+ (B) were sorted and cultured for 4 and 5 days respectively 
in the presence of M-CSF to stimulate macrophage development. At the end of the primary culture, ER-MP12 and ER-
MP20 expression was determined in two-color flow cytometry to assess the maturity of the cultured cells. Next, cells were 
grown for 9 days in secondary rGM-CSF-stimulated cultures. After this period cultures were analyzed for the presence 
of DC by immunocytochemical staining for MHC class II (C and D). Macrophages were also present in these secondary 
cultures (arrow). Original magnification (C and D) x670.
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Flt-3L is used as the growth factor. They also show 
that addition of GM-CSF to the culture medium 
completely blocks generation of PDC and increases 
myeloid DC development. Since we used GM-CSF 
alone, this is in agreement with the observation 
that in our cultures, no plasmacytoid, but only 
myeloid DC, were generated as all cells in the 
culture expressed high levels of CD11b (data not 
shown). An interesting question arises regarding 
the potential of our three populations to generate 
PDC with Flt-3L. For the BM monocyte population 
(ER-MP12–20high) we regard it unlikely that they 
may give rise to lymphoid-related PDC, as we 
have shown previously that BM monocytes are 
all CD11b+ and thus myeloid cells [21], Further, it 
has been reported that the CD31+/Ly-6C+ (i.e. our 
ER-MP12+20+) population contains precursor cells 
capable of differentiating into different cell types: 
CD8a+ DC, CD8a– DC, PDC and macrophages, 
depending on the experimental conditions [17]. 
Our current results support the concept that 
developing myeloid DC, which might eventually 
express CD8a, and macrophages progress through 
the same precursor stages in the BM including 
the CD31+/Ly-6C+ stage. However, as we have 
shown earlier, the CD31+Ly-6C+ population in 
BM is phenotypically heterogeneous [21] and 
might contain cells with different developmental 
capabilities; clonal assays are essential to prove 
whether PDC and myeloid DC derive from single 
precursors. Finally, we define the DC precursor, 
at the stage prior to the one previously reported, 
which is capable of differentiating in both 
myeloid DC and macrophages (CD31hi/Ly-6C–). 
As mentioned above, since GM-CSF directs cell 
development specifically to myeloid lineage, it is 
unclear from our data whether PDC might originate 
from the same population.
Taken together, in this report, we define 
different stages of GM-CSF-responsive DC 
precursors present in the BM and show their in 
vivo developmental pathway. Furthermore, we 
show that, throughout their BM development, 
myeloid DC precursors progress through the same 
stages as macrophages. Even when cells are induced 
in vitro with M-CSF to follow the macrophage 
developmental pathway, they can still be redirected 
to develop into DC when M-CSF is replaced with 
GM-CSF. This is in line with our hypothesis 
that over a prolonged stretch of development, 
progenitors of the mononuclear phagocyte system 
may either develop into macrophages or DC, 
depending on local conditions. However, additional 
clonal experiments are required to confirm this 
hypothesis. Finally, we feel that the ER-MP12/20/
58 identification of distinct BM subsets provides a 
powerful means to study the developmental pathway 
of lymphoid related PDC as opposed to the presently 
studied myeloid DC.
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3.2
Myeloid bone marrow precursors of non-obese diabetic mice show 
reduced proliferation and accelerated maturation into dendritic cells
in vitro
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Dendritic cells and macrophages play an essential role in the pathogenesis of type 1 
diabetes in the non-obese diabetic (NOD) mouse. In vitro differentiation of DC from 
the NOD BM demonstrated quantitative and qualitative abnormalities, but whether 
such defective development correlated to the problems in the myeloid progenitor pool 
has not been investigated. Using a combination of monoclonal antibodies against CD31 
(ER-MP12) and Ly-6C (ER-MP20) molecules, we defined three successive developmental 
stages of common myeloid DC and Mf precursors in the NOD mouse BM and investigated 
the capability of these three successive precursor populations to develop into DC, when 
stimulated with GM-CSF in vitro. All three populations contained DC precursors in both 
the NOD and C57BL control mice. However, during GM-CSF-induced maturation, NOD 
DC precursors did not follow the sequence of CD31 and Ly-6C expression as seen in the 
C57BL mouse. We found an accelerated maturation of NOD BM precursors, characterized 
by an almost immediate transition of the earliest precursors into DC accompanied by a 
virtual absence of proliferation of these early precursors. 
This preferred maturation over proliferation of NOD myeloid precursors probably points 
to an intrinsic defect in the signaling pathways of the cells. If existing, such an intrinsic 
precursor defect likely also causes differentiation errors of NOD DC from precursors at 
the local level in the pancreas.
 
An essential role of dendritic cells (DC) and macrophages (Mf) in the pathogenesis of type 1 diabetes has been demonstrated 
on several occasions in the non-obese diabetic 
(NOD) mouse, a widely used animal model for 
organ-specific autoimmune diseases. Blocking 
leukocyte migration into the pancreas or depletion 
of APC from the pancreas significantly delays and 
even prevents diabetes in NOD mice ([1-4] and 
Chapter 2). 
Bone marrow (BM) precursor cells are able to 
give rise to DC and Mf. In vitro differentiation 
of NOD DC from BM precursors demonstrated 
quantitative and qualitative abnormalities; i.e. a 
lower yield of cells and a poor T cell stimulatory 
capacity of the yielded DC when sub-optimally 
stimulated with GM-CSF alone [5, 6]. Other 
investigations point to a defective expression of 
the Ly-6C molecule on NOD BM precursor cells 
[7]. However, whether such defective expression 
correlates to the potential of myeloid progenitors 
to develop into DC has not been investigated.  
Using a combination of monoclonal antibodies 
against Ly-6C and CD31, we previously defined 
three successive maturation stages of common 
myeloid DC and Mf precursors in the BM of 
C57BL mice, i.e. the CD31highLy-6C–, CD31+Ly-
6C+ and CD31–Ly-6Chigh progenitor populations, 
respectively, which were all able to give rise 
to DC and Mf [8, 9]. In this study, we used the 
same methodology and found that also in the 
NOD mouse, a combination of Ly-6C and CD31 
defined the same three successive DC progenitor 
populations. However, when cultured in vitro, 
in the presence of GM-CSF, BM precursors of 
the NOD mouse demonstrated an accelerated 
maturation to DC together with a low expansion 
of early precursors. Taken together, our findings 
uncover defects in early myeloid progenitors of 
the NOD mouse that are unrelated to the Ly-6C 
expression defect but cause an aberrant maturation 
course of progeny.
Material and methods
The same experimental methods were used in this 
study as previously described in Chapter 3.1. [8] 
Chapter 3100 DC precursors in mouse bone marrow 101
Results and Discussion
Morphology and phenotype of DC progenitors 
in the NOD mouse BM  
The double labeling of fresh isolated BM from 
NOD mice, with monoclonal antibodies against 
Ly-6C and CD31, resulted in a different staining 
pattern as compared to that of the the C57BL 
mouse (Fig. 1-upper row). In the NOD mouse 
BM, we could define 5 BM subsets, instead of 6. 
There was a conspicuous absence of population 5. 
In the C57BL mice, monocytes and granulocytes 
reside in populations 5 and 6. 
contribution of the two myeloid lineages to the 
loss of population 5 in the NOD mouse BM. 
For that purpose, we made use of a recently 
generated antibody that recognizes the Ly-6G, 
also a molecule from the Ly-6 family, which 
distinguishes granulocytes (Ly-6G+) from 
monocytes (Ly-6G–). The simultaneous labeling 
with Ly-6C and Ly-6G (Fig. 1-lower row) clearly 
demonstrated that specifically Ly-6G+ cells (i.e. 
the granulocytes) were Ly-6C– in the NOD mouse. 
In addition we sorted the Ly-6C+ and Ly-6C– BM 
populations and analyzed these morphologically. 
We found that granulocytes in the NOD mouse 
indeed fail to express the Ly-6C molecule and 
therefore represent the CD11b+ population within 
the CD31–Ly-6C– niche of the NOD mouse BM. 
In conclusion, granulocytes and not monocytes 
of the NOD mouse show the Ly-6C deficiency for. 
This deficiency is complete and probably stems 
from the granulocyte-commited progenitors. This 
also indicated that the Ly-6C marker can be used 
to distinguish the monocyte-like DC and Mf 
precursor BM populations in the NOD mouse. 
Indeed the remaining Ly-6C+ positive cells in 
the NOD BM demonstrated a normal staining 
pattern and we could define both the CD31+Ly-
6C+ and CD31–Ly-6Chigh populations. However, 
we repeatedly found between 40-50% reduction 
in frequency of these two populations (Fig. 1 
upper row). 
In C57BL mice the Ly-6C+CD31+ subset is a 
heterogeneous population and contains monoblasts, 
granulocytic progenitors, plasmacytoid DC 
and other cells [9, 11]. The lower frequency is 
probably caused by the absence of granulocytes 
and PDC, which lack Ly-6C expression in the 
NOD mouse (Fig. 1 and unpublished observation) 
and therefore reduce the percent of cells present 
in this population. The same holds true for the 
NOD CD31–Ly-6Chigh population, in which a 
cell population was absent that has been defined 
as “ring-monocytes” [12]. These cells were 
morphologically recognizable in the CD11b+ 
fraction of the CD31–Ly-6C– subset in the NOD 
mouse (not shown). Importantly CD11c+ cells did 
not developed from the CD31–Ly-6C– subset, when 
stimulated with GM-CSF (Fig. 2), therefore ring-
monocytes lack a DC differentiation capacity. 
Figure 1. Different CD31/Ly-6C expression pattern in 
the NOD mouse BM. Analysis of the CD31, Ly-6C and Ly-
6G expression by BM cells in the NOD and C57BL mouse. 
The CD31/Ly-6C double labeling (upper row) showed 
different distribution of BM cells within six populations 
previously defined in the C57BL mouse. In addition, the 
Ly-6G/Ly-6C staining (lower row) demonstrated that the 
Ly-6C+ cells in the NOD mouse do not express Ly-6G, 
therefore cells of the granulocyte and not of the monocyte 
lineage are Ly-6C deficient.
Previously, a recombination in the 5’ region 
of the Ly-6C gene has been found to lead to an 
impaired expression of the molecule on the BM 
cells of NOD, NZB and ST mice [10]. Since cells 
of both the granulocyte and monocyte lineages 
express Ly-6C in the BM, we investigated the 
Chapter 3100 DC precursors in mouse bone marrow 101
Taken together, phenotypic and morphological 
analysis of freshly isolated BM and of the sorted 
subsets of the C57BL and NOD mouse provided 
information with regard to the expression of the 
Ly-6C molecule. Cells of the monocyte lineage in 
the NOD mouse remain capable of expressing the 
Ly-6C molecule, although with a lower intensity 
when compared to such cells of the C57BL mouse. 
The NOD mouse cells of the granulocyte and 
possibly other lineages were unable to express 
the Ly-6C molecule. The absence of population 
5 in the NOD mouse in Figure 1 is thus most 
certainly due to an allocation of granulocytes to 
the Ly-6C– populations (and other cells unrelated 
to mononuclear phagocytes) .
DC progenitors reside in the same three BM 
populations in NOD and control mice
Abnormal expression of the Ly-6C molecule in 
the BM of the NOD mouse has been related to 
a defective myelopoiesis [7]. Although cells with 
a morphology and phenotype of DC precursors 
were present in NOD in the same three CD31/Ly-
6C subsets as in the C57BL mouse, the question 
whether the modifications in the Ly-6C gene might 
have influenced the capacity of precursor cells to 
differentiate into CD11c+ DC was unanswered. 
When isolated from the BM and stimulated with 
GM-CSF in vitro, DC developed exclusively from 
the CD31highLy -6C–, CD31+Ly-6C+ and CD31–Ly-
6Chigh subsets in the NOD mouse, similarly to what 
we have already demonstrated for the C57BL 
mouse BM (Fig. 2.). Hence, the DC differentiation 
capacity was confined to equivalent progenitor 
populations in the NOD BM as demonstrated for 
the C57BL mouse (Chapter 3.1).
An accelerated maturation of DC from NOD 
BM progenitors.
As we did for the C57BL mouse (Chapter 3.1 - Fig. 
4 and 5), we followed the expression pattern of 
the CD31 and Ly-6C molecules in the NOD BM 
subsets when stimulated with GM-SCF in vitro.  
The CD31highLy-6C– cells sequentially up- and 
down- regulated the Ly-6C molecule within 8 
days of in vitro culture in both the NOD and 
C57BL mouse. However, the full elution of the 
Ly-6C molecule from the NOD cells occurred 
faster than in the C57BL mouse (Fig. 3A and 3B). 
Also, cells of the CD31+Ly-6C+ and CD31hiLy-6C– 
subsets of the NOD mouse were all Ly-6C– before 
day 5 of culture while in the C57BL mice some 
cells remained  Ly-6C+ till day 8 and longer (not 
shown). 
The accelerated loss of Ly-6C expression was 
accompanied by a rapid acquisition of the DC 
specific marker CD11c on the surface of the NOD 
cells (Fig. 3B). This rapid change of phenotype 
happened between days 2 and 5 of culture. At day 
5, the majority of the cells of all three fractions 
had a CD31+CD11c+Ly-6C– phenotype in the 
NOD cultures. In addition, acquisition of CD11c 
Figure 2. The same populations in the NOD and the C57BL BM contain progenitors with a DC differentiation 
potential. Sorted BM progenitors from the NOD BM were stimulated with GM-CSF in vitro. After 8 days, generated 
cells were labeled with the CD11c antibody. CD11c+ cells were present only in the cultures derived from CD31hiLy-6C–, 
CD31+Ly-6C+ and CD31–Ly-6Chi populations.
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was accompanied by the up regulation of MHC 
class II (not shown), indicating that the NOD 
cells rapidly gain DC characteristics. Due to a 
low cell yield obtained in these experiments, we 
were not able to test whether these DC were also 
functionally competent APC. However, our focus 
in this study was the capacity of the NOD BM cells 
to enter the DC developmental pathway, which 
is probably driven by different mechanisms than 
the final DC maturation. In addition, functional 
analysis in this setting could bias our conclusions, 
since we found that GM-CSF alone cannot ensure 
proper maturation of NOD BM cells into DC in 
vitro (Chapter 3.3), 
A further obvious divergence from the 
previously seen CD31/Ly-6C expression pattern 
in C57BL was an absence of the CD31 down 
regulation by DC progenitors in the NOD mouse 
(Fig. 3A). Even more so, the NOD monocytes 
isolated as CD31–Ly-6Chigh cells, regained CD31 
and remained positive throughout the observation 
period (not shown). 
In conclusion, during in vitro maturation to 
DC, NOD BM precursors did not follow the same 
sequence of acquisition and reduction of Ly-6C, 
CD11c and CD31 molecules as we previously 
found for the C57BL mouse. A rapid loss of Ly-6C 
and acquisition of CD11c and MHC class II show 
an accelerated maturation/differentiation of NOD 
BM progenitors to DC at least at the phenotypic 
level. The importance of the difference in CD31 
expression levels in the NOD progenitors cannot 
be assessed from our current data.
Early DC progenitors in NOD BM fail to expand 
when stimulated with GM-CSF
Early progenitors change not only their phenotype 
Figure 3. 
Different maturation 
sequence of NOD BM 
progenitors. Expression 
of CD31, Ly-6C and 
CD11c molecules was 
examined during the 
cultivation of sorted BM 
populations, at different 
time points. A. Cells 
isolated from the NOD 
BM lost Ly-6C much 
faster than the control. In 
addition, they continued 
to express CD31 till the 
end of the culture period. 
B. Rapid downregulation 
of Ly-6C happened 
simultaneously with the 
rapid expression of CD11c 
on the surface, indicative 
of a differentiation to DC. 
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in the course of maturation to DC but also 
proliferate (Chapter 3.1). The further the cells 
are in the differentiation, the less they expand 
when stimulated. As shown in Figure 4, at the 
end of the culture period the expansion of the 
earliest BM progenitors of C57BL mice was 
40-fold, of the myeloid progenitors about 10-
fold, while the differentiated monocytes did not 
expand when stimulated with GM-CSF in vitro. In 
contrast, all precursor cells (including the earliest 
progenitors) obtained from NOD BM had virtually 
no proliferation capacity GM-CSF (Fig 4).
In the culture of the sorted populations of 
the NOD BM precursors we did not observe a 
spontaneous generation of appreciable numbers of 
macrophages, so it is unlikely that macrophages 
had influenced the proliferation rate. Therefore, 
the failure to proliferate when stimulated in vitro, 
probably comes from an intrinsic defect of NOD 
BM precursors to respond to the cytokine stimulus. 
A similar expansion defect has been observed when 
non-separated BM cells of the NOD mouse were 
stimulated with cytokines other than GM-CSF 
[7], which points to alterations in the intracellular 
signaling pathways downstream from the cytokine 
receptors. 
Concluding remarks
Taken together, analysis of the fresh isolated NOD 
BM cells did not reveal significant differences, 
with regard to the quantity and phenotypic 
quality of the DC progenitor pool. However 
when isolated and stimulated in vitro, the precursor 
cells deviated from the previously established 
maturation sequence defined in C57BL mice. 
When stimulated with GM-CSF in vitro, NOD 
BM precursors acquired faster the CD11c+ DC 
phenotype but failed to proliferate.
The focus of this small study was on the 
GM-SCF induced generation of myeloid DC. We 
did not investigate the potential of the same cells 
to generate other cell types, like Mf or PDC. It 
would be interesting to test whether the accelerated 
maturation without expansion also takes place 
when the NOD BM precursor cells are stimulated 
with other growth factors, like M-SCF or Flt3-L. 
In conclusion, our observation of the 
seemingly normal DC progenitor pool in the NOD 
mouse BM that displays different activities when 
isolated from the natural surroundings, point to 
latent defects present in the earliest myeloid 
progenitors of the BM. They may appear mild 
in the broader context of all leukocytes in vivo 
but become quite exaggerated in vitro. Although 
latent and seemingly insignificant in vivo, these 
deficiencies might contribute to the faulty outcome 
Figure 4. NOD BM progenitors fail to expand when stimulated in vitro. Three BM populations (that contain DC 
progenitors) were isolated from the BM:  the early myeloid progenitors (CD31hiLy-6C–), the myeloid blasts (CD31+Ly-6C+) 
and BM monocytes (CD31–Ly-6Chi) populations. Expansion index is calculated as an output/input ratio of cells stimulated 
with GM-CSF for a given time period. The highest proliferation index was found in the least differentiated population and 
it gradually decreased with the differentiation in the C57BL cultures (black bars). In contrast, the expansion was virtually 
absent in anu of the NOD cultures (grey bars). 
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of the immune regulation and predispose the NOD 
mouse to autoimmunity. 
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3.3
Bone marrow precursors of non-obese diabetic mice develop into 
defective macrophage-like dendritic cells in vitro 
Tatjana Nikolic, Marjolijn Bunk, Hemmo A. Drexhage, Pieter J. M. Leenen
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The non-obese diabetic (NOD) mouse spontaneously develops autoimmune diabetes. 
Dendritic cells (DC) play a crucial role in the autoimmune response. Previous studies have 
reported a defective DC generation in vitro from the NOD mouse bone marrow (BM), 
but a deviated development of myeloid precursors into non-DC in response to GM-CSF 
was not considered. In this study we demonstrate several abnormalities during myeloid 
differentiation of NOD BM precursors using GM-CSF in vitro. 1) We found reduced 
proliferation and increased cell death in NOD cultures, which explain the previously 
reported low yield of DC progeny in NOD. Cell yield in NOR cultures was normal. 
2) In a detailed analysis GM-CSF-stimulated cultures, we observed in both NOD and 
NOR mice an increased frequency of macrophages, identified as CD11c+/MHCII– cells 
with typical macrophage morphology, phenotype and acid phosphatase activity. This 
points to a preferential maturation of BM precursors into macrophages in mice with 
the NOD background. 3) The few CD11c+/MHCIIhigh cells that we obtained from NOD 
and NOR cultures, which resembled prototypic mature DC, appeared to be defective in 
stimulating allogeneic T cells. These DC had also strong acid phosphatase activity and 
a raised expression of monocyte/macrophage markers. In conclusion, in this study we 
describe a deviated development of myeloid BM precursors of NOD and NOR mice into 
macrophages and macrophage-like DC in vitro. Potentially, these anomalies contribute 
to the dysfunctional regulation of tolerance in NOD mice, yet are insufficient to induce 
autoimmune diabetes since they occurred partly in NOR mice.
Insulin-dependent diabetes mellitus (IDDM) or type I diabetes develops as a result of an autoimmune destruction of the b-cells in 
the islets of Langerhans [1]. To investigate the 
pathogenesis of IDDM, animal models such as 
the non-obese diabetic (NOD) mouse and the 
biobreeding (BB-DP) rat have proven to be 
valuable tools. These animals develop IDDM 
spontaneously. In NOD mice the sequence of 
events that occurs during this process closely 
resembles the disease development in humans 
[2]. 
Dendritic cells (DC) and macrophages play a 
pivotal role in the initiation and progression of 
the autoimmune response and the final destruction 
of the b-cells. In the pancreas of neonatal NOD 
mice elevated numbers of DC and macrophages 
are present [3]. Furthermore, an accumulation of 
DC and macrophages, around 4 weeks of age, 
marks the initiation of the autoimmune insulitis 
prior to the infiltration of lymphocytes [4, 5]. The 
final b-cell destruction is thought to occur by the 
activity of both lymphocytes and macrophages [4, 
6]. Together, these findings underline the important 
roles of DC and macrophages in the different stages 
of the inflammatory process in the pancreas. 
As antigen-presenting cells (APC), DC play 
a prominent role in both central and peripheral 
tolerance. Therefore, deficient induction and 
maintenance of tolerance by aberrant DC would be 
key to the initiation of autoimmunity [7]. According 
to such a view, a hampered negative selection by 
aberrant thymus DC leads to the incomplete 
deletion of autoreactive T cells. In addition, 
abnormal DC in the periphery might not stimulate 
regulatory T cells sufficiently, thus contributing to a 
failing control of the autodestructive process in the 
target organ. These notions have led to an extensive 
investigation of a putative deficient function of DC 
in type I diabetes. In both humans and BB-DP rats 
a functional deficiency of DC has been observed. 
Lower numbers of DC, an immature phenotype 
and an impaired stimulatory capacity have been 
found in both human and rat DC [8-10]. In contrast 
to these studies, ex vivo isolated NOD mouse DC 
from spleen and lymph nodes demonstrated only 
minor phenotypic and functional aberrations [11, 
12]. 
In marked contrast to the reports on ex vivo 
DC isolated from pre-diabetic NOD mice, in 
vitro studies show significant abnormalities in 
DC yield and development when NOD DC are 
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generated from bone marrow (BM) precursors 
[12-16]. Studies where NOD BM precursors are 
stimulated with GM-CSF alone show generation 
of low numbers of DC that display an immature 
phenotype and a poor T cell stimulatory capacity 
[13, 14, 17]. However, in the latter reports the 
authors describe the phenotypic and functional 
anomalies of the in vitro generated NOD myeloid 
DC, without assessing a possibly deviated 
development of NOD myeloid precursors 
into non-DC. Since GM-CSF is an important 
inflammatory cytokine that influences the function 
and development of DC but also of other myeloid 
cell types [18], we decided to investigate the in 
vitro effects of GM-CSF on the generation of 
NOD BM cells in detail, with emphasis on the 
heterogeneity of the developing cell types. 
Our study shows several anomalies in myeloid DC 
differentiation and maturation in NOD and NOR 
(as compared to C57BL and BALB/c) cultures 
that lead to a strongly decreased generation 
of prototypic and mature DC. Furthermore, 
phenotypically mature DC, when separated, appear 
to have various macrophage characteristics and a 
reduced T cell stimulatory capacity, despite normal 
expression levels of MHC and costimulatory 
molecules. The aberrant maturation of myeloid 
DC also occurs in Flt3-ligand (Flt3-L)-stimulated 
BM cultures, which points towards an intrinsic 
defect in myeloid DC development in mice with 
the NOD background. 
in the MLR. Undiluted culture supernatants of the 
hybridomas 2.4G2 (anti- FcRgII/III - CD16/32), ER-
MP21 (anti-transferrin R - CD71) as well as unlabeled 
Ab against the scavenger R type I (SR-AI/II - 2F8; 
kindly provided by Dr. S. Gordon) were detected by 
FITC- or R-phycoerythrin-(R-PE)- labeled goat-anti-
rat IgG (mouse-absorbed; GaRa-FITC or GaRa-PE) 
purchased from Caltag Laboratories, San Francisco, 
CA. Directly labeled 53-6.7FITC (anti-CD8a), RM4-5PE 
(anti-CD4) and HL3PE (anti-CD11c) were purchased from 
BD Biosciences (San Diego, CA). Biotinylated ER-TR3 
(anti-MHC class II; I-A) was kindly provided by BMA 
Biomedicals AG (Augst Switzerland) and 10-2.16 (anti-
MHC class II for NOD; I-Ag7) was produced, purified 
and biotynilated in our lab. These antibodies were 
detected by R-PE (Caltag) or allophycocyanin (-APC) 
(BD Biosciences) –conjugated streptavidin (SAV-PE or 
SAV-TC, respectively). 
rGM-CSF- and Flt3-ligand- stimulated BM cultures
Single cell suspensions of BM, isolated from femora 
and tibiae, were prepared as described previously [19]. 
Total BM cells were cultured in RPMI-1640 (without 
Hepes; Biowhittaker) supplemented with 10% FCS 
(heat-inactivated; 0.2 mm filtered), 60mg/ml penicillin 
and 100mg/ml streptomycin (further referred to as 
culture medium). Growth factors were used according 
to published protocols for DC generation [20, 21]. 
In GM-CSF-stimulated cultures a final concentration 
of 20ng/ml recombinant GM-CSF (Biosource 
International, Camarillo, CA, USA) was used, while 
100ng/ml of recombinant mouse Flt3-ligand (Flt3-L; 
R&D Systems Europe Ltd, Abingdon, UK) was used 
in Flt3-L-stimulated cultures. Cells were cultured at 37° 
C, 7% CO
2
 for various periods of time, as indicated, up 
to 10 days.
Cell suspensions
Cultured BM-derived cells were isolated from culture 
dishes by vigorous pipeting to collect all cells. Cells 
were washed and kept until further use in culture 
medium containing no additional growth factors. When 
used for phenotypic analysis, cultured cells were washed 
with PBS supplemented with 0.5% (v/v) BSA (Organon 
Teknika, Boxtel, The Netherlands) and 20mM sodium 
azide. Single cell suspensions of spleen and lymph 
nodes were prepared and used for T cell isolation as 
described [11].
Cell sorting and flow cytometric analysis
For cell sorting, BM-derived cultured cells were labeled 
with two (anti-CD11c and anti-MHC class II) monoclonal 
antibodies as described previously [22]. Prior to sorting 
(FACS Vantage; Becton Dickinson), cell suspensions 
Materials and Methods
Mice
Female NOD/Ltj (prediabetic) and C3Heb/Fej mice 
between 5 and 10 weeks of age were bred at the animal 
facility of the ErasmusMC, Rotterdam. Female C57BL, 
BALB/c female mice were purchased from Harlan (Horst, 
The Netherlands) and female NOR mice from Jacksons 
Laboratory (Bar Harbor ME, USA). Female C3HeB/FeJ 
mice were used as a source of allogeneic responder T 
cells. Animals were specific pathogen free and kept with 
free access to food and water in the animal care facility 
at the Erasmus MC, Rotterdam under the institutional 
guidelines for usage of experimental animals.
Monoclonal antibodies and conjugates
Monoclonal antibodies were used for cell sorting, flow 
cytometric analysis and evaluation of T cell activation 
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were filtered over a 30mm sieve (Polymon PES, Kabel, 
Amsterdam, The Netherlands) to avoid clogging of the 
nozzle. After sorting, the purity of the cell suspensions 
was checked by re-running sorted samples and purity 
exceeded 95%. Suspensions were kept at 4°C throughout 
the staining and sorting procedure. Sorted cells were 
counted in a Bürker hemocytometer.
For phenotypic analysis by flow cytometry, samples 
of cultured cells (≥2x105 cells) were aliquotted into 96-
microwell plates (round bottom, Nunc, Denmark) and 
labeled with antibodies as described before [22]. For dead 
cell exclusion labeling with 7-AAD (7-aminoactinomycin 
D; Molecular Probes Europe BV, Leiden, The 
Netherlands) was used prior to the measurement [23]. 
Events (3–5×104) were scored using a FACSCalibur flow 
cytometer and analyzed by CellQuest software (Becton 
Dickinson, Sunnyvale, CA). 
Analysis of the cell cycle and apoptosis
Apoptosis and cell cycle characteristics were determined 
by using a propidium iodide (PI) staining as previously 
described [24, 25]. In short, 1x106 cells were fixed 
in ice-cold ethanol for >2h. Subsequently, cells were 
incubated at room temperature for 30 min in PBS 
containing 0.02 mg/ml PI, 0.1% v/v Triton X-100, and 
0.2 mg/ml RNAse, left overnight at 4°C and analyzed 
with FACSCalibur. Doublet cells were excluded from the 
analysis by measuring peak area and width. The number 
of proliferating cells was determined by gating the region 
of the DNA histogram that contained cells in G1/G0, S 
and G2/M phases of the cell cycle. The percentage of 
apoptotic cells was determined by gating the sub-G1 
peak in the same DNA histogram.
Cytochemistry
The acid phosphatase (AP) activity of the various 
culture-derived populations was determined using 
cytospins of sorted cells prepared on a Cytospin 
apparatus (Nordic Immunological Laboratories, The 
Netherlands). Cytospins were air-dried and used for the 
AP staining according to Katayama et al. [26], using 
naphtol AS-BI phosphate as a substrate and a hexazotized 
pararosanilin as a coupling agent (37ºC, 30 min). Slides 
were counterstained with hematoxylin. Preparations were 
mounted in DePex mounting medium (Gurr, BDH Ltd, 
Poole, UK). 
Stained cytospins were quantified by counting a 
minimum of 300 cells per sample. For each mouse 
strain, four independent samples per experiment were 
counted using the following characterization. Acid 
phosphatase stains the lysosomal compartment [27] 
and based on the staining intensity and distribution we 
classified four different staining patterns: negative cells 
- granulocytes and myeloid precursors; weak cytoplasmic 
staining - cells with several small positive lysosomes, 
immature DC [28]; strong cytoplasmic staining - cells 
with a strong acid phosphatase activity in numerous 
lysosomes spread throughout the cytoplasm, typical for 
macrophages [29] and single dot staining - mature DC 
with a dot-like acid phosphatase active region located in 
the cell center [28].
Mixed leukocyte reaction assay
The capacity of in vitro generated BM-derived cells to 
activate allogeneic T cells was measured as previously 
described [19]. Briefly, stimulator cells (cultured DC) 
and responder T cells, isolated from lymph nodes, were 
resuspended in RPMI-1640 supplemented with 25mM 
Hepes, 10% FCS (heat inactivated; 0.2 mm filtered), 
60mg/ml penicillin, 100mg/ml streptomycin, 20mg/l 
sodium pyruvate and 50 mM 2-mercaptoethanol 
(further referred to as MLR medium). T cells were 
resuspended at a concentration of 106/ml and the 
concentration of stimulator cells varied depending 
on the desired stimulator : responder cell ratio. 
The cells (100m l of each cell suspension) were 
incubated in round-bottom 96-well plates for 4 days 
at 37°C in 7% CO
2
. Stimulator and responder cells, 
incubated separately in MLR medium, were used as 
negative controls. Mitogenic stimulation of T cells 
by concanavalin A (final concentration 1.25mg/ml) 
(Sigma Chemical Co., St. Louis, MO, USA) was 
used as a positive control.
We used induced expression of the transferrin 
receptor (TfR/CD71) as a measure for T cell 
proliferation in the MLR since the iron uptake 
through transferrin by stimulated cells has been shown 
to be a necessary requirement for their proliferation 
[30]. Control experiments demonstrated that results 
obtained by 3H-thymidine incorporation method 
correlated directly with the results obtained with our 
method using the CD71/TfR expression detection 
([19] and not published). In addition, we compared 
the kinetics of the CD71/TfR-expression with other 
activation markers (CD25, CD69) on allogeneic 
T cells stimulated by in vitro generated NOD DC. 
Expression pattern of CD71/TfR was similar to the 
expression of CD25 or CD69 and therefore we have 
chosen to use CD71/TfR expression analysis as a 
representative read-out of the T cell stimulation in 
the allogeneic MLR.
After 4 days of co-culture, cells were harvested 
and analyzed by flow cytometry. Triple labeling of 
cells with anti-CD4, anti-CD8 and anti-CD71/TfR 
antibodies was performed and 1.5 x 104 events were 
acquired within the live-cell gate. Data analysis was 
performed using Cell Quest analysis software. The 
percentage of CD71/TfR-positive cells was determined 
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within the CD4+ and CD8+ population.
Statistical analysis
Statistical analyses were done by paired two-tailed 
Student’s t-test using the SPSS software package to 
determine differences within the means of the sample 
proliferating versus apoptotic cells at different time 
points of the culture (days 2, 5 and 7) by labeling 
the nuclear DNA content with propidium-iodide (PI). 
Proliferation appeared to be quite constant during the 
culture, but the different mouse strains had different 
proliferation rates (Table 1). Of three mouse strains 
tested, BM cells from the C57BL mouse showed the 
highest proliferation rate, significantly higher than 
the NOD at days 5 and 7 (p<0.01). Proliferation rate 
in the BALB/c culture was on average also higher 
than in the NOD culture but this difference did not 
reach statistical significance, except for day 5 of the 
culture (p<0.05). Therefore, increased proliferation 
partly contributed to the higher cell number in the 
culture of the control strains. 
Using the same DNA staining, we could 
determine apoptosis in the cultures (cells with 
the nuclear content <2n) and found the highest 
percentage of dead cells at the earliest time point 
(day 2) in all cultures (Table 1). This was due to 
apoptosis of many BM cells unable to respond 
and survive when stimulated by GM-CSF (mature 
granulocytes or cells that belong to the erythroid 
and lymphoid lineage). At later time points, the 
number of apoptotic cells decreased in the C57BL 
and BALB/c cultures, which was not the case in 
NOD cultures. Therefore, the observed higher cell 
death in NOD cultures additionally contributed to 
the lower yield at the end of the culture period. 
NOR mice were not tested in this assay.
A more sensitive method to quantify dead cells 
Figure 1. Low cell yield and increased cell death in NOD GM-CSF-stimulated BM cultures. Total BM was stimulated 
with GM-CSF for 7 days in vitro. A. Total yield of viable cells from NOD cultures was significantly lower than from NOR, 
C57BL or BALB/c cultures. Data represent average values ± SEM derived from 2 (of 10 performed) experiments in which 
the BM from all four strains was cultured simultaneously. p<0.01 NOD vs C57BL and p<0.05 NOD vs NOR and BALB/c 
B. The frequency of dead (7-AAD+) cells at day 7 of culture in NOD is significantly higher than in C57BL and BALB/c 
but not higher than in NOR cultures. Average values (± SEM) derived from all 10 experiments are shown in the figure. 
p<0.01 NOD vs C57BL and BALB/c.
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groups. Results are presented as the mean ±SEM, unless 
otherwise indicated.
Results
A low yield of DC in GM-CSF-stimulated NOD 
BM cultures is caused by reduced proliferation 
and increased apoptosis
The capacity of NOD BM precursors to generate 
DC in vitro has been studied previously and 
several groups reported a low yield of cells in 
NOD cultures when stimulated with GM-CSF 
alone [12-14, 17]. Similarly, we found that NOD 
cultures on average contained a significantly lower 
number of cells compared to the cultures from both 
C57BL and BALB/c mice (p<0.01). (Fig. 1A). This 
appeared not to be caused by a decreased frequency 
of GM-CSF - responsive precursors in NOD BM 
as determined by limiting dilution analysis (data 
not shown). Interestingly, the yield of cells in NOR 
cultures was similar to C57BL and BALB/c mice 
(Fig. 1A).
To study the events causing the low yield of 
cells in NOD cultures stimulated with GM-CSF, 
we followed kinetic changes in the number of 
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at the end of the culture was the uptake of 7-AAD 
shortly before the sample acquisition. Using this 
method we found an even more pronounced 
difference in the frequency of dead or dying cells 
in NOD cultures. Significantly higher percentages 
were found in NOD cultures as compared to both 
C57BL and BALB/c cultures (p<0.01) (Fig. 1.B). 
NOR mice were also tested and the percentage 
of dead cells was higher in NOR than in C57BL 
and BALB/c cultures. Therefore, NOR mice show 
aberrancy regarding cell apoptosis similar to NOD, 
yet cell yield is normal and comparable to C57BL 
and BALB/c mice (Fig. 1). 
Diverged differentiation of BM cells to 
macrophages in NOD and NOR cultures
To investigate the possibility that NOD BM 
precursors demonstrated a reduced proliferation 
and an augmented apoptosis due to an aberrantly 
fast maturation, we analyzed BM cultures at 
different time points by double labeling for 
CD11c and MHC class II antigens. From the 
expression pattern of these two markers three DC 
developmental stages can be defined in normal 
BM cultures ([20] and morphological analysis 
below): granulocytes and myeloid precursors 
(CD11c–/MHCII–), immature DC (CD11c+/
MHCIImed) and mature DC (CD11c+/MHCIIhigh). 
Table 1. Proliferation and apoptosis analysis of BM cultures at different time points
day of 
culture
proliferationa apoptosisb
NOD C57BL BALB/c NOD C57BL BALB/c
2 18.1 ± 3.8 26.5 ± 3.7 19.9 ± 4.5 25.8 ± 7 20.1 ± 4.9 23.1 ± 9.7
5 11.4 ± 0.5 23.2 ± 1.7c 19.0 ± 1.4d 11.4 ± 3.2 4.7 ± 1.6 10.5 ± 2.1
7 15.0 ± 1 24.6 ± 2.1c 19.7 ± 1.9 9.4 ± 2.2 3.1 ± 0.3 6.0 ± 1.9
a data represent average frequency (±SEM) of cells with nuclear content >2n
bdata represent average frequency (±SEM) of cells with nuclear content <2n
c p<0.01 NOD vs C57BL; d p<0.05 NOD vs BALB/c
Figure 2. Deviated development of NOD DC in vitro. GM-CSF-stimulated cells from NOD and control (C57BL) were 
harvested at different time points and labeled with CD11c and MHC class II antibodies. After gating out dead cells (7-
AAD+), at days 2 and 5 of culture, a reduced percentage of CD11c+ cells was present in NOD culture. Upregulation of 
MHC class II in NOD cultures was also diminished, leading to the development of fewer mature DC (CD11c+/MHCIIhi) in 
culture. In addition, an increased percentage of CD11c+/MHCII- cells developed. Numbers indicate the percentage of cells 
in the quadrants. Dot-plots are representative of five separate experiments with similar results.
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These three subsets were phenotypically easily 
discerned in cultures of C57BL mice (Fig. 2) 
as well as other control mouse strains (data not 
shown). In addition, a small population of CD11c+/
MHCII– cells was found in all BM cultures. These 
cells are considered to be monocytes/macrophages 
(from personal communication with Dr. M. Lutz 
and see below) and they measured less than 10% 
of viable cells in cultures of control mice.
In comparison to C57BL, the developing 
NOD BM cultures showed a strikingly different 
cellular composition over time. At days 2 and 5 
of culture a reduced frequency of CD11c+ cells 
was found in NOD cultures (6% in NOD vs. 13% 
in C57BL and 24% in NOD vs. 46% in C57BL, 
for days 2 and 5, respectively) (Fig. 2). This 
difference was less pronounced at day 7 of culture 
(55% vs. 64% CD11c+ cells in NOD and C57BL, 
respectively). However, in marked contrast to the 
C57BL cultures, at day 7 the majority of CD11c+ 
cells in NOD culture were MHC class II– and a 
significantly reduced proportion of cells expressed 
MHC class II molecules (17% in NOD cultures 
as compared to 58% CD11c+/MHCII+ cells in 
C57BL). From these data, we concluded that in 
response to GM-CSF NOD BM precursors do 
not show a fast maturation to myeloid DC but 
in contrast, a deviated maturation into CD11c+/
MHCII– cells. 
Cells from BM cultures of NOR mice 
Figure 3. 
Few mature DC (CD11c+/
MHCIIhi) develop in NOD 
and NOR cultures but they 
show normal expression of 
co-stimulatory molecules. 
NOD, NOR, C57BL and 
BALB/c cells obtained from 
7day-GM-CSF-stimulated 
BM cultures were double 
labeled with MHCII and 
CD80, CD86 or CD40 
monoclonal antibodies. Dot-
plots show all culture-derived 
cells, after gating out dead 
cells (7-AAD+). The figure 
shows representative dot-
plots for each mouse strain 
from the same experiment. 
In total 3-7 independent 
cultures per mouse strain 
have been performed with 
similar results. 
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displayed a CD11c/MHCII staining pattern 
similar to NOD cultures. At day 7 of culture, 
NOR cultures contained 27% myeloid precursors 
(CD11c–/MHCII–), 22% monocytes/macrophages 
(CD11c+/MHCII–), 29% immature DC (CD11c+/
MHCIImed), and 21% DC with mature phenotype 
(CD11c+/MHCIIhigh). 
Further, we analyzed the expression of the 
costimulatory molecules CD40, CD80 and CD86 
by the different subsets, distinguished on the basis 
of MHC class II expression (Fig. 3). Expression 
of costimulatory molecules by cells derived from 
mice of the NOD background (NOD and NOR) 
was similar to the control cultures. Mature DC 
(CD11c+/MHCIIhigh) from NOD and NOR cultures, 
although present at a reduced frequency, expressed 
similar levels of CD40, CD80 and CD86 compared 
to the C57BL and BALB/c. Immature, MHC 
class IImed DC in all mouse strains were CD80low, 
CD86low and CD40–, whereas MHCII– cells were 
negative for all three markers showing again that 
these cells in NOD and NOR cultures were not 
DC that merely failed to upregulate MHC class 
II molecules.
Taken together, subset analysis of BM cultures 
showed that NOD and NOR precursors have a 
decreased potential to develop into DC (MHCII+/
CD11c+) when stimulated by GM-CSF. Yet, the 
relatively few immature (MHCIIlow/CD11c+) and 
mature (MHCIIhigh/CD11c+) DC that develop 
in these cultures express normal levels of 
costimulatory molecules on their cell surface.
Poor stimulatory capacity of DC generated in 
GM-CSF cultures from NOD and NOR mice 
In addition to the different frequency of mature 
DC, BM cultures showed different strain-specific 
capacities to stimulate T cells in the allogeneic 
MLR (Fig. 4). In two independent experiments, 
NOD as well as NOR DC failed to stimulate 
significant expression of CD71/TfR on the surface 
of allogeneic (C3H) T cells upon 4 days of co-
culture (Fig. 4A and B). In control experiments, 
we excluded the low response of T cells due to 
the responder mouse strain as a possible cause for 
the low MLR outcome. In addition, poorer MLR 
capacity of stimulators from NOD and NOR 
cultures did not originate from the MHC diversity 
with the controls since DC of the congenic NODH2b 
mice with the MHC region derived from C57BL 
strain showed the same NOD-like low stimulation 
capacity (data not shown). Taken together, GM-
CSF-generated DC from the mice that share the 
NOD background also share a poor stimulation 
capacity.
The poor stimulation capacity of NOD and 
NOR DC could not be overcome by an additional 
maturation stimulus. Unlike DC from C57BL and 
BALB/c cultures, NOD and NOR DC failed to 
increase their T cell activation potential when 
stimulated overnight with 100ng/mL LPS (Fig. 
4C). However, the quality of T cells stimulated 
by any of the strains was similar with respect to 
the cytokine production: they produced significant 
amounts of IFNg and little IL-4 or IL-10, therefore 
Figure 4. Poor stimulatory capacity of total culture-derived cells generated from NOD and NOR mice. A. and B. 
Total BM culture-derived cells were co-cultured for 4 days with allogeneic T cells from C3Heb/Fej mice in different APC: 
T cell ratios. The capacity of total culture-cells from NOD mice is compared with C57BL or BALB/c mice in Exp.1 and 
with NOR or BALB/c mice in Exp.2. In contrast to the other two mouse strains, NOD and NOR cells exhibited similar poor 
stimulatory capacity. C. LPS stimulation increased the stimulation potential of BM cells from all four strains. However, 
stimulated NOD and NOR cells exhibited again a much lower stimulatory capacity than C57BL or BALB/c cells. Data 
present the percentage of T cells (CD4+ and CD8+) that express CD71/TfR as indication of their productive stimulation by 
APC. A representative of at least 3 independent MLR cultures for each mouse strain is shown. 
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were Th1-like. When calculated per cell, all T cells 
produced similar levels of cytokines irrespective 
of the origin of DC by which they were stimulated 
(data not shown). 
The very low frequency of mature DC in NOD 
cultures observed in phenotypic analysis might 
have been the reason for the poor performance 
of the whole population in the MLR. Therefore, 
BM subsets were purified by cell sorting and co-
cultured with allogeneic T cells (Fig. 5). Although 
devoid of potential inhibitory cells and present in 
the same numbers as in the control, purified mature 
NOD DC (CD11c+/MHCIIhigh) failed to stimulate 
T cells to a significant level when compared to 
C57BL mature DC (Fig. 5E). The percentage 
of T cells that had upregulated CD71/TfR when 
stimulated by NOD mature DC (Fig. 5E) was 
rather comparable to the proportion induced by 
the immature DC or monocytes/macrophages 
from C57BL culture (Fig. 5C or D). Other purified 
subpopulations from NOD cultures also exhibited 
lower stimulatory capacity than the corresponding 
C57BL subpopulations. 
Morphology of mature DC in NOD cultures is 
similar to the immature DC from the C57BL
To characterize further the four cell subsets 
identified in flow cytometric analysis (see 
before), we investigated the morphology of cells 
separated by cell sorting from day 7 BM culture on 
the basis of their differential expression of CD11c 
and MHC class II molecules (Fig. 6A). As shown 
in figure 6B, the CD11c–/MHCII– (R1) population 
contained myeloid precursors (slightly indented 
large nucleus with more basophilic cytoplasm) 
and neutrophillic granulocytes (typical segmented 
nucleus) in both NOD and C57BL cultures. The 
CD11c+/MHCII– (R2) fractions, abundantly 
present only in NOD, contained morphologically 
distinguishable monocyte/macrophage-like cells 
in both cultures (asymmetrically positioned oval 
or kidney-shaped nucleus and a high cytoplasm/
nucleus ratio). The CD11c+/MHCIImed (R3) cells 
derived from C57BL BM resembled immature 
DC (relatively large cells with an oval nucleus on 
one cell side and a large cytoplasm, more regular 
in shape) which formed relatively large clusters. 
In contrast, cells of the same CD11c+/MHCIImed 
Figure 5. Poor capacity of sorted mature DC from NOD BM cultures to stimulate T-cells. Sorted cells from 7 day 
cultures were co-cultured with allogeneic T cells at different APC : T cell ratios. Data are presented as percentage of T 
cells that express CD71/TfR. Unseparated NOD culture-derived cells were virtually unable to stimulate T-cell proliferation, 
in contrast to their C57BL counterparts. As expected, purified mature DC (CD11c+/MHCIIhi) from the C57BL culture 
displayed the highest stimulating capacity while NOD mature DC were poor stimulators even when purified. Data are a 
representative of two experiments performed independently, with similar results.
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Figure 6. 
Morphological analysis of cells 
in GM-CSF-stimulated culture 
shows similar subpopulations in 
NOD and control cultures. A. Four 
subpopulations of cultured cells can 
be defined with MHCII and CD11c: 
(R1) CD11c–/MHCII–; (R2) CD11c+/
MHCII–; (R3) CD11c+/MHCIImed and 
(R4) CD11c+/MHCIIhi. Represented 
gates are used for cell sorting. B. 
Sorted cells are morphologically 
identified as follows: R1-myeloid 
precursors and neutrophils; 
R2- monocytes/macrophages; 
R3- immature DC and R4- mature 
DC (more details in Results). 
Magnification x126.
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Figure 7. Elevated expression of monocyte/macrophage markers by mature NOD DC (CD11c+/MHCIIhi) generated 
with GM-CSF. Cells were triple labeled with CD11c, MHCII and a marker of interest. The light grey line indicates a 
histogram of the isotype control; the histogram indicated with the black line represents the marker expression by mature 
DC from NOD and the dark grey line of C57BL cells. Histograms are derived from a representative staining of at least six 
independent experiments per mouse strain. 
population in NOD cultures hardly formed any 
clusters. Finally, CD11c+/MHCIIhigh (R4) cells 
from C57BL cultures had an irregular shape and 
a number of dendritic protrusions, thus resembling 
mature DC that mostly occurred as single cells 
or formed small clusters. The morphology of 
phenotypically mature DC separated from NOD 
cultures did not differ significantly from their 
C57BL counterparts but they formed large clusters 
comparable to immature C57BL DC. 
Mature NOD and NOR myeloid DC 
express higher levels of markers typical for 
macrophages 
The defective T cell stimulatory capacity and large 
cluster formation of separated mature DC from 
NOD BM cultures prompted us to investigate their 
phenotype further. Since NOD BM precursors 
seem to develop more readily into monocytes/
macrophages (CD11c+/MHCII–) in vitro, we 
focused on macrophage markers in particular. As 
shown in Figure 7, mature DC (CD11c+/MHCIIhigh 
cells) from C57BL cultures express very low-to-
negative levels of FcRg II/III, scavenger R, F4/80 
and Gr-1. In contrast, much higher levels of these 
markers were found on mature NOD DC. When 
quantified from other mouse strains (Table 2), 
tested markers were higher on mature DC from 
NOD mice than on both C57BL and BALB/c 
mature DC. Interestingly, scavenger R and F4/80 
were expressed on the NOR mature DC similarly 
like in the NOD while FcRg II/III and Gr-1 values 
were intermediate between the NOD and the other 
two strains.
Mature DC from NOD cultures contain an 
abnormally high percentage of macrophage-
like cells with a strong lysosomal activity
To assess the putative macrophage-like nature 
of mature DC generated in NOD cultures, we 
performed a cytochemical staining of acid 
phosphatase (AP) (for categorization/scoring see 
Material and Methods) in sorted cell populations 
(Fig. 8A). Initial examination revealed that the 
AP pattern of the sorted populations from the 
C57BL cultures overlapped to a great extent to 
their phenotype. This was not the case in sorted 
cells from NOD cultures. When quantified (Fig. 
8B), the R3 population from NOD cultures with 
the phenotype of immature DC also included a 
significant percentage of cells with a lysosomal 
activity typical of macrophages (strong cytoplasmic 
staining) (49% for NOD vs. 8.3% for C57BL). An 
even more pronounced difference between NOD 
and C57BL existed in the sorted CD11c+/MHCIIhi 
population (R4) of phenotypically mature DC. This 
population isolated from NOD cultures contained 
few cells with the staining pattern typical of mature 
DC (single dot staining) (3.3% for NOD vs. 83% 
for C57BL) and a remarkably high percentage of 
marker
NOD     
(n=5)a 
NOR      
(n=3)
C57BL   
(n=4)
BALB/c 
(n=1)
FcRg II/III 118 ± 53b 59 ± 6 38 ± 22 44
scavenger R 162 ± 27 192 ± 6 11 ± 3 33
F4/80 148 ± 20 133 ± 8 28 ± 4 31
Gr-1 108 ± 26 70 ± 5 11 ± 4 7
a number of samples derived from a representative staining
b data represent an average MFI (± SEM)
Table 2. Intensity of monocyte/macrophage markers 
expression on CD11c+/MHCIIhi DC from different 
mouse strains
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cells with a staining like macrophages (67.3% for 
NOD vs. 7.7% for C57BL).
To investigate whether this low percentage 
of real mature DC and a high percentage of 
macrophages in the alleged mature DC population 
is indeed NOD specific, we sorted mature CD11c+/
CD86+ DC from 7 day GM-CSF stimulated 
cultures from NOD, NOR, C57BL and BALB/c 
cultures and quantified the AP staining. As shown 
in Figure 8C, NOD cells contained significantly 
lower number of cells with a single dot staining 
of mature DC than NOR, C57BL or BALB/c 
cells. However, both NOD and NOR contained 
more immature DC (weak cytoplasmic staining). 
Importantly, specifically CD11c+/CD86+ DC from 
NOD cultures contained significantly more cells 
with strong cytoplasmic (macrophage-like) AP 
staining than any other strain tested.
Aberrant myeloid DC development from NOD 
BM precursors stimulated with Flt3-L
It might be argued that the aberrant response we 
Figure 8. NOD mature DC have strongly increased acid phosphatase activity. A. Cytocentrifuge preparations of 
sorted cells were stained for AP and then counterstained with hematoxylin (magnification x285). B. Distribution of cells 
with different staining-pattern (see Material and Methods) in three indicated sorted populations from the NOD and C57BL 
cultures. Populations with a phenotype of immature and mature DC from NOD cultures contained a high number of cells 
with a strong AP activity (red area of the bar). C. Composition of the separated mature DC population (CD11c+/CD86+) 
from four different mouse strains (NOD, NOR, C57BL and BALB/c) with respect to the three cell types defined by the 
AP pattern (strong cytoplasmic staining – macrophages; weak cytoplasmic staining– immature DC; single dot pattern 
– mature DC). NOD and NOR cells contained more immature DC and fewer mature DC as judged by their AP activity. 
High frequency of cells with a high macrophage-like AP activity were found only in NOD CD11c+/CD86+ population. Data for 
A and B are representative of two independent experiments and C shows an average value ± SEM of four independent 
sortings for each mouse strain.
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observed mirrors the defect of NOD BM cells 
to respond to GM-CSF, rather than an inherent 
difficulty to develop into normal DC in culture. 
Flt3-L stimulates the development of both myeloid 
and plasmacytoid DC from mouse BM. Therefore, 
we cultured NOD, C57BL and BALB/c BM with 
Flt3-L according to the method of Gilliet et al. 
[21]
Similar to our findings for GM-CSF-stimulated 
cultures, the yield at day 10 of the Flt3-L-stimulated 
cultures was lower from NOD precursors compared 
to controls. In two independent experiments, the 
total cell yield in NOD cultures was 56% and 
43% of the C57BL and 67% of the BALB/c 
cultures. When analyzed by flowcytometry, the 
proportion and the phenotype of plasmacytoid 
CD11c+/CD11b– cells did not differ significantly 
among the strains (Fig.9). In contrast, the NOD 
cultures contained particularly fewer myeloid 
CD11c+/CD11b+ DC (16.2% in NOD vs 32.3% 
and 28.1% in C57BL and BALB/c, respectively) 
(Fig. 9A). Additionally, the phenotype of myeloid 
DC in NOD Flt3-L-stimulated cultures exhibited 
similar phenotypic abnormalities (Fig. 9B) as in 
GM-CSF-stimulated cultures. NOD myeloid DC 
failed to reach a mature phenotype, unlike the 
control, as they were primarily MHC class IIlow, 
CD80– and Gr-1+. 
Therefore, the deviated development of myeloid 
DC in both Flt3-L and GM-CSF-stimulated 
cultures suggests an inherent abnormality in 
myeloid differentiation, rather than an aberrant 
response to a specific cytokine.
Discussion
The results presented in our study demonstrate 
several anomalies in the generation of myeloid 
DC from BM precursors in vitro in NOD and NOR 
mice. A) A low cell yield from BM precursors was 
specific for the NOD and not found in NOR mice. 
B) Both NOD and NOR showed an increased cell 
death of BM DC precursors, but this was more 
outspoken in the NOD mouse. C) An abnormally 
increased frequency of macrophages was found 
in GM-CSF-stimulated NOD and NOR BM 
cultures. 
In addition, CD11c+/MHCIIhigh “DC” with 
an aberrant phenotype and macrophage-like AP 
activity were generated in NOD cultures. We 
conclude that myeloid precursors from NOD 
mice stimulated with GM-CSF predominantly 
mature into macrophage-like cells. Similar 
phenotypic abnormalities were evident in NOD 
myeloid DC generated with Flt3-L, pointing to an 
intrinsic deficiency of the precursors of mice with 
an NOD background to develop into real myeloid 
DC. The fact that only part of the NOD-associated 
anomalies in the generation of DC were present in 
the NOR underscores the multigenic complexity 
of the DC differentiation problems in mice of the 
NOD background.
Our first finding of the significantly lower 
yield of DC from NOD BM precursors in vitro 
is in agreement with previous reports [13, 14, 
17]. Furthermore, we demonstrated that in 
NOD/Ltj mice a combined low proliferation and 
an increased apoptosis of GM-CSF-stimulated 
BM precursors lead to such observed low cell 
yield. Our data concur with recently reported 
findings of a lower proliferation and an increased 
apoptosis of DC precursors in the congenic NOD 
H-2k mouse [31]. Together, these data point to an 
intrinsic problem of proliferation and apoptosis of 
DC precursors under the control of NOD-specific 
genes independent of the H-2g7 MHC region. NOR 
mice that share several gene segments with the 
NOD mouse (including the H-2g7 MHC region) 
[32] also shared part of the high apoptosis in the 
BM culture with NOD, but had no problems to 
generate a normal cell yield. 
Follow-up of DC maturation in NOD and 
NOR cultures revealed additional anomalies: 
BM derived cells ineffectively differentiated into 
CD11c+/MHCIIhi prototypic DC and a significant 
proportion of CD11c+ cells did not express MHC 
class II and costimulatory molecules. The latter 
cells were not immature DC incapable to bring 
MHC class II molecules to the cell surface, as 
evaluated by immunocytochemistry. Additionally, 
24-hour stimulation with LPS failed to induce 
maturation of these cells into typical mature DC. 
This, together with the morphology and phenotype 
of the cells supports the notion that the numerous 
CD11c+/MHCII– cells in NOD and NOR cultures 
were monocytes and macrophages and not DC. 
The co-development of macrophages during in 
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Figure 9. Aberrant generation of NOD myeloid DC in Flt3-L-stimulated cultures. BM cells were stimulated as reported 
by Gilliet et al.[21] A. Representative dot-plots of CD11c/CD11b staining indicates the development of different DC subsets 
under the influence of Flt3-L. Numbers express the frequency of plasmacytoid (CD11c+/CD11b-) and myeloid (CD11c+/
CD11b+) DC in NOD and control (C57BL and BALB/c) cultures. B. Histograms show the phenotype of plasmacytoid and 
myeloid DC in NOD vs. control. Vertical line indicates the upper threshold of the negative control, the black line indicates the 
marker expression of gated plasmacytoid or myeloid DC in NOD culture and the grey line indicates the marker expression 
of the corresponding population in control culture. NOD myeloid DC displayed a similar deviant phenotype as observed in 
GM-CSF-stimulated culture. Plasmacytoid DC obtained from NOD and C57BL BM precursors had comparable phenotype. 
Similar data were obtained in two independent experiments.
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vitro culture of BM precursors with GM-CSF 
has been reported previously in normal non-
autoimmunity prone mice [33]. Likewise, we also 
found CD11c+/MHCII– monocytes/macrophages in 
control cultures, but the frequency of these cells 
was very low in controls and noteworthy in NOD 
and NOR. Therefore, our data suggest that the 
decreased frequency of mature DC results from a 
deviated differentiation of myeloid precursors into 
macrophages (rather than DC) in BM cultures of 
mice with the NOD background.  
A further abnormality we detected was that 
CD11c+/MHCIIhigh/CD86+ DC from NOD cultures 
that did express costimulatory molecules and 
approached the phenotype of prototypic mature DC 
the best, nevertheless had low T cell stimulation 
capacity, expressed increased levels of monocyte/
macrophage markers and had an abnormally high 
percentage of cells with a strong AP activity. These 
by phenotype “mature” DC therefore seemed 
more related to macrophages (hence we called 
these cells macrophage-like DC). Interestingly, 
DC from NOR mice shared properties with the 
NOD DC like a similar low maturation rate and 
a poor T cell stimulatory capacity and some 
of the macrophage characteristics, such as the 
higher expression of scavenger R and of F4/80. 
However, NOD cultures exclusively contained a 
high percentage of macrophage-like DC as judged 
by acid phosphatase. 
Our data once more indicate the complexity of 
the gene-background determinants that establish 
various deviations in the development of DC from 
BM precursors in mice with the NOD background. 
According to Prochazka et al , NOR mice possess 
C57BL/KsJ-derived genes on chromosomes 
2, 4, 11, and 12. The remaining markers on 14 
chromosomes, including the diabetogenic H-2g7 
complex on chromosome 17, are of NOD origin. 
Interestingly, NOR mice, although being diabetes-
resistant, share with NOD mice the T-lymphocyte 
accumulation in peripheral organs and a depressed 
IL-1 secretion by peritoneal macrophages. Yet, 
unlike NOD, NOR mice have a robust suppressor 
T-lymphocyte function. 
The mechanisms that lead to the aberrant 
generation of DC in NOD cultures remain elusive. 
They might originate from intrinsic and genetically 
determined defects in BM precursors, or they might 
be induced by the numerous macrophages present 
and arising in the NOD cultures. Studies have been 
published that provide circumstantial support for 
each of the two possibilities [34-40]. 
With regard to the intrinsic defects in BM 
DC precursors, a deficient upregulation of the 
GM-CSF receptor or an abnormal downstream 
signaling from the receptor are good candidates 
for the abnormal cell maturation and increased 
cell death in culture, particularly in view of the 
defective response of NOD myeloid precursors to 
GM-CSF and IL-5, which share signaling-chain of 
the receptor [34]. However, we show that aberrant 
myeloid DC also develop when using Flt3-L as 
stimulator, which signals through a different 
receptor. Hence, we consider aberrations in a 
common signaling pathway more likely. Several 
studies so far have shown abnormalities in NF-
kB degradation in NOD splenocytes and in vitro-
derived NOD APC [35, 36]. It would be interesting 
to investigate whether similar defects can also be 
found in NOD and NOR DC precursors, thus at an 
earlier developmental stage. 
Alternatively, the numerous macrophages 
present in the culture might inhibit a normal 
maturation of DC in the NOD and NOR cultures. 
Presence of macrophages in a culture is usually 
considered to be beneficial since they produce 
TNFa and thereby support spontaneous maturation 
of DC [37]. However, the abnormal cytokine profile 
that has been shown for NOD macrophages [38] 
might make them inhibitory instead of supportive 
for the growth and maturation of DC in culture. A 
potential inhibitory cytokine might be IL-6 as it has 
been shown that IL-6 shifts the differentiation of 
human monocytes from DC toward macrophages, 
while TNFa favors maturation into DC [39, 40]. 
Yet, in the supernatants collected from day 7 BM 
cultures we could not detect appreciable levels 
of TNFa, IL-6 or IL-1b and when stimulated 
with LPS, C57BL and NOD BM-derived cells 
produced similar levels of these cytokines (data 
not shown). Therefore, it is less likely that an 
increased production of inhibitory cytokines 
in NOD cultures is the decisive factor in the 
deviated DC generation. However, macrophages 
in the GM-CSF-stimulated NOD and NOR cultures 
could still inhibit DC maturation by direct cell-
cell interactions or by soluble factors produced at 
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earlier stages in the culture. 
An important difference between our current 
investigation and previous studies, in which an 
increased generation or enhanced stimulatory 
capacity of DC generated from NOD BM have 
been reported [15, 16], is that we did not use 
IL-4 in our culture system. A supportive effect 
of IL-4, added to GM-CSF, for the generation 
and maturation of NOD BM-derived DC was 
observed in several studies before [13, 14, 41, 
42]. Also in our hands, NOD cultures showed an 
improved DC yield and stimulatory capacity in 
MLR when cultured with IL-4 added to GM-CSF 
(unpublished observation). Normally, IL-4 is not 
added to GM-CSF-driven DC culture in mice 
since GM-CSF alone is considered sufficient for 
the optimal generation of DC from the mouse BM 
[20]. However, unlike other mouse strains, BM 
precursors from NOD mice apparently critically 
depend on the presence of IL-4 for a normal and 
optimal development of DC. IL-4 is known to 
inhibit macrophage outgrowth in the culture [43] 
but it may also function by increasing the cells’ 
sensitivity for DC-maturation factors such as 
TNF-a [44]. Whatever the mechanism may be, the 
beneficial effect of IL-4 in NOD cultures points to 
a subtle intrinsic deficiency in NOD BM precursors 
to develop into mature DC. This deficiency, 
magnified in vitro, might not be a decisive factor 
leading to obviously malfunctioning DC in vivo 
but probably contributes to the sensitivity of the 
DC system in NOD and NOR mice, which may 
be more prone to imbalance when challenged by 
external triggers in the NOD and protected by 
C57BL-inherited genes in the NOR mouse. In such 
way this subtle abnormality in DC differentiation 
might contribute to the autoimmune-prone genetics 
of NOD mice. However, since these anomalies are 
also largely present in NOR mice they are certainly 
not sufficient to precipitate autoimmune diabetes 
on their own.
It is unclear whether the correlate of a 
macrophage-like DC that we find in NOD BM 
culture exists in vivo. GM-CSF-stimulated 
culture might be considered a system in which 
inflammation-related DC are generated, and 
therefore one could imagine that NOD myeloid 
precursors could encounter similar problems to 
undergo normal maturation during inflammation in 
vivo. The immature CD11c+/MHCIIlow DC produced 
under such circumstances would be the correlate of 
our macrophage-like DC in vitro. Findings from 
a recent study support this idea since NOD cells 
increasingly develop into CD11c+MHCIIlow DC 
when reconstituting mixed BM chimeric mice [31]. 
Further studies on development and function of 
different DC subsets in the NOD mouse in steady 
state and inflammation would be necessary to 
confirm or reject this hypothesis. 
In conclusion, in this study we describe an 
anomaly of myeloid BM precursors in NOD and 
NOR mice to develop preferentially into macrophages 
and abnormal macrophage-like DC when stimulated 
in vitro. Potentially, this defect contributes to the 
dysfunctional regulation of tolerance in NOD mice.
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3.4
A subfraction of B220+ cells in murine bone marrow and spleen 
does not belong to the B cell lineage but has dendritic cell 
characteristics
Tatjana Nikolic, Gemma M. Dingjan, Pieter J. M. Leenen and Rudolf W. Hendriks
Chapter 3128 DC precursors in mouse bone marrow 129
Chapter 3128 DC precursors in mouse bone marrow 129
Although CD45R/B220 is commonly used as a pan-B cell marker in the mouse, not 
all B220+ cells belong to the B cell lineage. Here we report the characterization of a 
subpopulation of B220+CD19– cells in murine bone marrow, which failed to express 
markers that are present in early CD19– B cell precursors. Instead, these cells expressed 
low levels of MHC class II and CD11c, which are typically found on dendritic cells (DC). 
Moreover, these B220+CD19–CD11c+ cells expressed Gr-1, indicating that they are related 
to the recently identified murine plasmacytoid DC or their progenitors. Therefore, we 
evaluated surface marker expression of the B220+CD19–CD11c+ cells in lymphoid tissues 
of C57BL/6 mice, recombinase activating gene-1 deficient mice, lacking mature B and T 
lymphocytes, and mice with a targeted disruption of the Ig H chain m membrane exon 
(mMT), lacking mature B lymphocytes. When comparing bone marrow and spleen, we 
found that the surface profiles of B220+CD19–CD11c+ cells were remarkably similar, 
indicating that they are in a comparable maturation or activation stage in the two 
lymphoid compartments. In addition, the almost complete absence of peripheral B220+ 
B-lineage cells in mMT mice allowed the anatomical localization of the B220+CD19–CD11c+ 
cells to the red pulp and the T cell areas in the spleen. Taken together, our findings indicate 
that the mouse bone marrow contains a recirculating population of B220+CD19– CD11c+ 
plasmacytoid DC, the development of which is largely independent of the presence of 
mature T and B cells. 
In the mouse, B-lineage cells express the high molecular weight form of the common leukocyte antigen CD45, termed B220, on 
their cell surface [1]. B220 is already present 
on the earliest identified CD43+ pro-B cells and 
expression is continued in pre-B, immature B and 
mature B cells, and is only downregulated at the 
late plasma cell stage [2, 3]. Although B220 is 
commonly used as a pan- B cell marker, it is also 
present on non-B lineage cells in the bone marrow 
(BM): a small subpopulation of B220+ cells, which 
also expressed the NK1.1 marker, was shown to 
contain NK cell progenitors [4]. CD19 provides 
a more lineage-restricted marker in vivo, as it is 
a direct target gene of the transcription factor 
pax-5, which is critical for commitment to the B 
cell lineage [5]. Nevertheless, a subpopulation of 
CD19+ cells can give rise to dendritic cells (DC) 
in culture [6].
The nature of the earliest B cell precursor 
populations in the mouse is not well defined and 
different, partially conflicting, models of early B 
lymphopoiesis have been devised [2, 3, 7]. In recent 
years, research has focused on the characterization 
of specific subpopulations of B220+CD19– cells 
in the BM. In the model by Hardy et al. [2, 8], 
fraction A cells (CD43+B220+CD19–HSA–) are 
subdivided and only the fraction expressing the 
AA4.1 surface molecule was shown to include 
B lineage precursors, as identified by expression 
of Ig H chain m
o
 germline transcripts and the 
transcription factor pax-5. Tudor et al. [7] have 
identified a subfraction of DX5–Ly-6C– primitive 
B220+CD19– B cell precursors, which does not 
appear to overlap with the AA4.1+ subpopulation 
of Hardy’s fraction A cells.
Rolink et al. [4] have distinguished three 
subpopulations of CD43+B220+CD19– cells, 
including (1) NK1.1–CD4– B cell precursors, (2) 
NK1.1+ NK cell precursors, which are probably 
contained within the AA4.1– fraction A cells 
[8] and (3) NK1.1–CD4+ cells, which were not 
further studied. Potentially, these latter cells might 
represent DC, since recently B220+ DC populations 
have been described that can be propagated from 
mouse liver [9] or are present in lymph node and 
spleen [10]. The latter population of B220+ cells 
was shown to contain a significant proportion 
of CD4+ cells and displayed characteristics of 
plasmacytoid
DC [10]. These cells have the capacity to 
stimulate T cell proliferation after activation with 
CpG and are major producers of IFNa after viral 
stimulation [11, 12]. They differ from most DC 
types as they are thought to enter lymph nodes 
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directly from the blood by transmigrating high 
endothelial venules. We hypothesized that if these 
plasmacytoid DC are also present in the BM, they 
may be contained within the NK1.1–CD4+ fraction 
of CD43+B220+CD19– cells.
In this report we have addressed this issue 
by phenotypical characterization of the NK1.1– 
subpopulation of CD43+B220+CD19– cells in the 
BM. These cells express surface markers that are 
typically present on DC, such as MHC class II and 
CD11c, albeit at low levels. We conclude that this 
cell population is similar to the CD11c+B220+Gr-1+ 
plasmacytoid DC that were previously identified 
in lymph nodes and spleen [10]. Therefore, the 
B220+CD19– CD11c+ cells in the BM do not belong 
to the B cell lineage, but reflect a recirculating 
population of this specific subset of DC.
80 and SLC/LM34 were biotinylated according to standard 
procedures. Secondary antibodies were PE, Tri-Color or 
APC-conjugated streptavidin and FITC-conjugated goat 
anti-rat, purchased from Caltag Laboratories (Burlingame, 
CA). Intracellular flow cytometric detection of cytoplasmic 
Ig H or L chain (FITC-conjugated anti-Igk or anti-IgM) was 
performed on cells that were first stained for cell surface 
markers and subsequently fixed in 2% paraformaldehyde 
and permeabilized using 0.5% saponin, as previously 
described [22].
Immunohistochemistry
Tissue samples were embedded in OCT compound and 
frozen 6-mm cryostate sections were acetone fixed 
and double labelings were performed as previously 
described [25]. The mAb antiB220/RA3-6B2 [1], 
anti-CD11c/N418, and MOMA-1 [26] were applied as 
purified hybridoma culture supernatants. Biotinylated 
anti-CD4 was purchased from BD Pharmingen.
Results and Discussion
The identification of B220+CD19–CD11c+ cells 
in BM
To investigate B220+CD19– cells in detail, four-color 
flow cytometry experiments were performed on 
lymphoid tissues from C57BL/6 mice, recombinase 
activating gene-1 deficient (RAG-1–/–) mice [13] and 
mice with a targeted disruption of the Ig H chain m 
membrane exon (mMT mice[14]). The RAG-1–/– and 
mMT mice were included to facilitate the analysis 
of non-B cell lineage B220+ cells, as in these mice 
B-lineage cells are virtually absent in the peripheral 
lymphoid organs and limited to a small fraction of 
B220+CD19+ pro-B cells in the BM. 
The B220-CD19 flow cytometry profile of BM 
cell suspensions from normal, RAG-1–/– and mMT 
mice revealed a population of CD19– cells in which 
the expression level of B220 was heterogeneous 
(Fig. 1). As early B cell progenitors were shown 
to express relatively low levels of B220 [15], 
we hypothesised that the putative non-B cell 
lineage cells would be present in the B220+CD19– 
subfraction in which the expression level of B220 
was higher than the level in B220lowCD19+ pro-B 
cells. In all three mouse strains, ~3–5% of the BM 
cells with low side scatter characteristics, typical for 
lymphocytes or DC, were B220+CD19–.
On the basis of the expression profile of CD11c 
and NK1.1, the B220+CD19– cell fraction was 
Materials and Methods
Mice
RAG-1–/– [13] and mMT [14] mice, which were on a 129/
Sv and C57BL/6 background, respectively, were purchased 
from the Jackson Laboratory, Bar Harbor, ME. All mice 
were bred and maintained in the animal care facility at the 
Erasmus University Rotterdam.
Flow cytometric analysis
Preparations of single-cell suspensions and flow 
cytometry have been described previously [21, 22]. 
Events (1-3x105) were scored using a FACSCalibur flow 
cytometer and analyzed by CellQuest software (Becton 
Dickinson, Sunnyvale, CA). Low side scatter cells were 
gated to exclude contaminating Mf. The following 
mAb were obtained from Pharmingen (San Diego, CA): 
FITCconjugated anti-BP-1/6C3, anti-B220/RA3-6B2, 
anti- CD11c/HL3, anti-CD86, anti-k/R5-240 and anti-
IgM (II/41); PE-conjugated anti-CD11c/HL3, anti-CD19, 
anti-CD25, anti-CD43, NK1.1, anti-MHCII (M5/114), 
anti-CD69 and anti-CD80; Cy-Chrome-conjugated anti-
B220/RA3-6B2; biotinylated anti-IgM (II/41), anti-CD19, 
anti-CD24/HSA (M1/69) and APC-conjugated anti-CD4. 
PE-conjugated IgD was obtained from SBA (Birmingham, 
AL). FITC-conjugated DEC205 monoclonal antibody 
was purchased from RDI (Flanders, NJ). The hybridomas 
PB493/AA4 [23, 24] and SLC/LM34 [17] were kindly 
provided by A. Rolink,( Basel Institute for Immunology, 
Switzerland), while F4/80 was provided by S. Gordon 
(University of Oxford, GB). PB493/AA4, ER-BMDM1, 
and 33D1 were used as purified hybridoma supernatants. F4/
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Figure 1.
Identification of  CD11c+ B220+ 
CD19– cells in BM. Flow cytometric 
analyses of BM of wild-type, 
RAG-1–/– and mMT mice. The 
immunofluorescent profiles of 
B220+CD19– cells are displayed 
as dot plots. Subsequently, the 
indicated gated B220+CD19– cells 
were analyzed for the expression of 
CD11c, in combination with CD43, 
cSLC, NK1.1, CD4, or Gr-1 as 
indicated. A parallel analysis of these 
surface markers on B220+CD19+ 
cells from mMT BM is shown for 
comparison. Percentages within the 
indicated gates or quadrants are 
given. Data shown are representative 
for four to eight mice examined within 
each group.
divided into three separate subpopulations (Fig. 
1). The small population of NK1.1+ cells, which 
most likely reflected the previously characterized 
B220+CD19–NK1.1+ population of NK cell 
precursors [4], was found to be CD11c+. This is 
consistent with the finding that also mature NK cells 
in the spleen express low levels of CD11c (data 
not shown). Another small population consisted 
of NK1.1–CD11c– cells. The largest population, 
containing 80–90% of the B220+CD19– cells, 
consisted of NK1.1–CD11c+ cells. The CD11c 
molecule is the a
x
 chain that pairs with b2/CD18 
to form the gp150,95 integrin, also known as CR4 
and is present on the cell surface of DC [16]. We 
therefore hypothesized that the CD11c+ B220+CD19– 
cells may represent a unique DC subpopulation, 
probably related to the CD11c+B220+Gr-1+ cells 
with characteristics of plasmacytoid DC in lymph 
nodes and spleen [10].
CD11c+B220+CD19– cells in the BM do not 
belong to the B cell lineage
As it has been demonstrated that early B cell 
precursors  are positive for CD43, AA4.1 and 
cytoplasmic surrogate light chain and may 
express low levels of surface CD4 [2, 4, 7, 17], 
we analyzed the expression of these markers in 
combination with CD11c (Fig. 1). Like CD19+ 
B cell precursors, the B220+CD19–CD11c+ cells 
were CD43+. However, in contrast with the CD19+ 
B cell precursors, they did not express surrogate 
light chain in their cytoplasm and were surface 
AA4.1– (Fig. 1 and not shown). The expression 
of CD4 was heterogeneous (Fig. 1). In additional 
four-color analyses, the CD11c+B220+ CD19– cells 
in C57BL/6 mice were negative for surface IgM, 
intracellular Ig mH or k L chain, or BP-1 (data not 
shown), which excluded the possibility that these 
cells (partially) reflected a more mature B-lineage 
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subpopulation that had lost CD19 expression. We 
therefore conclude that we have identified in the 
BM a novel population of CD43+B220+CD19–
CD11c+ cells, which apparently does not belong 
the B cell lineage, as these cells do not express 
markers that are typically present in early CD19– B 
cell precursors.
Surface characterization of B220+CD19–CD11c+ 
cells in BM and spleen
To further investigate if the CD11c+B220+CD19– 
cells are related to the peripheral plasmacytoid DC, 
we analyzed the expression of Gr-1, a granulocyte 
marker that is also expressed on plasmacytoid DC 
in the mouse [10]. We found that the majority of 
Figure. 2. 
Comparison of the surface phenotype 
of CD11c+B220+CD19– cells from BM 
and spleen, and splenic CD11c+ DC. 
(A–B) In flow cytometry experiments, cell 
suspensions from RAG-1–/– mice were 
stained for B220, CD11c, CD19, together 
with a fourth marker. (A) CD19– cells were 
gated and analyzed for CD11c and B220. 
The regions set to define the B220+CD19–
CD11c+ cells and the CD11c+ DC in the 
analyses are indicated. (B) Expression 
profiles of the specified markers in the DC 
populations in BM or spleen, displayed as 
histograms (C) B220+CD19– cell fractions 
from BM and spleen of the indicated mice 
were gated and analysed for the expression 
of CD62L and CD8. The numbers represent 
the percentage of cells that are positive for 
the specified markers.
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B220+CD19–CD11c+ BM cells expressed moderate 
levels of Gr-1 (Fig. 1), supporting the notion that 
these cells in the BM are plasmacytoid DC or 
their progenitors. Indeed, we were able to identify 
similar B220+CD19–CD11c+Gr-1+ cells in spleen 
and lymph nodes. They were also found in the 
thymus, where they comprised ~ 50% of the small 
population of B220+ cells (data not shown).
Next, we evaluated the surface profile of 
B220+CD19–CD11c+ cells in the BM and the spleen 
of C57BL/ 6, RAG-1–/– and  mMT mice (Fig. 2). We 
performed flow cytometric analyses, using CD11c, 
B220 and CD19 and a fourth marker. The marker 
expression profiles of B220+CD19–CD11c+ cells 
in the two lymphoid tissues from the three groups 
of mice were similar, although some quantitative 
expression differences were noticed (see below). 
Also the CD11c+ B220+CD19– cell population in 
the spleen expressed CD43 and Gr-1. Consistent 
with the previous findings for B220+CD19–CD11c+ 
plasmacytoid DC in lymph nodes and spleen [10], 
these cells expressed low levels of MHC class II 
were either or not positive for CD4 or CD8, but 
did not express the myeloid marker Mac-1/CD11b 
or co-stimulatory molecules, such as CD40, B7.1/
CD80 and B7.2/CD86 (Fig. 2 and data not shown). 
Since the CD4 or CD8 staining was present in 
RAG-1–/– mice that lack mature CD4+ or CD8+ T 
cells, it could not be attributed to pickup of marker 
protein from associated T cells, but rather reflected 
authentic CD4 or CD8 expression. As a control, 
we also analyzed the population of CD11chighB220– 
DC. These cells displayed high levels of CD80, 
CD11b and MHC class II of which the expression 
level was ~10x higher, when compared with 
CD11c+B220+ DC (Fig. 2). When additional DC- 
and Mf-specific markers [16] were tested, we 
found that CD11c+B220+CD19– cells in BM or 
spleen did not express F4/80, ER-BMDM1/CD13, 
33D1 or DEC-205 (Fig. 2 and data not shown). 
We noticed that the CD69 very early activation 
antigen was expressed on a higher proportion of 
B220+CD19–CD11c+ cells in the spleen than in the 
BM (Fig. 2). 
As plasmacytoid DC are thought to enter lymph 
nodes by L-selectin-mediated extravasation across 
high endothelial venules (HEV), we specifically 
analyzed B220+CD19– cells for CD8 and CD62L 
expression in BM and spleen. We noticed that small 
fractions of the CD8a– population and a significant 
portion of the CD8a+ population expressed CD62L, 
in particular in the spleen. Interestingly, RAG-
1–/– mice specifically lacked the CD62L+CD8a+ 
subpopulation of B220+CD19– cells, when 
compared with C57BL/6 or mMT mice (Fig. 2 
C). This finding indicates that the development of 
the CD62L+CD8a+ subpopulation is dependent 
on the presence of T cells. This may relate to the 
observation that CD8a expression is induced in 
some DC by interaction with CD40L, expressed 
by activated T cells [18]. In addition, the finding 
of a fraction of CD62L-expressing cells in BM and 
spleen indicates that some of these plasmacytoid 
cells, once in the circulation, have the ability to 
enter the lymph nodes by extravasation across 
HEV.
Taken together, we conclude that the cells that 
we have identified in the BM are similar to the 
CD11c+B220+ Gr-1+ cells with plasmacytoid DC 
characteristics in lymph nodes and spleen. The 
surface phenotype of CD11c+B220+Gr1+ cells in 
BM and spleen is remarkably similar, suggesting 
that most of the CD11c+B220+Gr-1+ cells within 
these organs are in a comparable stage of maturation 
or activation with equal functional abilities. This 
would imply that the CD11c+B220+Gr-1+ cells in 
BM are not the precursors of the cells identified 
in spleen and lymph node, but rather that these 
cells reflect a recirculating population. However, 
we also observed that CD11c+B220+CD19– cells 
in the BM had lower forward scatter values and 
lower proportions of cells positive for CD4, 
CD8, MHC class II, L-selectin (CD62L) and 
the CD69 activation marker (Fig. 2). Therefore, 
the CD11c+B220+CD19– fraction in the BM may 
contain an additional subpopulation of more 
immature cells. The finding that the expression 
of particular markers varied between individual 
cells within the CD11c+B220+Gr-1+ cell fractions, 
both in the BM and in the spleen, implies that 
these fractions may contain phenotypically and 
functionally distinct cell populations.
Localization of CD11c+B220+CD19– cells in the 
spleen
The absence of a unique marker for 
CD11c+B220+CD19– cells precluded the analysis 
of the localization of this cell population in 
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normal mice. However, we took advantage of 
the almost complete lack of B220+CD19+ cells 
in the spleen of B cell-deficient mice. As a result, 
the B220 marker almost exclusively identifies 
the CD11c+B220+CD19– DC in RAG-1–/– and 
mMT mice (Fig. 3A). By immunohistochemical 
analyses, using antisera specific for CD4, B220, 
CD11c and MOMA-1 (specific for metallophilic 
Mf), the spleens of 2-month-old C57BL/6 mice 
demonstrated a characteristic organisation in terms 
of segregation of red and white pulp (Fig. 3C and 
F). In the mMT mice, B220+ DC were partly found 
as isolated cells in the T cell areas of the white pulp 
(identified by anti-CD4), and partly as isolated cells 
in the red pulp (Fig. 3B and E). The white pulp T 
cell areas also contained CD11clow interdigitating 
cells and were surrounded by a “marginal zone”, 
which did not contain B cells, but had CD11chigh 
DC, separated by a ring of MOMA-1+ metallophilic 
Mf (Fig. 3H). RAG-1–/– mice did not contain T 
Figure 3. Localization of CD11c+B220+CD19– cells in the spleen. (A) The majority of splenic B220+ cells in RAG-1–/
– and mMT mice do not belong to the B cell lineage. Spleen and BM cells were analyzed for B220 and CD19 expression. 
Percentages of cells within the indicated gates are given. (B–H) Immunohistochemical analyses of 6- mm frozen spleen 
sections from the indicated mice. Sections were stained with anti-B220 (blue, B–E), anti-CD4 (brown, B–E), MOMA-1 
for marginal zone metallophilic Mf (blue, F–H) and anti-CD11c for DC (brown F–H). (B) Detailed high magnification view 
of the spleen of a mMT mouse (original magnification: 400 x). (C–H) Original magnification: 50 x. RP = Red pulp; WP = 
White pulp; T = T cell area; B = B cell area.
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cell areas, but nevertheless did show “white pulp” 
areas in which CD11c-expressing DC were present 
around central arterioles. These areas contained 
clusters of B220+ DC, which were well separated 
from rings of MOMA-1+ metallophilic Mf (Fig. 
3D and 3G). Also in the RAG-1–/– mice, isolated 
B220+ DC were present in the red pulp.
In summary, although the B220+ DC showed 
a heterogeneous localization in the spleen, their 
major presence in T cell areas is consistent with 
the reported finding that CD11c+B220+ Gr-1+ DC 
localize within T cell zones of the lymph nodes 
[10]. Because of the presence of the B220 marker 
on splenic B cells, we were unable to analyze the 
presence of B220+ DC in the splenic B cell areas.
Concluding remarks
In this report, we have characterized a 
subpopulation of B220+CD19– cells in murine 
BM, which express Gr-1 and low levels of MHC 
class II and CD11c on their cell surface. This 
unusual combination of markers was recently 
reported to be present on plasmacytoid DC [10]. 
In an evaluation of several cell surface markers, 
including CD4, CD8, CD43 and CD62L, we found 
that the surface profiles of CD11c+B220+Gr-1+ 
cells in BM and spleen were remarkably similar. 
Therefore, we conclude that these cell populations 
are in a comparable maturation or activation stage 
in the two lymphoid compartments, suggesting that 
B220+CD19–CD11c+ cells in the BM comprise a 
recirculating population of plasmacytoid DC.
The cells manifest an immature surface 
phenotype, characterized by low MHC class 
II expression and the absence of substantial 
co-stimulatory molecule expression. In line 
with these observations, we found that sorted 
B220+CD19–CD11c+ cells from RAG-1–/– spleen 
did not activate naive allogeneic CD4+ or CD8+ 
T cells or induced cytokine production by T cells, 
consistent with the published data [10]. In our 
preliminary experiments, the isolated plasmacytoid 
DC did not proliferate in response to GM-CSF or 
IL-3, but produced IL-12 and IL-10 as a response 
to these cytokines. Furthermore, these cells were 
reported to produce high levels of IFNa after viral 
stimulation and to stimulate T cell proliferation 
after activation with CpG [10]. Therefore, the 
B220+CD19–CD11c+ cells in the BM could also 
represent a major resource of IFNa -producing 
cells able to respond to viral infection in the BM. 
Upon activation, they may enter the circulation 
and migrate across HEV into lymph nodes [11]. 
Alternatively, they may stay in the BM, where local 
cytokine production may control hematopoiesis, 
as it has been shown that type I interferons 
inhibit growth and survival of B cell precursors 
[19] and negatively regulate multipotential, 
erythroid or granulocyte-macrophage progenitor 
cells [20]. In this context, it is very well possible 
that the observed phenotypical heterogeneity of 
B220+CD19–CD11c+ DC, with respect to the CD4, 
CD8, CD62L and CD69 expression, may reflect 
their distinct in vivo functions in the BM. It is 
obvious that further experiments are required, not 
only to identify the possible functions, but also to 
investigate the origin of the B220+CD19–CD11c+ 
DC in the BM.
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4.1
Subpopulations of mouse blood monocytes differ in
maturation stage and inflammatory response
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Blood monocytes are well-characterized precursors for macrophages and dendritic 
cells. Subsets of human monocytes with differential representation in various disease 
states are well known. In contrast, mouse monocyte subsets have been characterized 
minimally. In this study we identify three subpopulations of mouse monocytes that can 
be distinguished by differential expression of Ly-6C, CD43, CD11c, MBR, and CD62L. 
The subsets share the characteristics of extensive phagocytosis, similar expression of M-
CSF receptor (CD115), and development into macrophages upon M-CSF stimulation. By 
eliminating blood monocytes with dichloromethylene-bisphosphonate-loaded liposomes 
and monitoring their repopulation, we showed a developmental relationship between 
the subsets. Monocytes were maximally depleted 18 h after liposome application and 
subsequently reappeared in the circulation. These cells were exclusively of the Ly-
6Chigh subset, resembling bone marrow monocytes. Serial flow cytometric analyses of 
newly released Ly-6Chigh monocytes showed that Ly-6C expression on these cells was 
down-regulated while in circulation. Under inflammatory conditions elicited either 
by acute infection with Listeria monocytogenes or chronic infection with Leishmania 
major, there was a significant increase in immature Ly-6Chigh monocytes, resembling 
the inflammatory left shift of granulocytes. In addition, acute peritoneal inflammation 
recruited preferentially Ly-6Cmed-high monocytes. Taken together, these data identify 
distinct subpopulations of mouse blood monocytes that differ in maturation stage and 
capacity to become recruited to inflammatory sites. 
Circulating peripheral blood monocytes provide a mobile source of functionally competent cells of the innate immune 
system. They are constituents of the mononuclear 
phagocyte system, which encompasses various 
subtypes of dendritic cells (DC) and macrophages 
as well as their precursors [1, 2]. Different subtypes 
of monocytes in humans can be distinguished 
according to their expression of CD64 or CD14 
and CD16 (see Ref. 3 for review). These subtypes 
both develop into macrophages or DC in vitro, but 
their developmental relationship is still unclear. 
Furthermore, differences in the occurrence of 
specific subsets in various disease states, such 
as systemic inflammation, suggest that monocyte 
subpopulations also are functionally specialized 
[3].
Compared with what is known about the human 
system, knowledge about mouse monocytes is much 
more limited. Bone marrow (BM) monocytes have 
been shown to develop into mature macrophages 
in vitro as well as in vivo [4, 5]. In addition, 
at least a fraction has the potential to develop 
into DC [6–8]. Monocytes can be identified in 
the BM on the basis of high level expression 
of Ly-6C (ER-MP20) and the absence of CD31 
(ER-MP12), but an exclusive marker for mouse 
monocytes in the BM or the bloodstream is not 
yet available [4, 9, 10]. Characterizing peripheral 
blood monocytes, Lagasse and Weissman [11] 
and, more recently, Henderson et al. [12] showed 
peripheral blood monocytes to be a homogeneous 
population. Nevertheless, experiments conducted 
by Palframan et al. [13] and Geissman et al. [14] 
using CX3CR1GFP/+ mice indicated that peripheral 
blood monocytes in these mice also encompass 
subtypes, differing in CX
3
CR1, CCR2, and CD62L 
expression. Interestingly, the monocytes expressing 
CCR2, CD62L, and low levels of CX
3
CR1 
appeared to be preferentially recruited to inflamed 
peripheral sites by virtue of their recognition of 
CCL2/monocyte chemoattractant protein-1 and the 
CD62L-mediated interaction with high endothelial 
venules. Conversely, the CX3CR1high monocytes 
migrated into noninflamed sites [14].
The goals of the present study were to identify 
and characterize the putative subpopulations of 
monocytes in normal mouse peripheral blood 
with respect to phenotype and function and to 
establish their hitherto unknown developmental 
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relationship. The initial criteria used to distinguish 
monocytes from other leukocyte types were their 
mononuclearity, which is read as low orthogonal 
(side)scatter in the flow cytometer, and their 
myeloid nature, as indicated by high level 
expression of CD11b/Mac-1. Additional required 
characteristics were high phagocytic capacity 
and the ability to develop into macrophages 
upon stimulation with M-CSF. Our results show 
that distinct subpopulations of monocytes can 
be identified in steady state peripheral blood of 
normal mice by differential expression of various 
surface markers, in particular Ly-6C (ER-MP20). 
Ly-6Chigh monocytes are recent immigrants from 
the BM and have the capacity to migrate into sites 
of peripheral in- flammation. In contrast, Ly-6Clow 
monocytes have lost this potential. Moreover, we 
show that Ly-6Chigh monocytes mature in the 
circulation and are the precursors for Ly-6Clow 
monocytes.
Materials and Methods
As the reported experiments comprise a collaborative 
effort among three different laboratories, materials 
and methods differed slightly between experiments 
performed at different locations, as indicated. However, 
results were validated by repetitions of experiments and 
extensive comparisons between our laboratories. All data 
shown are representative of at least three independently 
performed experiments.
Mice
Specific pathogen-free C57BL/6J female mice 
were purchased from The Jackson Laboratory (Bar 
Harbor, ME), Charles River (Sulzfeld, Germany), or 
Harlan (Horst, The Netherlands) and were housed in 
microisolator cages and given mouse chow and water 
ad libitum. Mice were 8–16 wk of age when used in 
experiments. All experiments with mice were performed 
with the approval of the animal care and use committees 
of Veterans Affairs Medical Center (Oklahoma City, OK), 
Erasmus Medical Center (Rotterdam, The Netherlands), 
or the State Review Board of Munster (Germany).
Antibodies
Specifications of mAbs and fluorescent conjugates 
against surface markers used in this study are listed in 
Table 1. Directly conjugated isotype control mAb were 
purchased from BD PharMingen (San Diego, CA). Anti-
rat IgG conjugated with FITC was obtained from Dianova 
(Hamburg, Germany).
Mouse models of inflammation
Listeria monocytogenes strain EGD was stored in brain 
heart infusion broth (Difco, Detroit, MI) at 109 CFU/ml 
at 70°C.  For experiments, 10 µl of stock culture were 
inoculated into 4 ml of broth and incubated overnight at 
37°C with shaking. An aliquot of the overnight culture was 
diluted 1/10 into fresh broth and cultured an additional 
4.5h. Bacteria were diluted to the desired concentration 
with sterile PBS before injection. Leishmania major 
(World Health Organization nomenclature: MHOM/IL/
81/SE/BNI) were maintained by monthly passages in 
BALB/c mice. Promastigotes were grown in a 5% CO
2
 
atmosphere at 25°C in Schneider’s Drosophila medium 
(Promocell, Heidelberg, Germany) supplemented with 
10% FCS, 2% human urine, glutamine, and HEPES 
buffer, with penicillin and streptomycin as antibiotics. 
Mice were infected i.p. with 5.1 log
10
 CFU (1–2 LD50) 
of L. monocytogenes or by s.c. application of 2x107 
promastigotes (stationary phase) of L. major in 20µl of 
PBS into the left hind footpad. Animals were sacrificed, 
and blood was harvested 24, 48, and 72h after L. 
monocytogenes or 3 wk after L. major infection.
In other experiments, sterile inflammation was 
induced by injecting mice i.p. with 1.0 ml of sterile 
FCS (HyClone, Logan, UT). Inflammatory peritoneal 
Table 1. Monoclonal Abs
marker monoclonal antibody
used form 
(conjugate) origin
CD3 145-2C11 FITC, APC BD Pharmingen
CD11b /   
Mac-1 M1/70
FITC, PE, 
PerCP-Cy5, 
PE-CY5, APC
BD Pharmingen
CD11c HL3 FITC, PE BD Pharmingen,
CD16/32/
FcgRII/III 2.4G2 Ø
a ATCC, Rockville, 
MD, USA
CD19 1D3 PE BD Pharmingen, 
CD43 S7 FITC, PE BD Pharmingen, 
CD54 /  
ICAM-1 YN1/1.7 Ø
ATCC,Rockville, 
MD, USA
CD62L /          
L-selectin MEL-14 PE BD Pharmingen, 
CD115 /         
M-CSF R AFS98 Ø
Dr. Nishikawa, 
Kyoto, Japan
ER-MP58 ER-MP58 Ø own laboratory
F4/80 F4/80 FITC Caltag Laboratories
Ly-6C ER-MP20 FITC own laboratory
MHC class II M5/114.15.2 PE BD Pharmingen,
NK1.1 PK136 PE BD Pharmingen,
scavengerR / 
SR-A 2F8 Ø
Dr. S. Gordon, 
Oxford, UK
a hybridoma supernatant
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exudate cells were harvested 24h later. Mononuclear 
phagocytes were eliminated in vivo by i.v. injection 
of 0.2 ml of dichloromethylene- bisphosphonate 
(clodronate) liposomes into the lateral tail vein, as 
described previously [15]. Clodronate was a gift from 
Roche (Mannheim, Germany) and was incorporated into 
liposomes as previously described [16]. As an alternative 
approach, mononuclear phagocytes were labeled in vivo 
by i.v. injection of PBS-containing liposomes that were 
labeled with DiI or DiD (Molecular Probes, Leiden, The 
Netherlands).
Preparation of leukocytes
Mice were euthanized with an overdose of ketamine 
(2mg; Parke-Davis, Berlin, Germany; or Morris Plains, 
NJ) and xylazine (0.2 mg; CEVA Tiergesundheit, 
Dusseldorf, Germany; or Vedco, St. Joseph, MO) or 
by CO
2
 exposure. Blood was obtained by axillary or 
femoral artery puncture or by heart puncture after 
exposing the organ and was collected in heparincoated 
tubes or in syringes containing 1.0 ml of PBS with 8mM 
EDTA. Control experiments showed that similar results 
were obtained by either method of exsanguination 
and anticoagulation. Erythrocytes were lysed using 
ACK lysis solution, and then leukocytes were washed 
twice by centrifugation at 250xg in DMEM (Life 
Technologies, Gaithersburg, MD) containing 5mM 
EDTA and 0.5% BSA. Peritoneal cells were collected 
18–24h after induction of inflammation by lavage with 
8ml of sterile iced PBS and were similarly prepared for 
further analysis.
Flow cytometry and cell sorting
Aliquots of ~106 cells in 1% BSA in HBSS (Biochrom, 
Berlin, Germany; or Life Technologies) were put into 96-
well microtiter plates and then incubated with unlabeled 
mAb or directly conjugated primary mAb for 30min on 
ice. In experiments using PE-Cy5-conjugated mAb, 
the cells were first incubated with 3% normal mouse 
serum and anti-CD16/32 mAb (BD PharMingen) for 
30min on ice before addition of directly conjugated 
mAb to block nonspecific binding. After the first 
incubation, the cells were washed three times and then 
incubated with fluorochrome-conjugated secondary 
Abs as needed. Controls included cells incubated with 
or without fluorochrome-conjugated control Abs and 
with unspecific isotype Ab, followed by fluorochrome-
conjugated secondary Abs as needed. The cells were 
analyzed using a FACSCalibur equipped for four-color 
flow cytometry. Each measurement contained a defined 
number of 2x105 cells. Data were analyzed using 
CellQuest (BD Biosciences, Mountain View, CA) or 
WinMDI 2.8 software. Cell sorting was performed on a 
Moflo High Speed Cell Sorter and Analyzer (Cytomation, 
Ft. Collins, CO) with data acquisition using CyCLOPS 
version 2.1 software (Cytomation).
Morphological analysis
For morphological characterization of sorted cells, at 
least 2x104 cells from each population were sorted 
into FCS-coated plastic tubes filled with 2ml of HBSS. 
Suspensions of freshly sorted cells were cytocentrifuged 
onto slides, air-dried, and then fixed with equal parts 
ethanol/methanol. Differential counts, according to the 
morphological criteria established previously [10], were 
performed on May-Grünwald-Giemsa-stained cytospin 
preparations of peripheral blood leukocytes and blood 
smears by counting at least 200 cells/cytospin or blood 
smear at x400 magnification.
Culture of sorted cells
For analysis of in vitro development of sorted populations, 
6–9x104 cells from each population were collected into 
24-well glass tissue culture chambers (Nunc, Roskilde, 
Denmark). To test for macrophage development, cells 
were seeded at a density of 1x103 or 2x104 cells/ml in 
DMEM supplemented with 10% heat-inactivated FCS, 
10% L cell-conditioned medium (as a source of M-CSF), 
L-glutamine, kanamycin, and nonessential amino acids. 
The cells were incubated at 37°C with 7% CO2 for 1–8 
days, after which time they were fixed and stained for 
differential counting as described above.
Adherence and proliferation of cultured cells were 
evaluated daily with an inverted microscope using an 
ocular with eyepiece graticule. When several cells were 
found in close contact with each other and distinctly 
separated from neighboring cells, they were referred 
to as groups of 2–10 cells, clusters of 10–50 cells, or 
colonies when counting –50 cells. 
Phagocytosis of latex particles and L. major 
promastigotes
Phagocytic activity was quantified by adding 2.5µl of a 
suspension of 5.4x109 latex particles/ml with an average 
diameter of 0.81µm (Difco) to adherent cells on 24-well 
plates for a final ratio of cells to latex particles of 1:14. 
Cells and latex particles were incubated for 4h at 37°C 
and then fixed with ethanol/acetone (50/50, v/v). In 
some experiments, phagocytosis was studied using L. 
major promastigotes. For this, freshly sorted cells were 
coincubated with promastigotes for 4h at a ratio of 1:5. 
Cells were washed and fixed in ethanol/acetone (50/50, 
v/v), and phagocytosis was quantified after staining 
with May-Grünwald-Giemsa. Cells were examined by 
light microscopy at x200 and x400 for the presence 
of intracellular parasites or ingested latex particles, 
respectively.
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Results
Mouse blood monocytes are SSClowCD11bhigh 
cells heterogeneous for Ly-6C
To establish the flow cytometric identification of 
monocytes in normal mouse peripheral blood, 
we hypothesized that monocytes should be 
distinguishable from granulocytes and lymphocytes 
by their lower granular content, as reflected in low 
SSC, and their high level expression of Mac-1/
CD11b [4, 10, 11]. To test this, we sorted different 
peripheral blood subsets based on SSC and Mac-
1 expression (Fig. 1A) and determined which 
population contained monocytes. Morphological 
characterization by May-Grünwald-Giemsa 
staining showed that 95% of SSClowCD11bhigh 
cells were monocytic (see below). In addition, 
we observed that almost 95% of SSClowM-CSF 
receptor (M-CSF R)+ cells could be found within 
the CD11bhigh window (Fig. 1A), suggesting that 
virtually all monocytes were contained in this 
population. When sorted, these SSClowCD11bhigh 
cells became adherent when cultured in M-
CSF-containing medium and proliferated to 
some degree (Fig.1B). In contrast, almost all 
cells from the SSChighCD11bhigh population were 
granulocytes, whereas lymphocytes constituted 
the majority of SSClowCD11blow cells. Neither of 
these populations survived in the culture conditions 
for macrophages (Fig. 1B). More than 90% of the 
SSClowCD11bhigh cells were able to phagocytose 
L. major, whereas only SSChigh granulocytes, but 
not cells from other sorted populations, showed 
relevant phagocytic activity (Fig.1C). Further 
analysis of the SSClowCD11bhigh population with 
markers for NK cells (NK1.1), T cells (CD3), or 
B cells (CD19) showed that the SSClowCD11bhigh 
population contained no NK cells or lymphocytes 
(Fig. 2A). In contrast, SSClowCD11bhigh cells 
uniformly expressed significant levels of M-
CSF R. Together, these findings indicate that the 
SSClowCD11bhigh population in peripheral blood 
encompasses almost exclusively monocytes on the 
basis of phenotype, morphology, and function.
After establishing parameters to discriminate 
monocytes from other leukocytes by flow 
cytometry, we tested whether this population 
displayed phenotypic heterogeneity. Initial analysis 
indicated that Ly-6C (ER-MP20) was variably 
expressed among SSClowCD11bhigh monocytes and 
allowed the distinction between subpopulations: 
Ly-6C–/low, Ly-6Cmed, and Ly-6Chigh cells (Fig. 
2A). The level of Ly-6C expression found on 
Ly-6Chigh cells resembles that on BM monocytes 
[4]. Sorting and analysis of SSClowCD11bhigh cells 
according to the Ly-6C (ER-MP20) expression 
level showed that virtually all cells presented 
monocytic morphology (Fig. 2B) and extensive 
phagocytosis of latex beads and L. major.
Analysis of their proliferative activity in M-
CSF-containing medium showed that cells from 
each subpopulation formed several groups of 
2–10 cells in culture after a few days. Larger 
clusters (11–50 cells) and colonies (–50 cells) 
were most frequently seen in cultures of the Ly-
6Chigh population. This indicates that monocytes 
in all three subpopulations have the capacity 
to proliferate, but that cells with the highest 
proliferative potential reside in the Ly-6Chigh 
population. Cells developing in these cultures 
were typically adherent and showed macrophage 
morphology (our unpublished observations). 
When we applied culture conditions suitable for 
the development of DC, using GM-CSF and IL-4, 
cells with morphological characteristics of DC and 
CD11c and MHC class II expression developed 
in a few days from all three different subsets (our 
unpublished observations), in accordance with the 
previously characterized development of DC from 
mouse monocytes [8, 17].
Further phenotypic characterization of the 
Ly-6C-defined monocyte subsets showed a 
uniform high level expression of ER-MP58, 
characteristic for cells of the myeloid lineage 
[18] (Fig. 2D). The ability to detect F4/80 varied 
between experiments, with all subsets expressing 
the Ag in some experiments, whereas in others 
no positive subsets were present. In the currently 
shown profile, most, but not all, monocytes in 
the different subsets express F4/80. The various 
subpopulations expressed only marginal amounts 
of mature macrophage markers such as FcgRII/
RIII (CD16/CD32) or scavenger receptor type A 
(Fig. 2D). However, the subsets did show clear 
heterogeneity with regard to the expression of 
CD11c, CD43, and CD62L, with the latter being 
present primarily on Ly-6Chigh monocytes, whereas 
CD11c and CD43 were found in particular on Ly-
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6C–/low cells.
Down-regulation of Ly-6C marks the maturation 
of mouse blood monocytes
Previous studies have indicated that BM 
monocytes are Ly-6Chigh and that Ly-6C expression 
is rapidly lost during in vitro development into 
macrophages or DC [4, 8]. Using the same gatings 
as established for the peripheral blood monocytes, 
we confirmed that BM monocytes, identified as 
either SSClowCD11bhigh or SSClowM-CSF R+ 
cells, were almost exclusively Ly-6Chigh (Fig. 
3A). Therefore, we investigated the possibility 
that Ly-6Chigh peripheral blood monocytes might 
correspond to BM monocytes, which developed 
into Ly-6C–/low cells subsequently. In vitro we found 
that sorted Ly-6Chigh peripheral blood monocytes 
lost expression of Ly-6C within 3 days (our 
unpublished observations).
To analyze the subset relationship in vivo we 
injected mice i.v. with liposomes loaded with 
clodronate to deplete all phagocytic cells in the 
circulation and followed the kinetics of monocyte 
repopulation in the blood. Figure 3B shows that 
almost 90% of the SSClowCD11bhigh monocytes 
were eliminated by this procedure 18h after 
liposome injection. This result seemingly contrasts 
with the reported finding that blood monocytes 
could be depleted only partially by this method 
[19]. However, in that study monocyte depletion 
was evaluated only 48h after depletion, whereas 
we found that after 24h monocytes had started to 
repopulate and had reached normal numbers in 3–4 
days (Fig. 3B). The monocytes reappearing at 2 and 
4 days after depletion were almost exclusivelyof 
the Ly-6Chigh BM phenotype (Fig. 3C). Ly-
6C–/low monocytes were found in the circulation 
in significant numbers only from 7 days after 
depletion. These findings are consistent with the 
interpretation that Ly-6Chigh monocytes give rise 
to Ly-6Cmed and Ly-6C– monocytes.
Attempting to approach this maturation 
sequence more directly, we sorted Ly-6Chigh 
monocytes from green fluorescent protein (GFP)-
transgenic mice and injected these into normal, 
unconditioned recipients. However, at  o time 
point after transfer could GFP+ cells be retrieved 
from the circulation of recipient mice,suggesting 
Figure 1. Phenotypic identification of mouse blood monocytes as SSClowCD11bhigh cells. A. Peripheral blood 
leukocytes were labeled with CD11b/Mac-1 Ab and analyzed on a flow cytometer. Gated cells (R1, R2+R3, and R2+R4) 
were separated by cell sorting. B. Cell survival and proliferation after 10 days of stimulation with M-CSF in vitro were 
analyzed under inverted microscope. C. Sorted cells were incubated for 6 h with L. major promastigotes (1:5 ratio) and 
then were fixed and stained. The frequency of phagocytic cells was quantified using light microscopy. A representative 
of three independent experiments is shown.
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that manipulation of these Ly-6Chigh monocytes 
might induce aberrant behavior, leading to rapid 
margination in vivo. As an alternative approach, 
we synchronized monocyte development by 
clodronate liposome-mediated depletion and then 
labeled reappearing monocytes in vivo to follow 
their kinetic response. At 48h after depletion, 
virtually all circulating monocytes were Ly-6Chigh 
(Fig. 3C). When we then injected fluorochrome 
(DiI)-labeled liposomes, we found that the vast 
majority of circulating monocytes became labeled 
and retained the Ly-6Chigh phenotype for 2 days (Fig. 
3D). From 3 days after fluorochrome application, 
DiI-labeled Ly-6Clow monocytes were observed 
Figure 2.
Blood monocytes show 
heterogeneous expression of Ly-
6C. A. SSClowCD11bhigh cells were 
negative for T- (CD3), B- (CD19), 
and NK-specific (NK1.1) markers, 
but uniformly positive for M-CSF R 
(CD115). They could be subdivided 
into three populations according to 
the expression of Ly-6C: Ly-6Chigh, 
Ly-6Cmed, and Ly-6C–/low. These three 
subpopulations were separated by 
cell sorting and showed uniformly 
monocytic morphology (B) and 
differential proliferative capacity (C) 
when stimulated with M-CSF in vitro. 
D. Monocyte subsets differentially 
expressed various myeloid and 
activation markers relative to 
Ly-6C expression. In particular, 
CD62L was expressed by Ly-6Chigh 
monocytes, whereas CD11c and 
CD43 were expressed by Ly-6Clow 
monocytes. Representative data are 
shown for at least four independent 
experiments.
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in the circulation, indicating that these cells had 
indeed developed from Ly-6Chigh monocytes. In 
contrast, the vast majority of Ly-6Chigh monocytes 
were not labeled at this point, demonstrating that 
they had been released into circulation after the 
fluorochrome pulse labeling. These experiments 
strongly support the concept that monocytes enter 
the circulation from the BM as Ly-6Chigh cells and 
then develop into Ly-6C–/low monocytes before 
emigrating into peripheral tissues.
To follow the kinetics of the distinct monocyte 
populations in steady state, we attempted to label 
all monocytes by i.v. injection of fluorochrome 
(DiD)-labeled liposomes. Unexpectedly, we found 
that all monocytes, identified as SSClowCD11bhigh 
cells, disappeared from the circulation within 30 
min after liposome injection (Fig. 3E) suggesting 
that phagocytosis of liposomes triggered monocyte 
margination. Monocytes started to reappear after 
2–4h, but these cells were not DiD-labeled, 
indicating that they were not in direct contact with 
the circulation when the liposomes were injected. 
Presumably, these cells resided in the BM and 
entered the circulation after the liposomes were 
Figure 3. 
Blood monocytes mature 
from Ly-6Chi into Ly-6Clow 
cells. A. Bone marrow 
monocytes were identified by 
similar gating as performed 
on peripheral blood cells (see 
Fig. 1). They had uniformly 
high expression of Ly-6C, as 
reported previously. B. Upon 
i.v. injection of clodronate 
liposomes, virtually all 
peripheral blood monocytes 
were depleted within 24h. 
Recovery to normal numbers 
of monocytes (identified 
as SSClowCD11bhi cells) 
occurred by 4 days after 
depletion. C. Analysis of Ly-
6C expression by monocytes, 
gated as SSClowCD11bhi 
cells, repopulating the blood 
after depletion. The first cells 
reappeared 2 days after 
clodronate liposome injection 
and were BM-like Ly-6Chi 
monocytes, whereas Ly-6Clow 
monocytes were detected in 
the circulation from 7 days 
after depletion.
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injected. This was confirmed by the observation 
that these cells were of the Ly-6Chigh BM monocyte 
phenotype. From 16h on, DiD-labeled monocytes, 
all of which were Ly-6C–/low, were found in the 
peripheral blood. Because the previous experiments 
showed that Ly-6Chigh and Ly-6C–/low  monocytes 
had similar phagocytic activity of L. major in vitro 
and clodronate liposomes in vivo, it is unlikely 
that the Ly- 6Chigh cells did not take up the DiD-
labeled liposomes. Thus, these results suggest 
that the Ly-6Chigh cells matured into Ly-6C–/low 
monocytes within the 16- to 48-h period. These 
experiments do not formally exclude, however, 
that only labeled Ly-6C–/low  monocytes reappear 
in circulation, whereas Ly-6Chigh monocytes have 
a different destination.
The immature Ly-6Cmed/high monocyte subset 
is selectively involved in inflammatory 
conditions
Previous studies have shown that monocytes 
recruited to peripheral inflammatory sites 
typically show a high level expression of Ly-6C 
[20, 21]. In view of our current findings, we asked 
whether this was due to a selective recruitment 
of immature BM-type monocytes. Therefore, 
sterile inflammation was elicited by i.p. injection 
of FCS. In the steady state peritoneal cavity, we 
observed that monocyte-like SSClowCD11bhigh cells 
were present, characterized by an intermediate 
expression of the macrophage marker BM8, well 
below that of resident peritoneal macrophages (Fig. 
4A). These resident peritoneal monocytes were 
uniformly lacking Ly-6C (Fig. 4B). In contrast, 
the first inflammatory monocytes examined 18 
h after FCS injection clearly showed significant 
Figure 3. (continued)
Blood monocytes mature 
from Ly-6Chi into Ly-6Clow 
cells. D. Ly-6Chi monocytes 
that reappeared on day 2 after 
depletion were pulse-labeled 
in vivo by injecting DiI-loaded 
liposomes. By 3 days after the 
DiI labeling, Ly-6Chi monocytes 
had developed into Ly-6Clow 
monocytes, whereas the vast 
majority of unlabeled monocytes 
at that time were of the Ly-6Chi 
BM type. E. Injection of DiD-
loaded liposomes into steady 
state mice caused all monocytes 
to disappear temporarily from 
the circulation within 30 min 
after injection. Measurable 
numbers of monocytes were 
found in circulation 2–4h later, 
but these were unlabeled 
Ly-6Chi BM-type cells. DiD-
labeled monocytes were again 
present 16h after application 
of DiD-labeled liposomes and 
expressed only low levels, if 
any, of Ly-6C reflecting their 
relatively mature status.
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Ly-6C expression (Fig. 4B). By comparison, the 
ratio between monocyte subsets in peripheral blood 
was unchanged. This suggested that Ly-6Chigh 
immature monocytes were selectively recruited 
to the site of inflammation, in accordance with 
recent findings [14]. In contrast, immigration 
of Ly-6Chigh monocytes was blocked completely 
when the inflammatory trigger was given to mice 
that were simultaneously depleted of circulating 
monocytes by i.v. injection of clodronate liposomes 
(Fig. 4B). The latter finding also indicates that 
FCS injection does not induce Ly-6C expression 
in resident peritoneal monocytes.
To investigate the monocyte subset kinetics in 
acute bacterial inflammation, we infected mice 
with L. monocytogenes. Fig. 4C shows that the 
ratio between Ly-6Chigh and Ly-6Cmed/low monocytes 
did not change in the first 48 h after infection, but 
the absolute number of circulating monocytes 
decreased during this time. In contrast, there was 
a significant influx of Ly-6Chigh monocytes 72h 
after infection, causing a notable monocytosis in 
the blood with a shift toward the immature Ly-
6Chigh subset. To test whether chronic infection 
caused a similar shift in the monocyte balance, 
C57BL/6 mice were infected s.c. with L. major. 
Figure 4. Selective contribution of Ly-6Cmed/hi monocytes to the inflammatory response. A. BM8 expression of 
monocyte-like SSClowCD11bhi cells (R1 + R3) in the peritoneal cavity at steady state is less than that of resident peritoneal 
macrophages (R2). The histogram showing the lowest BM8 expression is from SSClow cells with low or no CD11b 
expression (R1 + R6). B. Sterile inflammation induced by i.p. injection of FCS 24h previously recruited specifically Ly-
6Cmed/hi monocytes to the site of infection. This cellular influx is abolished by i.v. injection of clodronate liposomes at the 
same time as i.p. injection of FCS. C. Acute systemic infection with L. monocytogenes caused initial depletion of circulating 
monocytes during the first 48 h after infection, followed by specific accumulation of Ly-6Chi monocytes, resulting in a 
noticeable monocytosis by 72h. D. Chronic parasitic infection with L. major, analyzed at 4 wk after infection, stimulated 
a shift toward Ly6Chi monocytes in the blood.
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After 4 wk, chronic infection was established as 
indicated by marked swelling of footpads and by 
dissemination of parasites into draining lymph 
nodes. At this stage also a significant shift was 
found toward the Ly-6Chigh immature monocyte 
subset (Fig. 4D). Taken together, these findings 
confirm the idea that inflammatory monocytes are 
exclusively Ly-6Cmed/high cells. Furthermore, both 
acute and chronic infection are reflected in the 
blood by a shift in the balance between monocyte 
subsets toward the immature Ly-6Chigh BM type.
Discussion
The circulating monocyte compartment in the 
mouse has been studied to only a limited extent 
due in part to the limited number of available 
cells and the lack of solid criteria to identify 
this cell type. In this study we characterized 
mouse peripheral blood monocytes in genetically 
nonmanipulated animals using an approach 
that is generally applicable in both steady 
state and experimental conditions. To identify 
monocytes among peripheral blood leukocytes, 
we used criteria that are universally recognized 
as characteristic of mononuclear phagocytes 
[22]. These are 1) mononuclearity, seen as low 
orthogonal light scatter in the flow cytometer; 2) 
myeloid nature, shown by high level expression 
of CD11b; 3) uniform phagocytic potential; and 
4) the ability to develop into macrophages upon 
M-CSF stimulation. Application of these criteria 
indicated that monocytes in mouse peripheral 
blood were restricted to the SSClowCD11bhigh 
population and that this population included no 
other cells. These cells were uniformly positive for 
the M-CSF receptor (CD115), a proposed universal 
marker for mononuclear phagocytes (1). This way 
we identified ~6% of circulating leukocytes in the 
steady state as monocytes. With total leukocyte 
counts of ~10.106/ml, this amounts to 6 x 105 
circulating monocytes/ml of mouse blood, which 
is consistent with earlier data [23].
In previous studies, Lagasse and Weissman 
used high level expression of CD11b, the 
absence or low level expression of Gr-1 and low 
SSC as discriminating criteria for monocytes 
and identified these cells as a single population 
[11]. Similarly, Henderson and colleagues [12] 
found mouse monocytes to be a homogeneous 
population using high level expression of the 
myeloid marker 7/4 and intermediate expression 
of Gr-1 as discriminating criteria. In contrast, 
Geissmann and colleagues [14] recently recognized 
distinct subsets among circulating monocytes in 
CX
3
CR1GFP/+ mice which differed in phenotypic 
and functional characteristics. In accordance with 
these results, we distinguished monocyte subsets 
in normal mice according to differential expression 
of Ly-6C (ER-MP20), CD62L, CD11c, and CD43. 
Cells of each subset showed extensive phagocytic 
activity, displayed typical monocytic morphology 
and developed into macrophages in vitro upon 
M-CSF stimulation. Thus, each population of 
SSClowCD11bhigh leukocytes, distinguished by 
variable Ly-6C expression, contains bonafide 
monocytes.
To date a possible relationship between 
these monocyte subsets had not been addressed 
[13, 14]. Using various approaches, we found 
that the monocyte subsets differing in Ly-
6C expression represent different stages in a 
continuous maturation pathway. As such, recent 
immigrants from the BM enter circulation as Ly-
6Chigh monocytes, consistent with their BM-like 
phenotype [4], and gradually down-regulate Ly-6C 
expression while still in the bloodstream. In vitro 
studies indicate that this transition is performed 
within 24–48h [4, 8]. Under steady state conditions 
in vivo peripheral blood monocytes were estimated 
to have a similar average transit time in circulation 
of ~25h [24]. Our study provides evidence in 
support of such kinetics, because 16–24h after 
labeling monocytes with DiD in vivo, most 
monocytes were unlabeled and therefore recent 
immigrants, whereas labeled monocytes had 
developed into mature Ly-6C–/low cells within this 
time span. However, when we analyzed the kinetics 
of monocyte maturation in the circulation under 
certain inflammatory conditions, we found that it 
differs from steady state. When the forced release 
of monocytes from the BM during inflammation 
was simulated in a phagocyte depletion model, 
most Ly-6Chigh cells remained in the circulation 
for –2 days before maturing into Ly-6Clow cells. 
This is probably due to the fact that monocytes are 
released in a less mature state under conditions of 
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peripheral phagocyte depletion or inflammation. 
These cells might need more time to acquire a 
minimal level of maturation, which is necessary 
before they can emigrate from the circulation 
and undergo further differentiation. Typically, 
only 4 days after depletion, the first repopulating 
macrophages and DC are observed in peripheral 
organs, in particular spleen and liver [25] (our 
unpublished observations). Do the different 
monocyte subsets have different developmental 
capabilities? Stimulation with M-CSF in vitro 
resulted in the development of macrophages from 
all subsets (Figs. 1 and 2). Similarly, all subsets 
acquired DC-like morphology and phenotype 
when stimulated in vitro with GM-CSF and IL-4. 
Therefore, the different monocytes seem to share 
a similar developmental potential. Recent in vivo 
transfer experiments show that Gr-1– monocytes, 
corresponding to mature Ly-6C–/low cells, reside 
longer in peripheral tissues of uninflamed recipient 
animals compared with Gr-1+ monocytes, which 
correspond to Ly-6Chigh cells [14]. The more mature 
Ly-6C–/low monocyte subset shows enhanced or 
induced expression of CD11c and CD43 Ags. 
Increased expression of CD43 and stimulation 
via CD43 have been shown to be associated with 
DC maturation in humans and rats [27, 28]. In 
addition, there was a clear phenotypic resemblance 
between the mature Ly-6C–/low monocytes and the 
recently identified CD11cintCD45RA– pre-DC1, 
circulating DC precursors in the mouse [26]. 
Thus, the increased CD43 expression by the Ly-
6C–/low monocytes together with induced CD11c 
expression probably reflect the maturation of these 
cells into a monocyte subtype with high potential 
to develop into DC. 
The immature, Ly-6Chigh subset of monocytes 
is characterized by a higher level of L-selectin 
(CD62L+) expression compared with Ly-
6C–/low monocytes. Given that CD62L mediates 
recruitment of leukocytes [29], we tested whether 
differential expression of this molecule was also 
manifested in differences in recruitment of the 
different subsets during an elicited peritoneal 
inflammation. We observed that the inflammatory 
Ly-6Chigh monocytes [20, 21], but not the Ly-6C–/low 
monocytes, were recruited into acute inflammation. 
Recently, Palframan et al. [13] identified two 
populations of F4/80-positive mononuclear cells 
in peripheral blood of heterozygous CX
3
CR1GFP/+ 
mice, of which only one subset expressed CD62L 
and was recruited to lymph nodes draining inflamed 
skin. In accordance, Geissmann et al. [14] showed 
preferential migration of the CD62L+Gr-1+CCR2+ 
monocyte subset, which corresponds to our Ly-
6Chigh population, into the peritoneal cavity during 
thioglycolate-induced inflammation in CX
3
CR1GFP/
+ mice. We found in preliminary studies that Ly-
6Chigh monocytes express elevated levels of CCR5 
and CXCR4 compared with the mature Ly-6–/low  
monocytes. Together, these findings clearly show 
that particularly the immature Ly-6Chigh monocytes, 
but not the mature Ly-6C–/low monocytes have a 
high potential to migrate to inflammatory sites. 
Peripheral inflammation stimulates the production 
of monocytes in the BM and their subsequent 
release into circulation. When this is substantial, 
there is a skewing of the monocyte population 
toward a higher frequency of immature Ly-6Chigh 
cells. This can be considered a so-called left shift 
in the monocyte compartment comparable to 
that seen in the neutrophil compartment, when 
more immature bandforms are found during 
acute inflammation. Such a monocytic left shift 
is typically observed after 72h during primary 
infection with L. monocytogenes. It results in 
greatly increased numbers of monocytes in 
circulation, whereas the BM is fully occupied 
with myelopoiesis [9]. We observed a significant 
skewing toward immature cells also in chronic 
infection caused by L. major. This probably reflects 
the increased myelopoiesis that is long recognized 
in chronic infection with L. major [30]. 
The identification of distinct monocyte subsets 
in the mouse raises the question of how these relate 
to monocyte subsets present in humans. A recent 
comparison between human and mouse monocytes 
indicated that CX3CR1low (our Ly-6Chigh) monocytes 
correspond to the classical CD14highCD16– 
monocytes, whereas CX
3
CR1high (our Ly-6C–/low) 
monocytes resemble CD14lowCD16high cells [14]. 
Interestingly, in human patients with sepsis an 
increase has been observed of CD64+ monocytes, 
which primarily correspond to the major subset 
of CD14+16– monocytes [31]. In analogy to our 
findings in infected mice, this might represent a so-
called left shift toward immature monocytes also in 
severe inflammations in humans. Taken together, in 
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this study we identify different subsets of mouse 
monocytes in peripheral blood, which behave 
differently depending on host conditions. Our data 
indicate that the cells enter the circulation from the 
BM as Ly-6Chigh cells. Under steady state conditions, 
monocytes mature in circulation, which is reflected in 
strong down-regulation of Ly-6C and up-regulation 
of CD43 expression. In peripheral inflammation, 
however, only Ly-6Cmed/high monocytes are recruited 
to the affected sites to become inflammatory exudate 
macrophages. Increased monocytopoiesis under 
these circumstances is apparent from the increased 
frequency of immature Ly-6Chigh monocytes, which 
may be considered a left shift in the monocyte 
compartment. The destiny of the Ly-6C–/low 
monocytes remains more speculative at present. 
Their phenotypic change suggests maturation toward 
DC with increased CD43 expression facilitating 
stimulation through this receptor to become more 
mature DC. Furthermore, the anti- and proadhesive 
properties of CD43, depending on the presence of 
the appropriate ligands [32], suggest a more selective 
homing pattern for the mature Ly-6C–/low monocytes 
compared with the immature Ly-6Chigh monocytes.
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4.2
Diabetes-prone NOD mice show an expanded subpopulation of 
mature circulating monocytes, which preferentially develop 
into macrophage-like cells in vitro
Tatjana Nikolic, Gerben Bouma, Hemmo A. Drexhage, Pieter J.M. Leenen
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In the non-obese diabetic (NOD) mouse, a model of autoimmune diabetes, dendritic 
cells (DC) and macrophages are important for the initiation and progression of 
autoimmunity and the final destruction of b-cells. Monocytes are direct precursors 
of DC and macrophages. The recently described phenotypic discrimination between 
immature (Ly-6Chigh) and mature (Ly-6Clow) monocytes in the mouse circulation enabled 
us to investigate the apportioning between blood monocytes in the NOD mouse. NOD mice 
had an abnormal high number of mature monocytes in circulation and this phenomenon 
appeared to be intrinsic to the NOD background, since NOR and NOD-H2b mice also 
showed this altered balance. After depletion, immature Ly-6Chigh monocytes returned 
more rapidly to the circulation in NOD mice, while the transition of immature to mature 
monocytes had normal re-appearance kinetics. This suggests that the bone marrow in 
NOD mice is able to release more monocytes to ensure the restoration of a larger mature 
circulating compartment. In addition, while monocytes from C57BL mice down regulate 
their capability to adhere to fibronectin and ICAM-1 upon maturation, the mature NOD 
monocytes retained the high adhesion capacity. Furthermore, both monocytes groups 
of NOD mice differentiated preferentially into macrophage-like F4/80high cells during in 
vitro overnight culture.
In conclusion, mice with the NOD background show an enhanced monocyte-production 
capacity, raised numbers of mature monocytes in the circulation and a pro-inflammatory 
macrophage-directed set point of these monocytes.
Type I diabetes is an autoimmune disease in which a self-destructive immune process against the pancreatic b-cells leads to 
insulin deficiency. In the non-obese diabetic 
(NOD) mouse, a widely used animal model for 
autoimmune diabetes, dendritic cells (DC) and 
macrophages (Mf) are important for the initiation 
and progression of autoimmune diabetes and the 
final destruction of b-cells. Morphological studies 
show raised numbers of DC and Mf already in 
the pancreas of neonatal NOD mice [1]. A further 
accumulation of DC and Mf around islets at 4-5 
weeks of age precedes the peri-insular infiltration 
of lymphocytes. An infiltration of lymphocytes and 
Mf into the islets characterizes the initiation of the 
final b-cell destruction [2, 3]. 
Monocytes are direct precursors of DC and 
Mf [4-6]. It has been generally accepted that 
the majority of DC and Mf originate from blood 
monocytes, especially in inflammation [7, 8]. 
Mouse blood monocytes can phenotypically and 
functionally be separated into two subsets [9, 10]. 
Monocytes that have recently emigrated from 
the bone marrow (BM) and express high levels 
of the Ly-6C molecule belong to the first subset. 
These Ly-6Chigh, immature monocytes, are readily 
attracted to sites of inflammation, have the potential 
to develop into DC or F4/80+ inflammatory Mf 
[6, 10] and co-express CCR2, which enables the 
cells to be attracted towards inflammation-induced 
MCP-1 signals. These immature monocytes also 
express CD62L molecules and are therefore able to 
enter lymph nodes in non-inflammatory conditions 
through high endothelial venules (HEVs) 
[11]. The second subset of blood monocytes is 
generated through a maturation step from the 
immature monocytes, marked by a reduction of 
the surface expression of the Ly-6C molecule 
and an increase in expression of CD43 [10]. 
These Ly-6Clow monocytes that express CD11c 
and CX
3
CR1 (fractalkine receptor), migrate to 
peripheral organs, such as liver and lung, in the 
absence of inflammation and have been proposed 
to be the precursors for the steady state pool of 
DC and Mf [9]. 
Geissmann et al have suggested that the mouse 
monocyte subsets correspond to the previously 
discriminated subtypes of circulating monocytes 
in humans. According to this view, CX
3
CR1lo 
(Ly-6Chigh) mouse monocytes correspond to 
CD14+CD16– human monocytes, while the 
CX
3
CR1hi (Ly-6Clow) monocytes correspond to 
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the CD14+CD16+ human monocyte population. 
Changes in the composition of the monocyte 
pool due to different pathological conditions have 
been demonstrated in humans.The CD14+CD16+ 
monocytes expand greatly in acute and chronic 
infections, systemic inflammatory syndromes, 
AIDS and renal failure [12-17]. However, we found 
normal numbers of both monocyte populations 
in type-1 diabetic (T1D) patients and the same 
has been observed in multiple sclerosis (MS) 
patients [18, 19]. Other subdivisions in circulating 
human monocytes have been made, such as the 
subdivision based on the ability to adhere to 
fibronectin [20]. The fibronectin-adhering, 
so-called pro-inflammatory “P-monocytes” 
constitute 20-30% of the circulating monocytes, 
express high levels of adhesion molecules, 
have an enhanced chemotactic responsiveness, 
phagocytosis and pro-inflammatory cytokine 
production capability [21, 22]. Interestingly, we 
found that fibronectin-adhesive monocytes are 
present in equal numbers in both the CD14+CD16+ 
and the CD14+CD16– population, indicating that 
the division based on the fibronectin-adherence 
and the division based on the CD16 expression 
are probably not identical. This is also indicated 
by our finding of raised number of fibronectin-
adhesive monocytes in T1D patients as compared 
to healthy controls, in the presence of normal 
numbers of CD14+CD16+ cells [18]. 
The phenotypic discrimination between the Ly-
6Chigh immature and Ly-6Clow mature monocytes 
enabled us to investigate the apportioning between 
immature and mature blood monocytes in the 
mouse variant of autoimmune diabetes, i.e. the 
NOD mouse model. Here we describe an excess 
of mature Ly-6Clow monocytes in the blood of mice 
with the NOD background, which had abnormal 
high fibronectin adhesive properties. The kinetic 
studies on the re-appearance of the monocyte 
subpopulations after depletion with clodronate-
loaded liposomes (lip-CL
2
MDP) showed that in 
NOD mice more monocytes rapidly leave the 
BM to fill the larger mature blood monocyte 
compartment.
Previously we reported a hampered capability 
of monocytes of T1D patients to develop during 
an overnight culture into DC-like cells [23]. 
We therefore also tested the capability of both 
immature and mature monocytes of NOD mice 
to differentiate into cells with a DC- or Mf-like 
phenotype during an in vitro overnight culture 
and found an enhanced capability of NOD 
monocytes to create more progeny with a Mf-
like phenotype. 
Taken together we here give evidence in 
mice with the NOD background for an enhanced 
production of monocytes from BM precursors, 
raised numbers of mature monocytes in the 
circulation with an abnormal adhesion capability 
and a preferential development of Mf-like cells 
from both the immature and mature forms of 
circulating NOD monocytes.
Material and methods
Animals
Mice used in this study were all female and between 5-
16 weeks old when used in experiments. Diabetic NOD 
mice were 25 weeks old. C57BL/6j, BALB/c mice were 
purchased from Harlan (Horst, The Netherlands), NOR 
mice were purchased from Jacksons Laboratory (Bar 
Harbor ME, USA) and NOD/Ltj, NOD.B10H2b (NOD-
H2b) and C3Heb/Fej mice were bred in the animal care 
facility at the Erasmus MC, Rotterdam. All mice were 
specific pathogen-free and kept with free access to food 
and water in the animal care facility at the Erasmus MC 
Rotterdam, under the institutional guidelines for usage of 
experimental animals approved by Erasmus University 
Animal Welfare Committee. Glycosuria in NOD mice 
was tested with the Gluketur test (Roche Diagnostics 
GmbH, Mannheim, Germany). 
 
Antibodies 
Specifications of monoclonal antibodies and fluorescent 
conjugates against surface markers used in this study are 
listed in Table 1. Directly conjugated isotype control mAb 
were purchased from BD Pharmingen (San Diego, CA). 
Anti-rat IgG conjugated with FITC- or R-phycoerythrin-
(R-PE)- (mouse-absorbed; GaRa-FITC or GaRa-PE) 
were purchased from Caltag Laboratories, San Francisco, 
CA. Biotinylated Ab were detected by allophycocyanin- 
(APC) conjugated streptavidin (SAV-APC) purchased 
from BD Pharmingen.
In vivo elimination of mononuclear phagocytes
Multilamellar liposomes containing clodronate 
(dichloromethylene bisphosphonate, a gift from Roche 
Diagnostics) (lip-CL
2
MDP) in the aqueous phase were 
prepared as described previously [32, 33]. Liposomes 
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consisted of phosphatidyl choline and cholesterol in 
6:1 molar ratio. After washing, the liposomes were 
resuspended in PBS. Mononuclear phagocytes were 
eliminated in vivo by intravenous (i.v.) injection of 0.2 
ml clodronate liposomes into the lateral tail vein, as 
described before [34]. 
Preparation of leukocytes
Mice were euthanized by CO
2
 exposure. Blood was 
obtained by heart puncture and collected in heparin-
coated tubes. Erythrocytes were eliminated using BD 
lysing buffer (San Diego, CA) and leukocytes were 
washed by centrifugation at 1500rpm for 5 min in 
phosphate buffered saline (PBS) pH 7.8 containing 0.5% 
BSA (Biowhittaker, Verviers, Belgium) (further referred 
to as FACS buffer). Cells were finally resuspended, 
counted and used for further analysis.
Flow cytometry and cell sorting 
For phenotypic analysis aliquots of 0.5-1x106 cells 
were pipetted into 96-microwell plates (round bottom, 
Nunc, Denmark) and incubated with the prepared mix 
of monoclonal antibodies. Each incubation step was 
performed at a room temperature for 10min. Cells were 
analyzed using a FACSCalibur equipped for 4-color 
flow cytometry. Depending on the size of the sample 
up to 5x105 events were obtained. Data were analyzed 
using CellQuest software (Becton Dickinson, Sunnyvale, 
CA). 
Cell sorting was performed on a FACSDiva by applying 
a previously described protocol [4]. Lysed blood 
Table 1.  Monoclonal antibodies used in this study samples (pooled from 5 or 10 mice) were first washed 
in a sterile PBS supplemented with 5% heat inactivated 
FCS (Biowhittaker) (further referred to as a sorting 
buffer) and incubated for 30min on ice with the mix of 
CD11b, Ly-6C (clone ER-MP20) and Ly-6G antibodies. 
Subsequently, cells were washed with a sorting buffer 
and filtered over a 30mm sieve (Polymon PES, Kabel, 
Amsterdam, The Netherlands) to avoid clogging of the 
nozzle. After sorting, the purity of the cell suspensions 
was checked by re-running sorted samples and purity 
exceeded 95% (unless stated othervise). Cells were kept 
at 4°C throughout the staining and sorting procedure. 
Sorted cells were counted in a Bürker hemocytometer.
Adhesion test
For adhesion capacity test, sorted monocytes were 
suspended in RPMI-1640 culture medium (Biowhittaker) 
containing antibiotics (60mg/ml penicillin and 100 mg/ml 
streptomycin) supplemented with 1% heat-inactivated 
FCS. Monocytes were then plated on the coated 
chambertek glass slides (Nalge Nunc International, 
Naperville, USA) at a density of 0.2 x 105 cells per 
chamber. Slides were coated with 10 mg/ml fibronectin 
or 10g/ml ICAM-1 (Sigma, Steinheim, Germany). After 
60min incubation at 37°C, cells were washed with PBS 
and fixed with 4% paraformaldehyde (PFA; Sigma) 
supplemented with 3% glucose. Subsequently, cells 
were permeabilized using 0.5% Triton X-100 (Sigma 
Chemical, Saint Louis, USA) and stained with 0.1 mg/
ml FITC-labeled phalloidin (Sigma Chemical) for 30-45 
min. After washing and mounting the slides, the cells 
were counted using a fluorescence microscope. Adhesion 
was expressed as the number of cells in 10 high power 
fields (hpf) at 200x magnification. Two individuals 
performed the counting, independently.
Culture of sorted cells 
For analysis of in vitro differentiation capacity of 
monocytes, sorted cells were seeded into 96-well 
culture plate at concentration of 1x106/ml in the RPMI-
1640 medium supplemented with antibiotics and 10% 
FCS. The cells were incubated at 37°C with 5% CO
2
 for 
24h, alone or stimulated with 100ng/ml LPS (Sigma). 
After 24h incubation, cells were used for phenotypic 
analysis. 
Statistical analysis
To determine differences between the groups, data were 
compared by a two-tailed Student’s T-test using the SPSS 
software package. Results are presented as the mean ± 
SEM, unless indicated differently.
marker monoclonal antibody
used form 
(conjugate) origin
CD3 145-2C11 FITC, APC BD Pharmingen
CD11b M1/70 PerCP-Cy5.5, APC BD Pharmingen
CD11c HL3 FITC, PE BD Pharmingen
CD16/32 2.4G2 Øa ATCC, Rockville, MD, USA
CD19 1D3 PE BD Pharmingen
CD43 S7 FITC, PE BD Pharmingen
CD54 YN1/1.7 Ø ATCC, Rockville, MD, USA
CD62L MEL-14 PE BD Pharmingen
CD115 AFS98 Ø Dr. Nishikawa, Kyoto, Japan
ER-MP58 ER-MP58 Ø own laboratory
F4/80 F4/80 FITC Caltag
Ly-6C ER-MP20 FITC own laboratory
MBR MIV 38 Ø Dr. Falkenberg, Bochum, Germany
NK1.1 PK136 PE BD Pharmingen
a hybridoma supernatant
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Results
 
Both Ly-6Chigh (immature) and Ly-6Clow 
(mature)  are found in the blood of NOD mice 
In the NOD mouse blood, an identical definition 
of the two subsets of monocytes could be applied 
as the previously reported [10] (Fig. 1A). 
Similarly to the C57BL mouse, more than 97% 
of SSCloCD11bhi cells in the NOD mouse blood 
were M-CSF-receptor positive (CD115 in the Fig. 
1C) and could be separated into two populations 
defined by Ly-6C expression (Fig. 1A). The 
markers CD11c, CD43 and CD62L also had a 
similar distribution in NOD as in C57BL mice 
(Fig. 1B). Further phenotyping of Ly-6Chigh and 
Ly-6Clow monocytes did not reveal reproducible 
differences between the two mouse strains (Fig. 
1C), apart from the macrophage marker, F4/80, 
which had a reproducibly higher surface expression 
on both subsets of NOD monocytes. 
Figure 1. Definition and phenotypic analysis of blood monocytes in the NOD mouse. A. Application of the same 
gating of SSClo and CD11bhi cells separates two monocyte populations as seen from the bi-phasic profile of the Ly-6C 
histogram. B. Although lower on NOD monocytes, Ly-6C separation discriminates identical two monocytes populations 
as in the C57BL mice. C. Additional markers tested show a differential or similar expression between two monocyte 
subsets, but almost identical expression between NOD and C57BL mice within a particular population. Exceptionally, 
F4/80 molecule is higher on both Ly-6Chi and Ly-6Clo monocytes in the NOD mouse. Dot-plots and histograms show a 
representative staining of a minimum of 3 independent stainings for each marker.
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Figure 2. Different balance between Ly-6Chi and Ly-6Clo monocytes in the blood of mice with a NOD genetic 
background. A. Representative dot-plot of the Ly-6C/CD43 profile of NOD and C57BL monocytes shows a higher 
frequency of Ly-6Clo monocytes in the NOD mice. B. Analysis of the frequency of blood monocytes in different mouse 
strains revealed a specific shift towards Ly-6Clo monocytes in all mouse strains with the NOD genetic background. C. 
Analysis of the frequency within all nucleated cells. Frequency of Ly-6Chi monocytes is significantly lower in the NOD 
than in the C57BL and the C3H mice but not different from the BALB/s mice. In contrast, percent of Ly-6Clo monocytes 
in the NOD mouse blood is significantly higher than in all mouse strains tested. Graphs represent average value ±SEM 
calculated from 26 C57BL mice, 20 NOD mice and 6-9 mice of other mouse strains. 
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Mice with the NOD background have more 
mature Ly-6Clow monocytes in the blood.
Although the phenotype of the NOD monocyte 
subsets did not differ from that of C57BL mice, 
we noticed that the frequency of the Ly-6Chigh 
monocytes was repeatedly lower in NOD mouse 
blood when compared to C57BL blood, as 
demonstrated in a representative dot-plot (Fig. 2A). 
Correspondingly, Ly-6Clow monocytes in the NOD 
blood formed the major monocyte population. This 
overrepresentation of mature monocytes in the 
blood was specific to the NOD mouse. When we 
determined the frequency of monocyte subsets in 
several unrelated mouse strains (Fig. 2B), between 
58-67% monocytes were of the Ly-6Chigh type in the 
strains of mice unrelated to the NOD. In the strains 
with the NOD background, Ly-6Chigh monocytes 
never exceeded 44%. In addition, both healthy 
and diabetic NOD/Ltj mice, as well as NOR and 
NOD-H2b mice, had the higher percentage of the 
Ly-6Clow of monocyte (Fig. 2B). Hence, all mice 
with the NOD background had a reversed ratio of 
monocyte subsets in favor of the Ly-6Clow cells.
In addition we calculated the absolute numbers 
of the two subsets in the peripheral blood. 
All tested mouse strains had similar absolute 
numbers of leukocytes and similar frequency of 
monocytes (SSCloCD11bhi) within all leukocytes 
per ml blood (not shown). Absolute number of Ly-
6Chigh monocytes in the NOD mouse blood was 
significantly lower as compared to the C57BL 
and C3H mice (p<0.001 and p<0.05, respectively) 
(Fig. 2C), but BALB/c mice had similar numbers 
of circulating Ly-6Chigh monocytes like NOD mice. 
The number of Ly-6Clow monocytes was more 
discriminative and remarkably higher in NOD 
mice when compared to all other tested control 
strains (p<0.001 for all three control strains) (Fig. 
2C). Taken together, a mild shortage in the Ly-
6Chigh monocytes and a clear excess of Ly-6Clow 
monocytes, typify the disturbed monocyte-ratio in 
the blood of mice with the NOD background.
Ly-6Clow monocytes from NOD mice display 
unusually high adhesion to fibronectin and 
ICAM-1, typical for Ly-6Chigh monocytes
To check the ability of the two subsets of NOD 
monocytes to adhere to fibronectin and ICAM-1, 
we sorted Ly-6Chigh and Ly-6Clow monocytes from 
the mouse blood and tested their adhesiveness to 
these compounds in vitro.
As shown in Figure 3, majority of Ly-6Chigh 
monocytes isolated from both NOD and C57BL 
adhered to fibronectin and ICAM-1. In contrast, 
much lower percentage Ly6Clow monocytes from 
C57BL mice adhered to these compounds; hence 
the maturation of monocytes into resident cells in 
the circulation leads to a decline in the ability to 
attach. Interestingly, Ly-6Clow monocytes in NOD 
mice preserved the high adhesion capacity to both 
fibronectin and ICAM-1, comparable to that of Ly-
6Chigh monocytes (Fig. 3). 
NOD monocytes show an enhanced spontaneous 
differentiation in vitro, predominantly in the 
direction of Mf-like cells. 
To check for the capacity of the two subpopulations 
of monocytes to spontaneously differentiate in 
vitro, we again sorted and incubated them in 
culture fluid for 24h ,without adding additional 
cytokines.
In the case of C57BL cells, overnight culture 
of sorted immature Ly-6Chigh monocytes induced a 
spontaneous up regulation of the CD43 molecule 
– characteristic of mature monocytes - on the 
majority of the cells (Fig. 4A). In addition, the 
Figure 3. High in vitro adherence of sorted Ly-6Clo 
monocytes from the NOD mouse. Blood monocytes 
were sorted on the FACSDiva and put to adhere to (A) 
ICAM-1 or (B) fibronectin for 60min. Subsequently cells 
were washed, stained and quantified on the fluorescent 
microscope. A high number of Ly-6Chi monocytes from 
both mouse strains adhered to both substrates. In contrast, 
while Ly-6Clo monocytes from the C57BL downregulate the 
adhesion capacity upon maturation, the Ly-6Clo monocytes 
from the NOD mice failed to do so. Graphs represent 
an average±SEM from three independent pools of a 
minimum of 5 mice per pool, obtained in two independent 
experiments.
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Mf marker F4/80 became also higly expressed 
on some of the cells. In NOD mice, however, 
Ly-6Chigh cultured immature monocytes did not 
acquire CD43. Instead, the majority had strongly 
upregulated the F4/80 molecule (note that we 
already mentioned the higher F4/80 expression 
on the fresh blood monocytes from the NOD 
mouse). Quantitative analysis demonstrated that 
significantly more Ly-6Chigh monocytes of NOD 
mice spontaneously became F4/80high Mf-like cells 
(p<0.05) (Fig. 4B). LPS was an additional stimulus 
for C57BL immature monocytes to increase F4/80, 
after which the frequency of F4/80high cells from 
C57BL and NOD samples was not statistically 
different anymore.
Overnight culture of sorted mature Ly-6Clow 
C57BL and NOD monocytes spontaneously 
yielded three cell groups: undifferentiated mature 
monocytes (CD43+F4/80low), cells with a DC-like 
phenotype (CD43lowF4/80medCD11c+MHCIIhi) 
and cells with a Mf-like phenotype (CD43highF4/
80highCD11clowMHCIIlow). Although these three 
groups were present in both NOD and C57BL 
samples, they had a different frequency in these 
mice (Fig. 5A). In overnight cultures, more than 
half of C57BL Ly-6Clow monocytes remained 
unchanged, while in NOD cultures there were 
few remaining Ly-6Clow monocytes (p<0.001). The 
majority of the NOD cells had differentiated into 
Mf-like cells and their frequency was significantly 
higher in samples of the NOD mouse (p<0.05). 
These effects of an enhanced and preferential 
differentiation into Mf-like cells were more 
pronounced with LPS as an additional stimulus 
(Fig. 5B). The percentage of DC-like cells was 
similar in the 24-hour NOD and C57BL cultures. 
Taken together, in NOD both Ly-6Chigh immature 
monocytes and Ly-6Clow mature monocytes show 
an enhanced spontaneous differentiation, and 
predominantly in the direction of cells with a Mf-
like phenotype. 
An enhanced release of monocytes from the 
bone marrow in the blood of NOD mice.
To follow the monocyte maturation in vivo, we 
made use of  clodronate-loaded liposomes (lip-
CL
2
MDP). As shown in Table 2, a single injection 
of lip-CL
2
MDP caused an almost complete 
depletion of monocytes (SSCloCD11bhi) from 
the blood within the first 18h in both NOD and 
C57BL mice. Apparently the NOD monocytes 
were equally able to phagocytose and fragment 
liposomes as the C57BL monocytes. 
Monocytes started to appear in the blood 
around 48h post-injection in both NOD and 
C57BL mice. From this moment till the end of the 
Figure 4. Different in vitro maturation of Ly-6Chi monocytes from NOD mice. A. Maturation of Ly-6Chi monocytes upon 
in vitro cultivation for 24h with or without LPS goes through different phenotypic stages in NOD mice when compared 
to the C57BL. Dot-plots show a representative staining of Ly-6Chi monocytes prior and after the sorting as well as after 
24h incubation alone or with LPS. B. Frequency (±SEM) of Ly-6Chi monocytes that become F4/80hi cells, in vitro. Data 
are derived from 4 independent samples per mouse strain obtained from a pooled blood of 5-6 mice per strain, in three 
independent experiments.   
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observation period, the percentage of monocytes 
(SSCloCD11bhi) was considerably higher in NOD 
mice (Table 2). However, due to the high standard 
deviation, this difference did not reach statistical 
significance. 
Like we previously established for the C57BL 
mice, the first monocytes found in the blood of NOD 
mice at 48h were exclusively immature Ly-6Chigh 
cells (Fig. 6). After 96h, the frequency of Ly-6Chigh 
monocytes started to decline in both mouse strains 
(Fig. 6A). Interestingly, the release from the BM of 
immature Ly-6Chigh cells was larger in NOD mice 
and at 48h the NOD contained significantly more 
Ly-6Chigh monocytes in the blood as compared to 
C57BL mice (Fig. 6A). Accordingly, the kinetics of 
the return of Ly-6Chigh monocytes in the circulation 
was noticeably different between NOD and C57BL 
mice (Fig. 6B). In C57BL mice the frequency of 
Ly-6Chigh monocytes rose gradually to the starting 
point (at 96h) and never exceeded the steady 
state range. In contrast, Ly-6Chigh monocytes of 
the NOD mouse reached the steady state level as 
soon as 48h and continued to rise to the level 2x 
higher than the steady state, at 96h. Thereafter 
the number of Ly-6Chigh monocytes in the NOD 
mouse rapidly declined to the steady state level at 
Table 2. Return of blood monocytes after the i.v. depletion with lip-CL2MDP
a percent within leukocytes/ml blood ±SD
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Figure 5.
Predominant maturation of 
Ly-6Clo monocytes from NOD 
mice into Mf. A. Phenotype of 
monocytes (CD43medF4/80lo), 
DC (CD43loF4/80med) and Mf 
(CD43hiF4/80hi) from NOD and 
C57BL mice after 24h culture with 
or without LPS is similar, as seen 
on representateive dot-plots. B. 
Graph represents the average 
frequency of monocytes (light 
grey bar), DC (dark grey bar) and 
Mf (black bar) ±SEM calculated 
from the 4 samples obtained in 
the same experiments as in the 
figure 6. NOD mouse shows as 
high spontaneous maturation of 
Ly-6Clo monocytes into F4/80hi 
Mf, in vitro.
Time after depletion with lip-CL2MDP (hours)
0 18 24 48 96 192
NOD 13.5 ± 2.9a 1.4 ± 0.9 1.3 ± 0.5 7.6 ± 4.9 13.5 ± 6.2 22.1 ± 13.2
C57BL 13.1 ± 8.4 2.2 ± 1.7 2.3 ± 1.5 3.4 ± 1.5 9.7 ± 5.9 15.9 ± 12.2
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Figure 6. Normal restoration but different kinetics of the monocyte-return after a depletion with lip-CL2MDP (i.v.) 
Changes in frequency of (A) Ly-6Chi and (C) Ly-6Clo monocytes in the NOD (black squares) and C57BL mice (empty 
squares) at different time points after injection of lip-CL2MDP. Kinetic of the return of (B) Ly-6C
hi and (D) Ly-6Clo monocytes 
in the NOD and C57BL mice when calculated relative to their own steady state. Data represent average frequency±SD 
of a minimum of 3 mice for each time point and each mouse strain.
192h (Fig. 6B). 
With regard to the return of the Ly-6Clow 
monocytes in the circulation, higher levels of Ly-
6Clow monocytes - similar to the situation before 
depletion - were found in the blood of NOD mice 
starting from 96h till the end of the observation 
period (Fig. 6C). Importantly, the return of Ly-
6Clow monocytes had identical kinetics in both 
NOD and C57BL mice (Fig. 6D). Therefore, an 
enhanced release of Ly-6Chigh monocytes from 
the BM might be the decisive determinant in the 
finally larger number of mature monocytes in the 
NOD circulation.
Efflux of Ly-6Clow monocytes from the blood of 
the NOD mice is normal.
Besides the enhanced monocyte influx from the 
BM, a reduced efflux of the mature monocytes to 
the periphery could also cause the elevated number 
of Ly-6Clow monocytes in the NOD mouse blood. 
We therefore determined the quantities of Ly-6Clow  
monocytes in the peritoneal cavity and the spleen 
in the steady state and after the application of lip-
CL
2
MDP. The Ly-6Chigh monocytes are virtually 
absent from these compartments (not shown).
In the steady state, the frequency of Ly-6Clow 
monocytes in the spleen and peritoneal cavity of 
NOD and several different mouse strains was 
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similar, across the group of different mouse strains 
(Fig. 7). After depletion, Ly-6Clow monocytes 
returned to the steady state point in both the 
spleen and peritoneal cavity within a week (Table 
3); importantly with similar kinetics in NOD and 
C57BL mice (not shown). Hence we found no 
sign of a reduced efflux of monocytes from the 
circulation to the periphery in NOD mice.
While performing these experiments we also 
noticed that Ly-6Clow monocytes were clearly 
underrepresented in the NOD mouse spleen 
(in favour of Mf and DC), when compared to 
the  C57BL strain. We therefore calculated the 
monocyte: Mf+DC ratio in the spleen of different 
mouse strains and found a significantly lower ratio 
(more mature cells than monocytes) in the NOD 
compared to all mouse strains tested including 
NOR mice (Fig. 7-insert). This indicated that the 
balance between monocytes and their progeny 
in the spleen is also tipped towards the more 
differentiated/mature cells in mice with the NOD 
background. 
Discussion
The recent advances in the phenotypic definition 
of two monocyte subsets in the normal mouse 
blood, i.e. the Ly-6Chigh immature monocytes and 
the Ly-6Clow mature monocytes, enabled us to 
analyze blood monocytes in diabetes-prone NOD 
mice and compare with our previously reported 
data on monocyte subsets in human T1D.
In this study we found that NOD mice display 
an altered balance between Ly-6Chigh immature 
circulating monocytes and Ly-6Clow mature 
monocytes, i.e. the mice displayed an abnormal 
high number of circulating mature monocytes. This 
Figure 7. Different balance between mature (Ly-6Clo) monocytes and DC and Mf in the spleen of NOD mice. Data 
are calculated as a frequency of all nucleated cells and an average±SEM of monocytes (light gray bars) and DC+Mf (dark 
grey bars) from different mouse strains are given in the graph. Insert-graph represent an average±SEM of a calculated 
ratio monocyte:mature cell (DC+Mf). P values are derived from a double-sided Student’s t-test. Data are calculated from 
13 C57BL mice, 19 NOD mice and 5-8 mice of other mouse strains. 
Table 3. Frequency of Ly-6Clo monocytes in different compartments
a percent of all leukocytes/ml blood ± SEM
** p<0.01 NOD vs. C57BL; * p<0.05 NOD vs. C57BL
blood spleen peritoneum
NOD C57BL NOD C57BL NOD C57BL
untreated a 8.56 ± 1.05* 5.55 ± 0.65 0.59 ± 0.05** 0.96 ± 0.08 6.81 ± 1.24 6.32 ± 1.50
treated (d7) 4.90 ± 0.74 3.57 ± 0.43 0.71 ± 0.05* 0.97 ± 0.07 6.07 ± 0.77 3.35 ± 1.56
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phenomenon appeared to be intrinsic to the NOD 
background, since NOR and NOD-H2b mice also 
showed this altered balance. In addition we found 
in the NOD spleen more DC and Mf relative to 
the monocytes as compared to control strains. 
These observations support a view that mice with 
a NOD background show a skewing of cells of 
the monocyte lineage towards more differentiated 
and mature forms in both the circulation and the 
periphery.
After depletion with lip-CL
2
MDP we found 
an overshoot of immature Ly-6Chigh monocytes 
released in the first two days in the blood of NOD 
mice, while the transition of immature to mature 
NOD monocytes had normal kinetics. The re-
appearance kinetics are compatible with a view 
that in NOD mice more monocytes are able to 
leave the BM after depletion (perhaps also in the 
steady state) to finally fill a larger compartment 
of more differentiated and mature forms of the 
monocyte lineage. 
What could be the mechanisms behind the 
raised release of NOD monocytes from the BM 
compartment? Theoretically more Ly-6Chigh 
monocytes are able to leave the BM when there 
is a larger production of monocytes per unit time 
or when there is an enhanced release of monocytes 
from stored pools of immature monocytes in the 
BM. For the latter mechanism we did not obtain 
evidence in a set of preliminary experiments: i.e. 
we found a similar composition of the myeloid 
BM cells in NOD and C57BL mice before and 
after depletion (unpublished results). Hence we 
favor the view that mice with the NOD background 
have a capacity for a larger and faster production 
of monocytes from monoblasts in the BM, when 
stimulated to do so.
The here described mature Ly-6Clow 
monocyte population corresponds to the Gr1–
CCR2–CX
3
CR1hi mouse monocyte as defined 
by Geissmann and colleagues [9]. But does it 
absolutely relate to the CD14+CD16+ monocytes 
described in the human? 
The CD14+CD16+ monocyte population is 
generally considered to act as an important 
pro-inflammatory effector subset based on their 
inflammation-related amplification in the blood. 
According to Geissmann et al the human CD16+ 
monocytes share many features with mouse 
CX
3
CR1hi monocytes. They are not recruited 
to inflammations but “resident” cells and the 
precursors for the steady state Mf and DC. Both 
mouse (CX
3
CR1hi) and human CD16+ “resident” 
monocytes are negative for the pro-inflammatory 
chemokine receptor CCR2 [9], suggestive of their 
exclusion from inflamed tissues. Hence, a parallel 
can be drawn between the enlarged CD16+ pool 
during acute and chronic inflammations in the 
human [12-17] and the enlarged pool of Ly-6Clow 
monocytes in the NOD mouse that suffers from 
various (autoimmune) chronic inflammations. 
However, our data showing the larger pool of 
mature monocytes in the inflammation-free 
mice with the NOD background, suggest that 
this expansion in the NOD mouse is most likely 
due to an enhanced generation of monocytes in 
the BM determined by the genetic background. 
This further implies that the imbalance towards 
mature forms of circulating monocytes relates to 
the proneness to develop (autoimmune) chronic 
inflammations rather than to the presence of such 
inflammations per se.
Our data point to the possibility that the Ly-
6Chigh /Ly-6Clow monocyte subdivision in the mouse 
might not completely correspond with the CD14/
CD16 division in the human. Quantitatively, there 
are clearly more Ly-6Clow monocytes in normal 
mouse blood than CD16+ monocytes in normal 
human blood (40% vs. 10%, respectively). Also, 
while we here describe that Ly-6Chigh monocytes 
have a selective capability to adhere to fibronectin 
and ICAM-1, we previously reported that both 
CD16– and CD16+ monocytes are capable of such 
adherence [18]. Finally there is the discrepancy 
between the populations in autoimmune diabetes: 
the frequency of CD16+ circulating mature 
monocytes in human cases was not raised, while 
we here show more mature Ly-6Clow monocytes in 
the NOD mouse blood. 
In fact, a better overlap might be between the 
Ly-6Chigh/Ly-6Clow subdivision and the distinction 
on the basis of fibronectin-adherence, since Ly-
6Chigh monocytes in normal mice have a clearly 
raised ability to adhere to fibronectin like the 
“P-monocytes” in humans [20]. However the 
overlap between the Ly-6Chigh and the “P-
monocytes” is also not absolute. In patients with 
T1D, we found a clearly raised adherence of 
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monocytes to fibronectin (i.e. a raised number of 
“P-monocytes”). We also found raised numbers 
of NOD monocytes that adhered to fibronectin, 
if taken irrespectively of whether they expressed 
the Ly-6C. Yet, the number of Ly-6Chigh monocytes 
(normally the fibronectin-adhering population in 
the mouse blood) was not raised (on the contrary). 
Taken together, the functional flexibility of 
monocytes might make a definition of monocyte 
subpopulations troublesome. 
As mentioned, the mature NOD monocyte 
population had the same high adhesive properties 
to fibronectin and ICAM-1 as that of NOD 
immature monocytes. This subset of in principal 
“non-inflammatory” monocytes hence with 
characteristics of inflammation-related monocytes, 
implies that the normal down regulation of this 
characteristic during monocyte maturation in the 
blood had not taken place in the NOD mouse.
Perhaps the abnormal Ly-6C molecule in 
myeloid cells of the NOD mouse plays a role 
in this aberrancy [24]. Cross-linking of Ly-6C 
molecules induces integrin expression on the cell 
surface and has been associated with cell adhesion 
[25]. It is unclear whether the recombination in the 
Ly-6C gene changed the function of this molecule 
in the NOD mice and will aberrantly influence 
the expression and avidity of integrins involved 
in fibronectin and ICAM-1 binding (It is here 
also important to note that the somewhat lower 
Ly-6C expression on the immature Ly-6Chigh NOD 
monocytes did not prevent the accurate separation 
of the NOD monocytes in our experiments). 
With regard to the capability of blood 
monocytes of the NOD mouse to differentiate 
into cells with a DC- or Mf-like phenotype, we 
here describe a tendency of both immature and 
mature monocytes to preferentially differentiate in 
vitro into cells with a Mf-like phenotype, i.e. F4/
80highCD11clowMHCIIlow cells. This strengthens our 
previously expressed view – using BM precursors 
- that a differentiation into the DC direction is 
hampered in NOD mice and skewed into the Mf 
direction [26]. This abnormally skewed production 
of Mf-like cells could be due to dysfunctional 
signaling pathways. This brings to mind the high 
NF-kB activity, that has been found previously in 
NOD mouse DC and Mf [27, 28]. 
In conclusion, mice with the NOD background 
show an enhanced production of monocytes when 
stimulated, larger numbers of mature monocytes 
in the periphery and a preferential development 
of Mf-like cells from both immature and mature 
forms of monocytes. We can only speculate on 
the contribution of the described phenomena to 
the proneness of NOD mice to develop various 
autoimmune conditions. 
We excluded the possibility that they are the 
consequence of the autoimmune inflammations, 
since they were also present in pre-diabetic NOD 
mice and inflammation-protected NOD-H2b and 
NOR mice. Interestingly, in autoimmune prone SJL 
mice we also found a shifted ratio in circulating 
monocyte subpopulations, similar to the NOD 
(not shown). 
So, if the here-described phenomena are 
causally related to autoimmunity, which could 
be the mechanisms? Firstly the larger number of 
mature forms of monocytes and Mf might support 
the destructive character of the autoimmune 
inflammations. In addition, the imbalance between 
the generation of DC and Mf from monocytes in 
favor of the Mf lineage may play a role. DC are 
essential not only in the induction of immunity, 
but also - and perhaps more importantly - in the 
tolerance maintenance. Indeed transfers with 
optimally functioning DC have proven to prevent 
the development of autoimmune diabetes in 
the NOD mouse [29-31]. Therefore, a deficient 
induction and maintenance of tolerance by 
insufficiently produced high-quality DC could 
form a key to the initiation of autoimmunity.
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Background of the study
The role of dendritic cells (DC) and macrophages (Mf) in the regulation of the immune 
homeostasis has been widely recognized. An important aspect of such regulation is the 
maintenance of immune tolerance. An inability of DC and Mf to adequately regulate immune 
responses, in either unengaged (steady state) or inflammatory situations leads to a potential 
break of tolerance and autoimmunity. 
In the non-obese diabetic (NOD) mouse, autoimmune destruction of pancreatic b-cells 
leads to the insulin deficiency and diabetes. Antigen-presenting cells - DC, Mf and B cells 
- are involved in the diabetogenic process. B cells play an important part in the conversion of 
the benign peri-insulitis into a destructive insulitis process [1]. DC and Mf are involved in 
both the initiation and the progression of the autoimmune process, both locally (in the target 
organ) and in the lymphoid tissues (reviewed in [2]). NOD mice benefit from therapeutic 
regimens that target the antigen-presenting system. 
An aberrant function of Mf and DC has been suggested to underlie the T1D not only 
in the NOD mouse, but also in the BB-DP rat and the human. Functional defects of Mf 
have been described in the NOD and other autoimmunity-prone mouse strains and include 
an abnormal cytokine production (an elevated interleukin IL-12 and an imbalance in TNF-
a/IL-10), a low phagocytosis of apoptotic cells (that fails to induce an anti-inflammatory 
cytokine pattern) and a poor antigen-specific T cell stimulation by APC from the NOD spleen 
[3-8]. Investigations of the DC function, which employed a generation of these cells in vitro, 
have led to a conclusion that DC show an abnormal differentiation [9-14]. However, various 
observations from the in vitro system were not accompanied with similar findings in vivo, 
especially for DC. Aberrancies of purified spleen and lymph node DC have been found in NOD 
mice, yet they are relatively mild or disputed [15, 16]. Whether such DC defects affect T cell 
tolerance is largely unknown. The proposed abnormal selection and apoptosis of autoreactive 
T cells or the defects in the regulatory T cell pool might be caused by intrinsic defects in NOD 
mouse lymphocytes, induced by the aberrant DC or may be mediated by other cells (thymic 
epithelial cells, B cells, Mf). 
This unclear contribution of DC to the tolerance defects was partially caused by the 
incompletely understood ontogeny of the DC system and the functional/developmental 
relations with other cells of the immune system. The approach described in this thesis mainly 
involved the application of monoclonal antibodies in the quest for a precise definition of the 
various differentiation stages of Mf and DC and their precursors in the normal mouse and in 
the diabetes-prone NOD mouse. Apart from that, depletion studies (using clodronate-loaded 
liposomes; lip-CL
2
MDP) have been carried to study the kinetics of return of the Mf, DC and 
their precursors both in the circulation and in the pancreas of NOD mice.
 
Chapter 5180 Conclusions and Discussion 181
Conclusions from the study
The following conclusions can be drawn from our studies:
1. DC and Mf return slowly to the islets after their depletion in NOD mice. In addition to the 
role in the induction of islet autoimmunity, they appear to be essential in the maintenance 
of T- and B-cells in the peri-insular infiltrate in later stages of the disease (Chapter 2).
2. DC and Mf share progenitors in the mouse BM. Three subpopulations are able to give rise 
to DC when cultured in the presence of GM-CSF: 
CD31highLy-6C–  → CD31+Ly-6C+  → CD31–Ly-6Chigh
The kinetics of DC differentiation indicates that the three populations are successive 
maturation stages of myeloid DC precursors. All precursor stages are also able to 
differentiate into Mf when stimulated with M-CSF (Chapter 3.1). In addition, the CD31+Ly-
6C+ population also harbors the precursors for a new DC type, the CD11b–CD11clowB220+ 
plasmacytoid DC (Chapter 3.4 and not shown)
3. Bone marrow of NOD mice contains normal numbers of DC progenitors with comparable 
phenotype. However, when stimulated in vitro with GM-CSF, the NOD DC progenitors 
exhibit a reduced proliferation capacity together with an accelerated differentiation (Chapter 
3.2). Also in vivo, when circulating monocytes need to be rapidly replenished (e.g. after 
depletion), the NOD mouse is able to produce more monocytes per unit time in the first 
phases of this replenishment than control mouse strains (Chapter 4.2).
4. An in vitro stimulated generation of myeloid DC from NOD bone marrow results in aberrant 
DC with a macrophage-like phenotype. These aberrant DC are functionally defective and 
have a lower capacity to stimulate T cells as compared to normal myeloid DC (Chapter 
3.3).
5. Mouse blood monocytes, an important precursor-reservoir for mouse DC and Mf, undergo 
maturation in the circulation. This results in two pools of blood monocytes, i.e. the Ly-
6ChighCD43low immature monocytes and the Ly-6ClowCD43high mature monocytes (Chapter 
4.1). The immature, inflammatory monocytes are predominantly recruited to sites of 
inflammation to become exudate Mf, in accord with their pro-inflammatory chemokine-
receptor make-up and integrin-mediated adherence capability (Chapters 4.1 and 4.2). The 
resident, mature population is thought to be the precursor population for the steady state 
DC and Mf in the non-inflamed tissues. Resident mature monocytes have down regulated 
their inflammatory chemokine receptors and up regulated the receptor for fractalkine [10]; 
they have also reduced their integrin-mediated adherence capability (Chapter 4.2).
6. In the NOD mouse, and also in other strains with the NOD background, the mature (Ly-
6ClowCD43high) circulating pool of monocytes is expanded, but has abnormally retained a 
high integrin-mediated adherence capability. Futhermore, in the NOD mouse, not only bone 
marrow precursors (see before), but also immature and mature blood monocytes differentiate 
more readily into Mf-like cells than into DC-like cells (Chapter 4.2). 
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A state of the art view on mouse monocyte-derived dendritic cells and 
macrophages
The various differentiation/maturation stages of mouse monocytes as common dendritic 
cell and macrophage precursors
DC and Mf are widely spread throughout the body. All lymphoid and non-lymphoid organs and 
tissues contain at least one type of Mf and/or DC. Due to the enormous diversity and plasticity 
of the DC and Mf system and due the lack of appropriate methodology, the development of 
DC and Mf from their precursors was not known in detail. However, in the last few years, 
significant information has been collected by us and others about the developmental stages of 
the monocyte-derived DC and Mf in the mouse. Figure 1 represents a schematic overview of 
the development of mouse monocyte-derived DC and Mf through the three compartments/
phases, starting in the BM through the circulation into the tissues.
Figure 1. Maturation sequence of myeloid cells in the mouse. Three developmental stages can be defined in the 
bone marrow (BM). The last BM stage are immature monocytes, which mature in the circulation into monocytes able to 
give resident DC and Mf in the periphery. Immature monocytes can also develop into inflammatory macrophages, if they 
encounter inflammation-related signals
Phase I – Maturation in the BM to immature monocytes. 
Three successive stages of the precursors for Mf have been defined previously in the BM 
of normal mice, using the markers Ly-6C and CD31 [18]. In the study described in Chapter 
3.1, we show that myeloid DC also derive from these precursor populations and share their 
precursors with Mf throughout the development in the BM [19]. Furthermore, we observed 
that an initial stimulation of the common DC/Mf progenitors with M-CSF did not deprive the 
cells from the capacity to develop into DC upon switching to GM-CSF. This demonstrates that 
over a prolonged period of development, progenitors of the mononuclear phagocyte system 
are capable to either developing into Mf or DC, depending on local conditions. Therefore, 
a maturation sequence of the Mf/DC progenitors in the BM, defined by Ly-6C and CD31 
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molecules goes as follows: 
CD31highLy-6C– → CD31+Ly-6C+ → CD31–Ly-6Chigh
With regard to the plasmacytoid DC, Bruno et al demonstrated that the CD31+Ly-6C+ 
population also contains the precursors for IFNa producing cells [20], which were the same as 
the B220+ PDC (not shown). In addition, it has recently been demonstrated that early precursors 
for all DC subtypes reside within the Flt3+ precursor population in the BM, regardless of their 
lymphoid or myeloid lineage orientation [21]. 
Phase II – Maturation in the blood to mature monocytes. 
The last stage of the DC/ Mf precursor development in the mouse BM represents monocytes. 
The cells are characterized histo-morphologically and have a high expression of the Ly-6C 
molecule. In the circulation, the name “inflammatory” monocytes was designated to the same 
cells, [17]. These monocytes have the capacity to rapidly extravasate and migrate to the 
inflammation site, where they develop into inflammatory exudate Mf [17, 22]. In addition, 
the expression of CD62L enables these monocytes to enter the lymph node through the HEV 
[23, 24]. 
As reported in Chapter 4.1, we demonstrated that the monocytes undergo a maturation step 
in the circulation, through which they loose Ly-6C, CCR2 and CD62L molecules (and therefore 
the ability to enter inflammations and lymph nodes) and gain CD43, CD11c, fractalkine receptor 
and several other markers [22]. Therefore we identified the Ly-6Clow monocytes as mature, 
and others as resident monocytes [17]. Apart from the change in phenotype, the maturation of 
monocytes also included the reduction of the ability to adhere to ICAM-1 and fibronectin when 
compared to the immature monocytes (Chapter 4.2). Mature, resident monocytes probably 
still have a high endocytic capacity as judged by their capacity to engulf and break up the 
lip-CL
2
MDP (Chapter 4.1). 
Peripheral non-inflamed compartments, such as the spleen and the peritoneal cavity contain 
almost solely mature monocytes (Chapter 2 and 4.1). In addition, transferred Ly-6Clow monocytes 
preferentially migrate to peripheral tissues, such as lungs and liver, independently of whether 
the transfer was performed in healthy mice or in an inflammatory setting [17]. Therefore, the 
fate of mature monocytes is to develop into resident DC and Mf of non-inflamed tissues. To 
enter non-inflamed tissues via blood endothelium, mature monocytes probably utilize adhesion 
molecules different than those employed by the immature monocytes, such as CD11c and 
CD31 chemo-attracted via the fractalkine receptor. With regard to the entry into the spleen, 
mature Ly-6Clow monocytes are able to reach this lymphoid organ directly without a migration 
through endothelial cell layers, i.e. via the sinuses in the red pulp.
It is not clear which interactions or stimuli are needed to promote the maturation of 
Ly-6Chigh into Ly-6Clow monocytes. Since Ly-6Chigh monocytes are integrin-adherent cells, a 
(transient) adhesion to endothelium might form a key stimulus. Soluble factors like hormones, 
cytokines or chemokines might play a role as well. Alternatively, monocytes might already 
be programmed in the BM to undergo a maturation sequence in a certain time-window. In 
this time window the cells are able to react to inflammation-related stimuli. If such stimulus 
were absent, cells would spontaneously undergo maturation to become Ly-6Clow monocytes 
with a different destiny.
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Phase III – Maturation in the periphery to DC and Mf. 
In vitro, various growth factors and stimuli have been defined that regulate the transition 
of monocytes to DC or Mf (GM-CSF, IL-4, M-CSF, Flt3-L, TLR, etc), yet the factors that 
determine the differentiation step of mature monocytes in the tissues in vivo towards Mf or DC 
are largely unknown. In vivo, this step is probably regulated by a combination of intracellular 
events induced through intimate contacts with other cells (e.g. endothelial cells in reversed 
transmigration) and/or with soluble factors or factors bound to the extracellular matrix, that 
monocytes meet upon arrival in the tissues. In such view local factors of inflammatory and 
non-inflammatory character determine which particular morphological, phenotypic and most 
importantly functional properties monocyte-derived cells will have. Alternatively, it might 
also be possible that pre-programming steps in the BM and/or the blood have prepared the 
cells to differentiate into distinct directions. 
The potential of monocytes to differentiate into both DC and Mf in vitro or in vivo, depending 
on the used growth factor, has been shown by us and others before [18, 19, 25]. Here we show 
that mature monocytes (Chapter 4.1) are capable to spontaneously differentiate into both DC- 
like (CD11c+MHCIIhi) and Mf-like (F4/80highMHCIIlow) cells. Due to the practical inability to 
purify high monocyte numbers for functional studies, we cannot firmly state that these cells 
are indeed functional DC and Mf. The obtained cells are reminiscent of the immature DC and 
Mf that need additional stimuli to mature into functionally competent cells. An investigation 
on whether the here described “spontaneously” generated immature DC and Mf could be 
diverged into only DC or only Mf would shed more light on the question until which point 
these two cell types blend together. 
The terminal differentiation of the immature steady state DC and Mf into potent cytokine-
producing professional APC requires an additional stimulus. Depending on the strength as 
well as the quality of the activating stimulus, DC and Mf will become either strong immune 
inducers or strong immune suppressors. The current dogma dictates that antigens met in a non-
inflammatory context will lead to APC that regulate/suppress immunity (so-called tolerogenic 
DC) (rev in [26]). Interestingly, the maturation level at which DC have a tolerogenic function, 
acquired through the uptake of the antigen under “non-danger” conditions, does not represent 
an end-stage, since these tolerogenic DC can be turned into immune stimulators; e.g. upon 
CD40 ligation [27]. 
Relation of the Ly-6Chigh and Ly-6Clow monocytes to other monocyte-like cells reported 
in the mouse
In the last few years, other groups have described monocytes and monocyte-like cells, which 
in our view overlap or are closely related to either Ly-6Chigh or Ly-6Clow monocytes. 
1. A precursor population for monocyte-derived DC1 cells has recently been reported 
in the mouse blood [28]. When stimulated with GM-CSF and TNFa in vitro, these 
CD11clowCD45RA– mouse pre-DC developed into mature MHCIIhi DC that stimulated T 
cell proliferation. Based on a closer analysis of the used cell purification from the blood 
(PBMC separation; the separation of the low-density fraction on the Nycodenz; depletion 
of CD3, CD19 and Gr-1 positive cells and thereafter of auto-fluorescent and DX5+ cells) 
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and the phenotype of the pre-DC (CD11b+CD11clowCD45RA–), it is highly likely that this 
population overlaps with our mature monocyte (Ly-6Clow) population.
2. Cells involved in the innate immunity and tumor-mediated suppression are also closely 
related or even overlap with immature blood monocytes. Serbina et al recently described 
a TNF/iNOS- producing DC population in the spleen that mediates an innate immune 
defense against infectious agents, for which immature (Ly-6Chigh) monocytes are likely 
precursors [29, 30]. Interestingly, cells with similar phenotype, CD11b+Gr-1+CD31+, so-
called iMacs, were also found to produce iNOS and to mediate an immune-suppression 
in the tumor bearing and in the immuno-suppressed mice [31, 32]. However, the iMacs 
population contains probably both granulocytes and Ly-6Chigh monocytes. We therefore 
doubt whether the claimed suppressor-function can solely be attributed to the monocytes 
in this cell fraction. 
3. Apart from being the precursors for mature APC, or involved in the innate immunity, as 
proposed by the groups of Geismann and Shortman, the mature monocytes might also 
have another function. In a recent study, cells with a potential to stimulate the generation 
of antigen specific regulatory T cells could be generated in vitro using as growth factors 
GM-CSF in combination with IL-10. These tolerogenic DC could also be isolated from 
the spleen as B220–CD11clowCD11b+CD45RB+ cells [33] and are thus clearly of myeloid 
origin. We were able to find the same CD11clowCD11b+CD45RB+ cells in fresh mouse spleen 
suspensions, but found these cells to overlap with the CD11b+CD43hiCD11clowLy-6Clow 
mature monocytes (Chapter 2). Therefore the Th/Tr stimulating profile of spleen mature 
monocytes needs to be tested to make a decesive link between the two populations. 
Comparison of Ly-6Chigh /Ly-6Clow monocytes to plasmacytoid dendritic cells
We were able to identify three pre-DC populations in the mouse blood: CD11b+CD11c–Ly-
6Chigh - immature monocytes, CD11b+CD11clowLy-6Clow - mature monocytes and CD11b–
CD11clowB220+ - plasmacytoid DC. These three cell groups share some functional properties, 
and differ in others. The overview of their comparison is presented in the Table 1.
All three types of cells are precursors for the mouse APC. They can all differentiate into 
DC of different sort (Chapter 4.1, [25, 34]), but only the myeloid-related monocytes are able 
to differentiate into Mf (Chapter 4.1,[25]).
Functionally, a direct contribution to innate immunity is clear for immature monocytes and 
PDC. Yet, the two groups of cells produce different mediators to exert this function (TNFa/
MCP-1 and IFNa, respectively) (unpublished observation and [34]). In addition, PDC play a 
part in the manipulation of the adaptive immune response, which is the task for monocytes as 
well. However, PDC exert this function in both the steady state and in inflammation; monocytes 
have divided these tasks between the two subsets [17, 35, 36]. PDC mediate the stimulation of 
both Th1 and Th2 immune response [36]. In addition, an immune regulatory role of the PDC 
has been suggested in the steady state [35, 37]. Immature monocytes are under inflammatory 
conditions engaged in innate immunity and in the steady state will proceed toward the mature 
circulating monocyte-stage, which will finally contribute to adaptive immunity.
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Table 1. Specific and shared properties of the two subsets of monocytes and PDC
Ly-6Chi 
Mo1
Ly-6Clo 
Mo PDC
Differentiation
Macrophage yes yes no
Dendritic cell yes yes yes
Function
Activation of innate immunity yes no yes
Activation of adaptive immunity no yes yes
Regulation of immune response no yes yes
Migration
Lymphoid organs 
Steady-state no yes? yes
Inflammation yes no yes
Non-lymphoid tissues
Steady-state no yes no
Inflammation yes no no
1 monocytes; ? not clear
Monocytes and PDC also differ in migration patterns. Immature monocytes enter both lymph 
nodes and site of inflammation; mature monocytes exclusively go to non-inflamed tissues, 
while PDC home only to the T cell areas in spleen and lymph nodes (Chapter 4.1, [17, 37]).
Taken together, the three circulating DC-precursor populations differently contribute to 
pro- and the anti- inflammatory immune forces. Their traffic in the steady state or in response 
to danger signals is dynamic and controlled by cytokines and chemokines. They are responsive 
to different signals and able to stimulate different aspects of the immune response. Further 
studies are needed to provide detailed knowledge on the importance of the balance between 
these three populations of DC precursors in the circulation for the maintenance of immune 
homeostasis.
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Monocytes and monocyte-derived dendritic cells and macrophages in 
autoimmune-prone NOD mice
Monocytopoiesis in the NOD mouse bone marrow – an accelerated maturation at the 
expense of cell proliferation under extreme conditions? 
In BM and blood DC and Mf precursors went through the same developmental stages in 
the NOD mouse as in the C57BL mouse, i.e. through the three stages in the BM and the two 
maturation stages of monocytes in the blood. 
However, when isolated from the natural surroundings (bone marrow) and stimulated with 
GM-CSF in vitro, the earliest progenitors (CD31hiLy-6C–) and the myeloblasts (CD31+Ly-6C+) 
isolated from the NOD mouse BM exhibited an aberrant differentiation pace. The cells rapidly 
differentiated into CD11c+ cells, without going through several proliferation cycles necessary 
for renewal and high output such as C57BL cells did. We found a similar reduction in precursor 
renewal when undivided NOD BM was cultured in the presence of GM-CSF (Chapter 3.3.). 
When stimulated with Flt3-L, the expansion rate was any way small in the cultures of all mice 
strains (not shown). However, the number of obtained myeloid DC was in particular low in 
the NOD cultures, again pointing to a potential problem of the NOD mouse to continuously 
produce sufficient numbers of myeloid DC due to a diminution of precursor pools.
In contrast to these in vitro stimulation assays, we did not observe any quantitative deficiencies 
of DC or precursor monocytes in vivo in the NOD mouse. After a complete depletion of 
phagocytic cells by lip-CL
2
MDP in the spleen, a normal functional DC pool was replaced in 
both the NOD and the C57BL mouse within one week (Chapter 2). Furthermore the experiments 
in which we depleted blood monocytes by lip-CL
2
MDP (Chapter 4.2) demonstrated that also 
blood monocytes reached original levels after 8 days in both the NOD and C57BL. This 
excludes the in vivo existence of a deficient continuous renewal of precursors for DC in the 
NOD mouse.
However, it must also be noted that after lip-CL
2
MDP depletion of blood monocytes in the 
NOD mouse there was an even higher release of immature monocytes from the BM noticeable 
2 days after depletion in comparison to C57BL mice. Is this faster release in the first 48 hrs 
related to the potency for an accelerated differentiation of NOD bone marrow DC precursors 
in vitro under the above-described cytokine-stimulated conditions? 
The larger mature pool of circulating monocytes in NOD mice.
NOD mice had an abnormal high number of mature Ly-6Clow monocytes in circulation and 
this phenomenon appeared to be intrinsic to the NOD background, since NOR and NOD-H2b 
mice also showed this altered balance. After depletion, the re-appearance kinetics showed that 
immature Ly-6Chigh monocytes returned more rapidly to the circulation in NOD mice, while the 
transition of immature to mature monocytes had normal kinetics. This suggests that the BM 
in NOD mice is able to release more monocytes to ensure the restoration of a larger mature 
circulating compartment in the same period. However, this transition to mature monocytes in 
the NOD mouse is not ordinary. While normally Ly-6Clow mature monocytes down regulate 
their capability to adhere to fibronectin and ICAM-1, mature NOD monocytes retained this 
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high adhesive pro-inflammatory property. 
These data in autoimmunity-prone mice, when interpreted in light of findings in human 
diabetic patients [38], point to the possibility that the Ly-6Chigh/Ly-6Clow monocyte subdivision 
in the mouse does not correspond with the CD14/CD16 division in the human, as was previously 
suggested [17]: while we here show more mature Ly-6Clow monocytes in NOD mouse blood, 
the frequency of CD16+ circulating mature monocytes in human type 1 diabetes (T1D) is not 
raised. Moreover, there are quantitatively clearly more Ly-6Clow monocytes in normal mouse 
blood than CD16+ monocytes in normal human blood. Also, while we here describe that Ly-
6Clow monocytes have a low capability to adhere to fibronectin and ICAM-1 as compared 
to Ly-6Chigh cells, we previously reported that CD16– and CD16+ monocytes have the same 
capability for such adherence [38]. Hence, a word of caution is necessary in trying to define 
monocyte subpopulations. The functional flexibility of the cells might make such definition 
troublesome. Monocyte compartment is flexible and dynamic and it is probably more 
worthwhile to characterize monocytes functionally and on the basis of complex patterns of 
CD molecule expression in different situations. Subdivision of the cells suggests a fixation in 
states, which might not be compatible with the inherent property of monocytes to change in 
order to adapt to their surroundings.
The preferential in vitro maturation of NOD myeloid precursors into Mf and Mf-like 
DC with a reduced T cell stimulatory capacity
Others have previously reported that NOD BM cells require the presence of IL-4 in addition 
to GM-CSF and IFNg in addition to M-CSF to induce a complete maturation to DC and Mf 
respectively [11, 14, 39-41]. Also in our experience GM-CSF alone was insufficient in the 
NOD mouse system to induce the in vitro maturation of normally competent DC: the cells had 
a reduced capability to stimulate T cells. Moreover we found a clear skewing of the cells into a 
Mf direction. In Chapter 3.3 we report that the DC in the NOD GM-CSF-stimulated BM culture 
had an expression pattern of surface molecules typical of Mf: FcRg II/III, SR-A, F4/80 and 
Gr-1. Interestingly, up regulation of the same surface molecules, characterized as the induction 
to differentiate into Mf, occurred when myeloid precursor (M1) cells were transfected with 
the human GM-CSF receptor (GMR) and stimulated with hGM-CSF in vitro [42]. 
A common feature of NOD cells is to develop into Mf or Mf-like cells. Besides BM 
precursors, also sorted monocytes from the NOD mouse blood demonstrated a spontaneous 
maturation into cells with a Mf phenotype (Chapter 4.2). Whether these cells are indeed real 
functional Mf, and which typical Mf functions they would be able to perform, or more related 
to the Mf-like DC as we found in GM-CSF stimulated cultures, remains to be investigated. 
Increased adherence capacity might be related to an unusual behavior of NOD cells in vitro. 
In all studies in NOD mice in which we found Mf-like cells or the preferential development 
into Mf, increased adherence was also evident. Mature monocytes, which overnight promptly 
acquired a Mf-like phenotype, had an unusual capacity to adhere to fibronectin and ICAM-1 
(Chapter 4.2). The Mf-like cells from the GM-CSF-stimulated NOD BM (Chapter 3.3) were 
also strongly adherent and stretched on the bottom of the culture dish. Finally, when the sorted 
BM progenitors were cultured in the Teflon bags (a culture condition that does not promote 
adherence) (Chapter 3.2), the majority of the NOD cells were stretched and adherent on the 
bottom of the bag. In the latter study, we did not check for the Mf markers, but the preferential 
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maturation without expansion pointed to an atypical behavior of these cells as well.
It is generally assumed that Mf adhere more and stronger to surfaces than DC. However, DC 
stimulated overnight with LPS also adhere to the bottom of the culture dish. Since we observed a 
rapid maturation in all above-mentioned studies, in our system we cannot discriminate between 
attachment related to an increased maturation or to Mf-like characteristics of the cells. 
The putative mechanisms that might underlie the aberrant maturation pathways in the 
NOD mouse
In the process of cell development, progenitors proliferate and differentiate, yet en route on 
the developmental pathway, the proliferative and lineage potentials are progressively lost 
while specific differentiated functions are acquired [43]. The factors that are required for the 
proliferation and differentiation of specific cell types have largely been identified, but the 
mechanisms for the coordination of proliferation and differentiation and the mechanisms that 
ultimately ensure a permanent exit from the cell cycle in terminally differentiated cells are 
poorly understood. Differentiation and proliferation are often viewed as antagonistic, however 
mechanisms that control these different processes work concomitantly and probably influence 
each other. There are signaling pathways that play a role in both of the processes, but also 
those that are specific for either proliferation or differentiation. For example, mechanisms 
that inhibit proliferation and support Mf differentiation are becoming more clear [44]. They 
include CREB proteins that indirectly stimulate growth-arrest and promote Mf differentiation. 
Interestingly, the same factors were found to regulate ICAM-1 expression, adhesion and cell 
morphology in U937 leukemia cell-line [45]. In contrast, Notch signaling inhibits myeloid 
differentiation and promotes expansion of hematopoietic stem/progenitor cells [46].
Our data suggest that the proliferation and differentiation capacity of NOD BM cells are 
not disturbed in the natural surroundings. All studies, in which we found a poor development 
Figure 2. Skewed maturation of myeloid progenitor cells towards Mf in the NOD mouse might underlie pronness 
to autoimmunity. In the normal, healthy situation, a proper balance between the anti-inflammatory and pro-inflammatory 
forces (in this case viewed as the balance between DC and Mf) secures the proper function of the immune system. In 
the autoimmunity-prone NOD mouse, the pro-inflammatory forces tip the balance and disturb a proper regulation of the 
immune system. 
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of competent DC from precursors and a preferential differentiation into Mf-like cells, were 
performed with cells that had been isolated and cultured in vitro (Chapter 3.3 and Chapter 
4.2). We did not find the same aberrancies in vivo. Hence, support cells or the non-disrupted 
architecture in the tissues must play a prominent part in correcting the aberrancies we found in 
vitro. Direct contacts between the cells that support haematopoiesis and myeloid progenitors, 
as well as locally provided cytokines and growth factors, play an important role in the fate 
of the hematopoietic progenitors [47]. The NOD BM cells might be more dependent on the 
support from such stromal cells for proliferation and cell renewal than BM cells of other mouse 
strains. Isolation from this support and exposition to the differentiation-stimulating cytokine 
(e.g. GM-CSF) led NOD cells into a precocious maturation neglecting cell renewal. 
Irrespective of their relevance in vivo, the poor renewal capacity of NOD myeloid precursors and 
the generation of NOD Mf-like DC found in vitro point in the direction of an aberrant function 
of signaling molecules down stream from the GM-CSF-R and other cytokine receptors.
The GM-CSF receptor consists of an a-chain (a low affinity receptor) and a b-chain; 
together they form a high affinity complex, capable of transducing a proliferative signal [48-
50]. In mouse, the b-subunit of the GM-CSF receptor is shared with the IL-5 and in humans 
also with the IL-3 receptor. It is thus of interest that not only defective in vitro responses of 
NOD myeloid precursors to GM-CSF and Flt3-L have been found (this thesis), but also to 
IL-5 and IL-3 [51]. Interestingly, similar cell renewal defects as found here for the NOD 
myeloid precursors have been found when the signaling from the human GM-CSF receptor 
was inhibited in CD34+ cells and cells subsequently stimulated with cytokines that signal 
through the b-subunit of this receptor [52]. However, the signal inhibition did not influence 
the lineage composition of the progeny, indicating that only part of the NOD differentiation 
problem is related to the might be related to b-chain of the GM-CSF receptor.
Problems in three major signaling pathways have been found in the NOD mouse. BM 
cells from the NOD mouse have a reduced ability to stimulate PKC-coupled second messenger 
pathways [41]. A mutation in the Stat5b gene within the Idd4 region has recently been found in 
the NOD mouse [53]. Interestingly, similar intrinsic defects to expand myeloid cells in vitro, 
like in NOD mice, have been found in STAT5 deficient mice [54]. Furthermore, stimulated 
NOD mouse BM cells (DC, Mf and B cells) exhibit a hyper-activation of the NF-kB pathway 
[3, 55, 56]. A faster activation of the ERK1/2 pathway after LPS stimulation of NOD peritoneal 
Mf, leading to a faulty regulation of the CD49d expression[57]. 
The three pathways found aberrant in NOD have been linked to cell functions and 
behavior. The NF-kB pathway is the major regulating mechanism for cytokine production and 
an abnormal cytokine production pattern found in NOD mice is caused by a hyper-activation 
of NF-kB [4, 58]. PI3K and ERK1/2 pathways are differentially involved in the stimulation 
of cell survival, cell proliferation, and cell death after stimulation with the LPS [59]. The 
importance of LPS-activated (TLR4) pathways is further illustrated by the observation that 
activation through LPS leads to a block conversion of inflammatory monocytes into DC and 
directs it into Mf [60]. This is precisely one of the aberrancies characteristic of the NOD 
found in our studies. It would be interesting to investigate this conversion in vivo in the NOD 
mouse, having in mind the skewed maturation of monocytes into Mf that we found in vitro 
and the fact that also other molecules like extracellular matrix proteins can be ligands for 
TLR4 [61] (Note that we also found an enhanced adhesion of mature circulating monocytes 
to fibronectin). 
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Can we relate the here-described aberrancies in NOD monocytes, DC and Mf to the 
proneness for autoimmunity in the NOD mouse? 
The role of DC and Mf in the process of the peri-insular accumulation of lymphocytes in the 
NOD mouse has been suggested previously [62]. In chapter 2 of this thesis, we investigated 
the effect of the depletion of phagocytic cells (monocytes, DC and Mf) in NOD mice that 
have already progressed to an advanced stage of peri-insulitis. Both Mf and DC appeared to 
be important for the organization of the lymphocyte accumulations in the pancreas of NOD 
mice. 
The transient depletion of the DC and Mf in the target organ also significantly delayed the 
progression to destructive insulitis. A beneficial role of phagocytic cell depletion to prevent 
diabetes development has been reported previously [63, 64]. The focus of our studies were 
the alterations in the (peri-)insular infiltrate as a result of the DC and Mf depletion and 
the new message from our study is that DC and Mf in the endocrine pancreas are not only 
important for the initiation of the inflammation and attraction of new lymphocytes to the site, 
but that they are also essentially required to keep lymphocytes at the spot. There are also other 
reports in non-autoimmune conditions that show that elimination of phagocytic cells reduce 
lymphocytic infiltration in the pancreas, e.g. lymphocyte infiltration is reduced by phagocytic 
cell depletion in transplanted fetal pig pancreas xenografts in NOD mice [65]. A similar 
vision of DC being important for the maintenance of autoimmune lesions has been proposed 
in the RIP-LCMV mouse model. [66]. Similarly, the loss of marginal zone Mph as the result 
of chronic Leishmania infection severely abrogates normal trafficking of lymphocytes in the 
white pulp of the spleen [67]. 
Interestingly, the DC and Mf came back to the NOD pancreas and were again capable of 
organizing the inflammatory infiltrate. This points to a persistent signal that comes from the 
pancreas to initiate a local inflammation. It is therefore unlikely that age-related defects in the 
pancreas or age-related defects in the function of APC and T cells cause the initiating signal 
for the lymphocyte accumulation.
How can we relate the in this thesis described enhanced production of NOD monocytes 
from NOD monoblasts, the raised numbers of mature NOD monocytes in the periphery and 
an in vitro aberrant development of Mf-like and less competent DC from NOD precursors to 
the proneness of NOD mice to develop various autoimmune conditions?
To begin with, we can exclude the possibility that the above described phenomena are the 
consequence of the autoimmune inflammations, since they were also present in pre-diabetic 
NOD mice and inflammation-protected NOD-H2b and NOR mice. So, if the here-described 
phenomena are causally related to autoimmunity, the question of the mechanisms causing 
them remains.
Mf are generally considered as pro-inflammatory cells. In such view, the larger 
number of mature forms of monocytes and Mf might support the destructive character of 
the autoimmune inflammations in the tissues. However an opposite point of view can also 
be taken by considering Mf as anti-inflammatory. In the steady state, Mf together with DC 
mediate the uptake of apoptotic cells as a physiological mechanism of the disposal of old and 
non-functioning cells. Disposal of apoptotic cells and maintenance of T cell tolerance are linked 
by the fact that phagocytes that take up apoptotic cells produce anti-inflammatory mediators 
such as IL-10 or TGFb [68-70] and uptake of apoptotic cells by Mf actively modulates the 
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cells and prevents autoimmunity [59, 71]. It is therefore noteworthy that a decreased uptake 
of apoptotic cells by NOD Mf has been found [7], which might deprive them from an anti-
inflammatory potential and render most NOD Mf pro-inflammatory. Indeed, a imbalanced 
cytokine production has been found in NOD and SJL mice [6]. In addition, mice with genetic 
defects in the disposal of apoptotic cells or in which Mf had a reduced ability to take up 
apoptotic cells, had constitutive activated APC and were prone to develop autoimmunity 
[72-74]. However, these mice developed a lupus-like systemic autoimmunity. Therefore, we 
cannot directly translate these findings to the diabetes in NOD mice. However, in view of the 
shared and similar cytokine imbalance with SJL mice and in view of the fact that antinuclear 
antibodies have also been found in NOD mice [75], a Mf defect as exemplified in a deficient 
uptake of apoptotic cells might contribute to the proneness to autoimmunity in general. 
In addition, the imbalance between the generation of DC and Mf from NOD bone marrow 
precursors and from NOD monocytes may play a role. DC were produced in lower quantities 
and had a reduced T cell stimulatory capacity. DC are essential not only in the induction of 
immunity, but also - and perhaps more importantly - in both central and peripheral tolerance. 
Furthermore, self-antigens that originate from dying cells, molecule shedding or direct capture 
from live cells, are presented by DC in draining lymph nodes, in which the highly autoreactive 
cells that encounter the congnate self either die or rapidly expand and acquire the activated 
T
reg
 phenotype [76, 77]. Therefore, a deficient induction and maintenance of tolerance by 
insufficiently produced high-quality DC could form a key to the initiation of autoimmunity in 
the NOD mouse. Compensation of such a defect could be accomplished by inducing optimally 
functioning DC. Indeed, transfers of competent DC have proven to prevent the development 
of autoimmune diabetes in the NOD mouse [39, 78-80]. 
Last but not least it must be noted that we did not find indications that the NOD mouse 
possesses relatively more Mf than DC in vivo and that the spleen and lymph node DC were 
functionally defective in vivo, although the in vitro aberrancies were clear. Hence, our in vitro 
data may just reflect the aberrancies found in intracellular signalling in the NOD mouse, i.e. 
the reduced ability to stimulate PKC-coupled second messenger pathways [41], the mutation 
in the Stat5b gene within the Idd4 region [53], the hyper-activation of the NF-kB pathway 
[3, 55, 56] and the faster activation of the ERK1/2 pathway after LPS stimulation [57]. In 
such view these signaling aberrancies might also play a role in vivo in the function of cells 
other than the DC and Mf or in the function of monocytes, DC and Mf  in the pancreas, cell 
populations which we have not tested.
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Future directions
Studies presented in this thesis contribute to a better understanding of the normal development 
and the heterogeneity of the monocyte-macrophage-dendritic cell system. Studies in which 
the development of this system was addressed in the NOD mouse resulted in the discovery 
of a plethora of (sometimes) discrete aberrancies of which the relevance is not yet clear. In 
fact more questions can now be raised than answers given regarding the role of this system in 
autoimmune diabetes. Several directions for follow-up investigations can be proposed; whether 
all of them are equally appealing to pursue remains to be seen.
The various members of the monocyte-macrophage-dendritic cell system contribute in 
different ways to immune homeostasis. Since we are now familiar with the differentiation 
pathways and means to define different stages of cell development in the monocyte-macrophage-
dendritic cell system and since imaging systems have become available to study labeled cells in 
vivo, studies become feasible in which precursors would be labeled to follow the development 
into the three cell groups (Mf, DC and PDC) and possibly their behavior in the NOD mouse 
pancreas and immune system in vivo. This would significantly contribute to our understanding of 
the development and function of the system in these mice. It must be noted in this respect that it 
is difficult to separate precursor and monocyte subpopulations without functionally influencing 
the cells. More sensitive techniques of cell labeling or applying transgenic mice might be 
helpful to unravel above posed questions. Such approach would be particularly valuable since 
it would provide not only means to investigate the role of the system in the pathophysiology 
of autoimmune diabetes but would also provide the technology to (exogenously) manipulate 
cells of the monocyte-macrophage-dendritic cell system for therapeutic applications.
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Immune system protects us from harmful microbes and tumor development. At the 
same time, the immune system makes sure that the unnecessary immune reaction against 
harmless foreign substances (known as antigens) or self-originating structures (self-antigens) 
either does not occur or is stopped before it induces irreparable damage to a healthy organ. 
Therefore, the immune system is able to make a distinction between the “dangerous” and the 
“harmless” irrespective of its origin. If a “dangerous” is encountered, defense mechanisms 
are activated that generate an inflammation. Elimination of the inflammation inducers leads 
to a deceleration of inflammation and a wound healing, which is actively regulated. The 
response against harmless antigens (either foreign or self) is also actively suppressed and is 
called tolerance. The mechanisms utilized for the controlled activation and inhibition of the 
inflammation and for the tolerance acquisition enable the balanced function of the immune 
system, called immune regulation. 
In some situations the immune regulation can be disturbed and the immune system starts to 
destroy healthy cells leading to an irreparable damage. This action of the immune system 
is called an autoimmune reaction and as a consequence an autoimmune disease develops. 
Such a process directed against b-cells in the islets of Langerhans in the pancreas leads to the 
autoimmune disease termed type 1 diabetes (also known as a sugar disease).
Macrophages (Mf) and dendritic cells (DC) importantly contribute to the proper 
function of the immune system. These two cell types comprise a heterogeneous group of 
cells called mononuclear phagocytes, which differ in the phenotype, function or the origin. 
They are sentinels that reside in all organs and are the first that encounter the infectious 
agents, transformed cells, or some other harmful substances. As an immediate reaction, they 
activate the inborn immunity and start an inflammatory reaction that subsequently leads to the 
activation of other immune forces. Later, they also mediate the reduction of the inflammation 
and help the wound healing. In addition, they are also important for the activation of the specific 
immune forces (including tolerance): DC take up the antigen, present it to other cells of the 
immune system and transduce a signal whether that antigen should be destroyed or ignored. 
Taken together, mononuclear phagocytes can perform several different function and enable a 
balanced function of the immune system, called homeostasis. 
Besides heterogeneity in the function, the origin of DC and Mf can be diverse. Most 
of them are generated from the bone marrow (BM). The origin of DC can be myeloid and 
lymphoid while most Mf are of myeloid origin. Myeloid DC have a close developmental link 
with Mf, but can perform quite distinct functions. It has not been clear at which point in the 
development they start to diverge. 
Taken together, immune tolerance/regulation prevents the development of autoimunity. 
DC and Mf are actively involved in these processes. Therefore we have hypothesized that a 
proper immune regulation/tolerance depends on a correct function of DC and Mf; abnormal 
function of these cells will lead to the break of tolerance en autoimmunity. Furthermore, 
abnormal development could precede an abnormal cell function. Therefore, in the mouse that 
spontaneously develops autoimmune diabetes (Non-Obese Diabetic - NOD mouse), abnormal 
development of DC and Mf leads to the failure of immune regulation and the autoimmunity. 
Therefore, we have focused our investigation on the developmental pathway of DC and Mf 
from the BM of healthy and autoimmune NOD mice. 
The experimental approach described in this thesis mainly involves application of 
monoclonal antibodies, which are generated to recognize the specific proteins present on a 
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cell surface. In this way, we could label the cells in quest for the precise definition of various 
differentiation stages of Mf and DC and their precursors in a normal mouse and in the diabetes-
prone NOD mouse. 
Previous investigation has shown that the NOD mouse pancreas contains higher 
number of DC and Mf from the earliest diabetes stages on, even before any other sign 
of autoimmunity is present. However, it is hard to evaluate from the histological studies 
whether the contribution of these cells in the pancreas is beneficial or harmful for the organ. 
Experimental methods applicable in a NOD mouse would not allow the isolation of substantial 
numbers of viable DC and/or Mf from the pancreas. Therefore no substantial information 
existed about the functionality of these cells in the pancreas, once the autoimmune process 
has already started. Therefore, we performed study (presented in the Chapter 2) in which 
we interrupted the autoimmune process in the pancreas by depleting phagocytic cells (DC 
and Mf) with clodronate-loaded liposomes (lip-CL
2
MDP). In this study we observed that the 
disappearance of DC and Mf from the pancreas did not follow the same time-line as in the 
spleen or the circulation. They started to disappear from the pancreas at the time that both the 
blood and the spleen were almost completely reloaded with new DC and Mf. Interestingly, 
the disappearance of DC and Mf from the pancreas resulted in the complete clearance of 
other inflammatory cells (which are not sensitive to lip-CL
2
MDP), leading to the significant 
delay of destructive autoimmunity in the pancreas. However, this protection was not absolute 
and several weeks after the treatment with lip-CL
2
MDP, DC and Mf returned to the islets and 
the autoimmune inflammation developed again in the NOD pancreas.
Taken together, data from this study pointed to a possibility of a beneficial treatment of the 
ongoing destruction in the pancreas by modifying the cells of the mononuclear phagocyte 
system.
In the Chapter 3 of this book, four studies encompass the investigation of the system 
of DC and Mf precursors in the BM. In the first study (Chapter 3.1), we investigated 
whether the DC and Mf share progenitors in the mouse bone marrow. We found that three 
subpopulations were  able to give rise to DC, when cultured in the presence of GM-CSF:         
  myeloid progenitors  →  myeloblasts   →   BM monocytes
The kinetics of DC differentiation from these cells indicated that the three populations were 
successive maturation stages of the myeloid DC precursors. Cell at all three stages were also 
able to differentiate into Mf when stimulated with M-CSF. 
In the Chapter 3.2, we investigated the BM of NOD mice and found no significant differences 
when compared to the healthy (C57BL) mice. The NOD BM also had normal numbers of DC 
progenitors with comparable phenotype to the C57BL mouse BM. However, when stimulated 
in vitro with GM-CSF, the NOD DC progenitors exhibited a reduced proliferation capacity 
and an accelerated differentiation. 
Similar abnormal behavior of the NOD BM cells in vitro was apparent in the following study, 
in which a GM-CSF stimulated generation of myeloid DC from NOD bone marrow resulted 
in aberrant DC with a macrophage-like phenotype. These aberrant DC were functionally 
defective and had a lower capacity to stimulate T cells as compared to normal myeloid DC 
(Chapter 3.3).
In the fourth study of the chapter 3, we identified an additional DC population. Those were the 
CD11b–CD11clowB220+ plasmacytoid DC, which were the recirculating cells present in the 
Summary200 201
BM, but also all other lymphoid organs that we investigated. These cells were the representa-
tives of the DC of lymphoid origin in the mouse. 
Taken together, the three circulating DC-precursor populations differently contribute to 
pro- and the anti- inflammatory immune forces. Their traffic in the steady state or in response 
to danger signals is dynamic and controlled by cytokines and chemokines. They are responsive 
to different signals and able to stimulate different aspects of the immune response. Further 
studies are needed to provide detailed knowledge on the importance of the balance between 
these three populations of DC precursors in the circulation for the maintenance of immune 
homeostasis.
The last developmental form of DC and Mf precursors in the BM is the monocyte. In 
the Chapter 4 we investigated further transformation of the monocytes in the blood on their 
way to become DC and Mf in the peripheral tissues. In the chapter 4.1, we identified this 
conversion through the differential expression of three molecules (CD11c, CD43 and Ly-6C) 
on the monocyte surface. The starting monocyte population had a high expression of Ly-6C 
and was CD11c and CD43 negative. The conversion included the gradual loss of the Ly-6C 
and acquisition of CD43 and CD11c. Although the gradual change resulted in a “smear” of 
different phenotypes (as presented in the Figure 1 of this chapter), majority of cells were 
localized in two easily definable groups, which we named immature (Ly-6Chigh) and mature 
(Ly-6Clow) monocytes, referring to their development stage. 
This change of the cell phenotype also affected their differentiation capacity. While the 
immature monocytes were able to rapidly migrate to the inflammation site and develop into 
exudates Mf, the mature monocytes failed to do so. The latter cells were ready to respond 
to the different kind of stimuli and move to the periphery to develop into Mf and DC that 
function in a non-compromised situation.
When we analyzed the same cells in the NOD mouse blood (Chapter 4.2), we found 
higher number than normal of mature monocytes and these cells had combined mature and 
immature properties. This pointed to a different maturation of monocytes in the NOD blood, 
which may influence their capacity to develop into Mf or DC.  Indeed, when we isolated the 
NOD monocytes and let them mature overnight, like the BM precursors in the Chapter 3.3, 
they differentiated more readily into Mf-like cells than into DC-like cells. The indication 
of the abnormally fast maturation in vivo, when circulating monocytes needed to be rapidly 
replenished (e.i. after depletion with lip-CL
2
MDP), the NOD mouse was able to produce more 
monocytes per unit time in the first phases of this replenishment than control mouse strains 
(Chapter 4.2).
In conclusion, the maturation of DC and Mf precursors in the NOD mouse follows the 
normal pathway when the phenotypic changes are taken in account. However, the maturation of 
these cells occurs much faster in the NOD mouse and this influences the functional properties 
of generated cells. This accelerated maturation of common DC and Mf precursors also affects 
their balanced maturation into these two cell types since they preferentially mature into Mf and 
NOD DC. Shifting the developmental balance between the DC and Mf potentially disturbs the 
balance between the pro- and anti-inflammatory forces, which unlocks the key to the initiation 
of autoimmunity in the NOD mouse.
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Het afweer (immuun) systeem is een systeem van cellen die ons verdedigt tegen 
gevaarlijke microben maar ook tegen tumoren die kunnen ontstaan. De eiwitten die het 
immuunsysteem kan herkennen en bestrijden, noemen we antigenen. Ons immuunsysteem 
is in staat om onderscheid te maken tussen vreemde antigenen en antigenen afkomstig uit 
het eigen lichaam (zelf-antigenen). Echter, de verdedigingsmechanismen kunnen worden 
aangezet tegen schadelijke antigenen ongeacht of ze van oorsprong vreemd of eigen zijn. 
Dit noemen we de ontstekingsreactie. Als de schadelijke prikkels geëlimineerd zijn, wordt 
de ontstekingsreactie geremd en het beschadigde weefsel geneest. Als de prikkels voor een 
langere periode aanwezig zijn ontwikkelt zich een chronische ontsteking, die grote schade 
in een weefsel kan veroorzaken. Als er een ontstekingsreactie tegen onschadelijke prikkels 
ontstaat, wordt dit door het immuun systeem actief afgeremd en dit proces heet tolerantie. 
Er zijn dus mechanismen in ons lichaam die zorgen voor de gebalanceerde functie van het 
immuun systeem ook wel immuun regulatie genoemd.
Helaas functioneert de immuun regulatie in sommige situaties niet zoals het hoort. De 
ontstekingsreactie kan zich tegen eigen cellen keren en dit kan tot onherstelbare schade in het 
lichaam leiden. Zo’n reactie noemt men “auto-immuun reactie” (immuniteit tegen eigen) en 
de ziekten die ontwikkelen als gevolg van deze immuniteit worden “auto-immuunziekten” 
genoemd. Een van de auto-immuunziekten is diabetes of suikerziekte. Diabetes ontwikkelt 
zich als gevolg van een immuunreactie tegen b-cellen in de eilandjes van Langerhans in 
de pancreas (alvleesklier). De b-cellen maken het hormoon insuline. Insuline zorgt voor 
de opname van suiker (glucose) die kan worden gebruikt als energie bron. Als er meer dan 
80% van de b-cellen vernietigd worden ontstaat er een tekort aan insuline en zo ontstaat 
suikerziekte.
Macrofagen (Mf) en dendritische cellen (DC) behoren tot de cellen van het 
immuunsysteem en ze zijn heel belangrijk voor het goede functioneren ervan. Deze twee typen 
cellen vormen een heterogene groep cellen (mononucleaire fagocyten) die zich onderscheiden 
door hun vorm (fenotype), door de functies die ze uitvoeren en door hun afkomst. De Mf en 
DC bevinden zich overwegend in het bindweefsel van alle organen. In deze positie, komen ze 
als eerste in aanraking met infectieverwekkers, getransformeerde cellen en andere gevaarlijke 
stoffen. Op deze manier functioneren ze als wachters van het immuunsysteem. Samen met 
andere mechanismen van het aangeboren (niet-specifiek) immuunsysteem, nemen Mf en DC 
dus plaats in de eerste verdedigingslijn. Zij fagocyteren ook de onbekende stoffen en vertonen 
stukjes ervan aan andere cellen van het immuunsysteem (T cellen). Hierbij stimuleren ze T 
cellen om op een bepaalde manier tegen een  bepaald antigen te reageren. Mf en DC kunnen 
dus ook stimuleren en activeren de cellen van het verworven (specifiek) immuunsysteem. 
Mononucleaire fagocyten zorgen in latere fase ook voor het verzachten van een ontsteking 
en/of helpen bij het helen van wonden. Bovendien zijn er een aantal soorten mononucleaire 
fagocyten die belangrijk zijn voor immuun tolerantie. Kortom, DC en Mf zijn belangrijk 
voor het evenwichtig functioneren van het immuunsysteem (immuun homeostase). 
Naast de verschillen in vorm en functie, variëren de mononucleaire fagocyten ook in hun 
afkomst. Cellen met dezelfde functie kunnen een verschillende afkomst hebben en cellen 
van dezelfde afkomst kunnen verschillende functies hebben. DC en Mf staan tijdens hun 
ontwikkeling onder invloed van factoren die ze tegenkomen in de omgeving waar ze 
verblijven. Zo kunnen onrijpe DC met dezelfde afkomst zich ontwikkelen in rijpe DC met 
Samenvatting202 203Samenvatting
verschillende eigenschappen, afhankelijk van het weefsel waar ze uiteindelijk terechtkomen. 
Dit bevordert hun heterogeniteit. 
De meeste DC en Mf zijn afkomstig uit het beenmerg. De onrijpe beenmergcellen van 
waaruit ze zich ontwikkelen heten precursoren (voorlopercellen). DC precursoren kunnen 
van afkomst lymphoid (verwant met lymfocyten - specifiek afweer) of myeloid (verwant met 
granulocyten - aspecifiek afweer) zijn. Mf precursoren zijn voornamelijk myeloid. Daardoor 
zijn Mf en myeloide DC vaak beschouwd als soortgelijke cellen die andere functies uitvoeren. 
Het was alleen niet bekend op welke punt de vertakking in hun ontwikkeling plaatsvindt.
Hoewel DC en Mf uit dezelfde precursoren komen, voeren ze als rijpe cellen verschillende 
(soms tegenovergestelde) functies uit. Wij stellen in onze hypothese dat het goede verloop 
van de immuun regulatie gedeeltelijk afhankelijk is van het goede verloop van DC en Mf 
ontwikkeling. Verder, stellen wij in dat een abnormale ontwikkeling van DC en Mf in ons 
proefdiermodel, Non-Obese Diabetic (NOD) muis, een basis vormt voor de abnormale 
functie van de immuun regulatie en leidt tot auto-immuniteit en diabetes. De NOD muis is en 
proefdier die, net als de mens, spontaan diabetes kan ontwikkelen.
Als experimentele aanpak in dit project hebben wij voornamelijk gebruik gemaakt van 
monoklonale antilichamen (eiwitten die aan specifieke antigenen binden) die gemaakt zijn 
om bepaalde antigenen op de oppervlakte van Mf, DC en hun voorlopercellen te herkennen. 
Hiermee waren wij in staat om onderscheid te maken tussen verschillende ontwikkelingsstadia 
van de DC en Mf zowel in de gezonde als in de NOD muizen.
Eerder onderzoek in de NOD muis heeft aangetoond dat DC en Mf aanwezig zijn in de 
pancreas van de NOD muis vanaf de vroegste stadia van diabetes ontwikkeling. Zelfs op 
het moment dat er geen aanwijzing is van een actieve auto-immuniteit, zijn er verhoogde 
aantallen van DC en Mf gevonden in de pancreas van een jonge NOD muis, vergeleken met 
de gezonde controle muizen. Dit aantal bleef hoog in de NOD muis tijdens het hele auto-
immuun proces. Toch, was onduidelijk welke functie deze cellen in de pancreas uitvoeren. 
In hoofdstuk 2 van dit proefschrift hebben we de studie beschreven waarin we met behulp 
van liposomen (lip-CL
2
MDP) de pancreas van de NOD muis hebben vrij gemaakt van DC 
en Mf op het moment dat de auto-immuun reactie al vol aan de gang was. Deze liposomen 
waren alleen giftig voor DC en Mf en niet voor andere cellen die in de pancreas aanwezig 
waren. Toch, was het hele ontstekingsproces platgelegd vanaf het moment dat DC en Mf weg 
waren. Dit resultaat heeft duidelijk aangetoond dat DC en Mf van essentieel belang zijn voor 
het activeren en onderhouden van de ontstekingsreactie in de NOD pancreas.
Aangezien onze hypothese was dat de afwijkende ontwikkeling van DC een bijdrage levert 
aan het ontstaan van auto-immuniteit, hebben we in het vervolg studies gekeken naar de 
ontwikkeling van dit celtype uit het beenmerg. 
In hoofdstuk 3 hebben wij gekeken naar de in vitro ontwikkeling van de DC voorlopers. Uit 
de analyse van het beenmerg van een gezonde muis is gebleken dat DC en Mf tot de laatste 
stap van hun ontwikkeling uit dezelfde voorlopers gekweekt kunnen worden (Hoofdstuk 
3.1). Wij hebben dezelfde ontwikkelingsfasen in het beenmerg van de NOD muis gevonden. 
Alleen ontwikkelden gingen deze cellen sneller dan normaal (Hoofdstuk 3.2). De snelle 
ontwikkeling van de NOD beenmerg voorlopers tijdens de kweek leidde tot de aanmaak van 
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verkeerde DC die de eigenschappen van zowel DC als Mf hadden. Deze cellen waren niet 
goed in staat om T cellen te stimuleren (Hoofdstuk 3.3).
Tenslotte, hoofdstuk 3.4. beschrijft een studie waarin wij een nieuwe cel type in het beenmerg 
van een muis gevonden hebben. Deze cellen zijn ook DC die een lymphoide afkomst 
hebben. 
Hoofdstuk 4 bestaat uit twee studies. Hierin hebben wij gekeken naar de verdere ontwikkeling 
van DC en Mf in de muis en met behulp van antilichamen tegen de eiwitten CD11c, CD43 
en Ly-6C, hebben wij een manier gevonden om twee ontwikkelingsstadia van monocyten 
(directe voorgangers van DC en Mf) in de bloedbaan te onderscheiden (Hoofdstuk 4.1). Als 
eerste zijn er onrijpe monocyten, die in staat zijn om deel te nemen in een ontstekingsreactie 
(als zij de juiste prikkel krijgen) en die zich ontwikkelen tot ontstekingsmacrofagen. Als deze 
monocyten geen ontstekingprikkel tegenkomen, worden het rijpe monocyten. Deze rijpe 
monocyten zijn voorlopers van de Dc en Mf die in het gezonde bindweefsel zitten.
In hoofdstuk 4.2 laten we zien dat deze indeling van monocyten ook voor de NOD muis 
toegepast kan worden. We vinden wel dat de NOD muis meer rijpe monocyten in het bloed 
had dan normaal. De rijping van monocyten van de NOD muis was ook abnormaal snel en 
deze cellen werden sneller Mf dan DC, vergeleken met de normale muizen. 
Samengevat kunnen we zeggen dat de ontwikkeling van DC en Mf uit de NOD muis 
beenmerg afwijkend is. De ontwikkeling van DC volgt alle normale stadia, maar wanneer het 
gestimuleerd wordt, verloopt het sneller in de NOD muis dan in een normale muis. Tijdens 
deze versnelde ontwikkeling, zijn NOD cellen gevoeliger dan normaal en wijken snel af 
richting macrofagen. Dit leidt tot de afwijkende balans tussen de activatie en de remming 
van het immuunsysteem een levert daardoor een bijdrage aan de verstoorde regulatie en 
ontwikkeling van auto-immuniteit in de NOD muis. 
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Abnormalno razvi}e dendriti~nih }elija 
kod autoimunitet-osjetqivog NOD mi{a
skra}eni sadr`aj
Imunski sistem nam omogu}ava za{titu (imunitet) od opasnih mikroba i tumora. 
Proteini koje imunski sistem prepoznaje, i protiv kojih usmjerava svoje djelovawe, 
se nazivaju antigeni. Imunski sistem je sposoban da razlu~i da li antigeni poti~u od 
"opasnih" struktura, koje su u stawu da nanesu {tetu organizmu (infektivni mikrobi 
ili transformisane tumorske }elije), ili su "bezopasni" mada mogu biti sopstvenog ili 
stranog (polen biqaka, pra{ina ...) porijekla. Ukoliko je primije}eni antigen opasan 
po zdravqe, dolazi do aktivirawa mehanizama uro|enog imuniteta i do zapaqewa. Pored 
toga, mehanizmi specifi~nog imuniteta se aktiviraju i naj~e{}e vode do eliminacije 
izvora opasnosti. Ukoliko se ovo ne desi, zapaqewe postaje hroni~no. Ako je strani agens 
eliminisan, zapaqewe se smiruje i o{te}eno tkivo zarasta. Inicirawe zapaqewa, kao i 
wegovo zaustavqawe su visoko regulisani.
Pored inicijacije i regulacije zapaqewa, imunski sistem je tako|e u stawu da sprije~i 
aktivaciju imunskog odgovora prema sopstvenim antigenima; ovo je imunska tolerancija. 
U pojedinim situacijama dolazi do naru{avawa imunske regulacije/tolerancije te tako 
aktivnost imuniteta protiv sopstvenih tkiva dovodi do nepopravqive {tete u organizmu. 
Ovakva reakcija je ozna~ena kao autoimunska reakcija (imunitet prema sopstvenom), a 
bolesti, koje se razvijaju kao posqedica ovakve reakcije, se nazivaju autoimunske bolesti. 
Jedna od autoimunskih bolesti je i dijabetes ili {e}erna bolest, koja se razvija kao 
posqedica reakcije prema b-}elijama u pankreasu (gu{tera~i). b-}elije proizvode hormon 
insulin koji je veoma bitan za uno{ewe energije u obliku {e}era (glukoze) u }elije. Kada 
vi{e od 80% b-}elija u pankreasu bude razoreno, dolazi do nedostatka insulina, koji 
organizam ne mo`e kompenzovati i pojavquju se prvi znaci bolesti.  
Makrofagi i dendriti~ne }elije pripadaju }elijama imunskog sistema i vrlo 
su bitne za wegovo pravilno funkcionisawe. U stvari, ova dva tipa }elija sa~iwavaju 
heterogenu grupu, koje se razlikuju po izgledu (fenotipu), funkcijama koje izvr{avaju, 
ili po porijeklu. Sve razli~ite vrste makrofaga i dendriti~nih }elija se jednim imenom 
nazivaju mononuklearni fagociti. Oni predstavqaju ~uvare koji se nalaze u vezivnom 
tkivu svih organa. Ovako postavqeni, oni prvi dolaze u kontakt sa infektivnim agensima, 
transformisanim }elijama ili drugim opasnim materijama. One fagocitiraju ("pojedu") 
taj nepoznati agens i wegove elemente prezentuju drugim }elijama (tzv. specifi~nog 
imunskog sistema, T }elijama) te im tako daju signale da li da na odre|eni antigen reaguju, 
ili ne, i na koji na~in. Ova posqedwa sposobnost se naziva prezentacija antigena. 
Funkcija mononuklearnih fagocita mo`e da bude razli~ita, jedan tip ovih }elija je 
zadu`en za podsticawe zapaqewa, drugi mononuklearni fagociti vode ra~una da se 
nepotrebno zapaqewe sti{a ili pomazu zara{}ivawe rana. Kona~no, odre|ene vrste 
mononuklearnih fagocita su jako bitne za imunsku toleranciju. Ukratko, dendriti~ne 
}elije i makrofagi su bitni za balansiranu funkciju imunskog sistema koja se naziva 
imunska homeostaza.
Pored razlika u izgledu i funkciji, mononuklearni fagociti mogu biti razli~itog 
porijekla. Ve}ina dendriti~nih }elija i makrofaga se razvija u kostnoj sr`i, i po 
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porijeklu pripadaju }elijama bijele krvne loze. Sve bijele krvne }elije se razvijaju iz 
}elija koje se nazivaju progenitori. Progenitori za dendriti~ne }elije i makrofage 
mogu da budu mijeloidni (srodni granulocitima) ili limfoidni (srodni limfocitima), 
pa prema tome dendriti~ne }elije i makrofagi mogu biti limfoidnog ili mijeloidnog 
porijekla. Svi makrofagi su uglavnom mijeloidnog porijekla, dok dendriti~ne }elije 
mogu biti i mijeloidne i limfoidne. Mijeloidne dendriti~ne }elije i makrofagi su, 
prema tome, veoma bliski po porijeklu, ali mogu izvr{avati vrlo razli~ite funkcije i do 
nedavno se nije sasvim sigurno znalo u kom trenutku wihovog razvi}a dolazi do razdvajawa 
ova dva tipa }elija. 
Pravilna funkcija imunskog sistema je uslovqena ispravnom funkcijom }elija 
pripadnika mononuklearno-fagocitnog sistema. Da li }e neka od ovih }elija ispravno 
funkcionisati zavisi i od wihovog razvi}a. Zbog toga smo mi postavili hipotezu, da kod 
eksperimentalnih mi{eva koji spontano razvijaju autoimuni dijabetes (NOD mi{evi), 
abnormalno razvi}e dendriti~nih }elija i makrofaga doprinosi pogre{noj imunskoj 
regulaciji. Fokus na{eg istra`ivawa u ovom projektu je bio definisawe razvojnih oblika 
dendriti~nih }elija i makrofaga kod zdravih i NOD mi{eva.
Eksperimentalni pristup opisan u ovoj tezi je uglavnom podrazumijevao kori{tewe 
monoklonalnih antitijela, koja su napravqena da prepoznaju specifi~ne proteine na 
povr{ini }elija. Na ovaj na~in je bilo mogu}e "obiqe`avati" }elije u ciqu wihove 
diferencijalne analize i definicije specifi~nih faza razvi}a dendriti~nih }elija i 
makrofaga i wihovih prekursora, kod zdravih i dijabeti~nih NOD mi{eva. 
Ranija istra`ivawa su pokazala da su dendriti~ne }elije i makrofagi prisutni 
u uve}anom broju u pankreasu mladih NOD mi{eva (u momentu kada jo{ nema znakova 
autoimunske reakcije). Ove }elije ostaju prisutne u pankreasu tokom ~itavog destruktivnog 
procesa u pankreasu. Ipak, iz ranijih histolo{kih studija je bilo te{ko donijeti 
zakqu~ak o stvarnom doprinosu dendriti~nih }elija i makrofaga tokom destruktivnog 
procesa, i pitawe da li one ubrzavaju ili usporavaju autoimunski proces u pankreasu je 
ostalo neodgovoreno. Eksperimentalne metode koje je mogu}e primijeniti u modelu NOD 
mi{a nisu omogu}avale izolovawe zna~ajnih koli~ina vijabilnih (`ivih) dendriti~nih 
}elija i makrofaga iz pankreasa. Zbog toga nije postojalo dovoqno informacija o 
funkcionalnosti ovih }elija u samom pankreasu u trenutku kada je autoimuni proces 
ve} zapo~eo. U studiji koja je prikazana u 2. poglavqu u ovoj kwizi, mi smo poremetili 
autoimunski proces u pankreasu tako {to smo eliminisali  dendriti~ne }elije i ve}inu 
makrofaga iz pankreasa koriste}i lipozome u kojima se nalazi klodronat (toksi~na 
supstanca). Po{to samo dendriti~ne }elije i makrofagi imaju sposobnost da "pojedu" 
(fagocitiraju) lipozome, oni su specifi~no eliminisani dok na ostale }elije u pankreasu 
nismo uticali. Lipozome smo injektirali u stomak mi{a, ~ime je postignuta wihova 
sistemska distribucija.
Zanimqivo zapa`awe proisteklo iz ove studije je da eliminacija  dendriti~nih }elija 
i makrofaga nije pratila istu kinetiku u pankreasu i ostalim organima (u slezini ili u 
krvotoku). Oni su po~eli da nestaju iz pankreasa mnogo kasnije nego iz ostalih organa, i to 
u momentu kada je slezina ve} u potpunosti bila popuwena novo-razvijenim  dendriti~nim 
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}elijama i makrofagima. Pored toga, iako smo lipozomima direktno eliminisali samo 
dendriti~ne }elije i makrofage  iz pankreasa, u momentu kada su ove }elije po~ele da nestaju, 
i sve ostale }elije imunskog sistema (T }elije, B }elije itd) su ga napustile. Kao rezultat, 
pankreas je bio potpuno o~i{}en od zapaqewa, 4 nedjeqe nakon tretmana lipozomima. Ipak, 
ova promjena nije bila apsolutna. Poslije 4 nedjeqe,  dendriti~ne }elije, makrofagi i sve 
ostale imunske }elije su se polako vratile u pankreas. Ipak, tretirani mi{evi su bili 
zna~ajno za{ti}eni i ve}ina wih nije vi{e razvila dijabetes do kraja perioda pra}ewa (25 
nedjeqa kasnije).
Iz ove studije smo zakqu~ili da je mogu}e uticati na razvoj dijabetesa i u momentu kada 
je autoimunski proces uveliko zapo~eo, i to manipulacijom }elija fagocitnog sistema, 
{to otvara nove mogu}nosti u dizajnirawu terapija za spre~avawe ili usporavawe razvoja 
autoimunskog dijabetesa.
Poglavqe 3 u ovoj kwizi je sa~iweno od 4 studije ~iji je fokus bio razvi}e  dendriti~nih 
}elija u kostnoj sr`i mi{eva. U prvom i u drugom radu (poglavqa 3.1 i 3.2) smo se bavili 
definisawem razvojnih stupweva dendriti~nih }elija kod zdravih i kod NOD mi{eva. Uz 
pomo} monoklonalnih antitijela, definisali smo tri faze razvi}a dendriti~nih }elija:
 mijeloidne progenitore  ® mijeloblaste ® monocite kostne sr`i
Ove tri grupe }elija su bile poznate i ranije i znalo se da su one u stawu da se razviju u 
makrofage, ali se nije znalo da li ove iste }elije imaju sposobnost da daju i dendriti~ne 
}elije. Tako|e smo pokazali da i kod NOD mi{eva, sve tri populacije imaju isti potencijal 
da se razviju u dendriti~ne }elije, a i da ne postoje razlike u broju ili fenotipu ovih }elija 
izme|u zdravih i bolesnih mi{eva. Ipak, kada smo izolovali ove }elije iz kostne sr`i NOD 
mi{a i stimulisali ih sa GM-CSF-om, faktorom rasta za dendriti~ne }elije, primijetili 
smo da NOD }elije po~iwu da sazrijevaju u dendriti~ne }elije mnogo br`e nego normalno, 
{to im nije davalo vremena da se umno`e. Zbog toga je broj dendriti~nih }elija koji bi 
se razvio iz kostne sr`i NOD mi{a bio zna~ajno manji nego kod kontrolnih `ivotiwa. 
Ova razlika je bila naro~ito uo~qiva kada su }elije kultivisane 7 dana (po klasi~nom 
protokolu) (poglavqe 3.3). Pored zna~ajno maweg broja dobijenih }elija, u ovom slu~aju ni 
wihov fenotip (izgled) nije bilo normalan niti su imale sposobnost da aktiviraju naivne 
T }elije ({to je wihova tipi~na funkcija). U stvari, dobijene }elije iz kostne sr`i NOD 
mi{a su po izgledu i funkciji vi{e li~ile na makrofage nego na dendriti~ne }elije, 
ukazuju}i na wihovo abnormalno razvi}e.
^etvrta studija u ovom poglavqu defini{e novu populaciju }elija, koje su nazvane 
plazmacitoidne dendriti~ne }elije. Ovo je nova vrsta dendriti~nih }elija koje su po 
porijeklu limfoidne i koje smo prona{li ne samo u kostnoj sr`i nego i u svim ostalim 
organima koje smo ispitali. Funkcija ovih }elija nije u potpunosti rasvijetqena. One 
najvjerovatnije igraju ulogu u aktiviranju imunskog sistema kao odgovor na virusne 
infekcije.
U ~etvrtom poglavlju smo pratili daqi razvoj monocita nakon {to napuste 
kostnu sr` i u|u u krvotok/cirkulaciju. Prona{li smo da monociti u krvi do`ivqavaju 
transformaciju na putu prema perifernim tkivima, gdje postaju dendriti~ne }elije i 
makrofagi. Ovu transformaciju smo detektovali pomo}u monokolnalnih antitijela koja 
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prepoznaju molekule CD11c, CD43 i Ly-6C (tzv. markere za monocite). Monociti, kada tek 
napuste kostnu sr`, su samo pozitivni za marker Ly-6C, da bi kasnije postepeno gubili ovaj 
marker, a dobijali sve vi{e CD43 i CD11c molekula na svojoj povr{ini. Na ovaj na~in smo 
definisali ~itavu skalu monocita koji su imale razli~ite koli~ine (ekspresiju) ova tri 
markera na svojoj povr{ini (fenotip). Ipak, ve}ina monocita je mogla biti podijeqena 
izme|u dvije faze, koje smo nazvali Ly-6Chigh (nezreli) i Ly-6Clow (zreli) monociti, 
imenom aludiraju}i na wihov stepen razvoja. Promjena fenotipa monocita je tako|e 
pra}ena promjenom wihovog razvojnog kapaciteta. Dok su nezreli monociti u stawu da 
ubrzano migriraju na mjesto zapaqewa i tamo se razviju u makrofage, zreli monociti to 
ne rade nego reaguju na signale druge vrste i imaju sposobnost da se razviju u dendriti~ne 
}elije ili makrofage u nekompromitovanoj situaciji.
Analiza je, naravno, izvr{ena i kod NOD mi{a (u poglavqu 4.2). Kod NOD mi{a smo 
na{li vi{ak zrelih monocita u krvi i uz to su ove }elije imale kombinovane osobine zrelih 
i nezrelih monocita. Ovo je ukazalo na razli~ito sazrijevawe monocita kod NOD mi{a, {to 
je potencijalno ukazivalo na wihovo abnormalno razvi}e. I stvarno, kada smo izolovali 
NOD monocite i ostavili ih da sazriju u kulturi preko no}i, sli~no kao i prekursori iz 
kostne sr`i, i NOD monociti su ubrzano sazreli u makrofage a ne u dendriti~ne }elije. 
Indikacija da se ovo de{ava i u stvarnosti, u mi{u, je proizi{la iz eksperimenta u kome 
smo monocite iz krvi eliminisali upotrebom lipozoma i pratili kojom se brzinom ponovo 
razvijaju iz kostne sr`i. Kostna sr` NOD mi{a je bila u stawu da proizvodi mnogo vi{e 
monocita u jedinici vremena nego normalno. 
U zakqu~ku, razvoj i sazrijevanje dendriti~nih }elija i makrofaga iz prekursora u 
NOD mi{a prati normalan put kada se uzme u obzir promjena fenotipa. Ipak, sazrijevawe 
se de{ava mnogo br`e, {to uti~e na funkciju nastalih }elija. Ovo ubrzano i abnormalno 
sazrijevawe zajedni~kih prekursora za dendriti~ne }elije i makrofage tako uti~e na 
balansiran razvoj ova dva tipa }elija, po{to kod NOD mi{a prekursori postaju prije 
makrofagi nego dendriti~ne }elije. Ovo pomijerawe razvojne ravnote`e prema makrofagima 
potencijalno mijewa i ravnote`u izme|u aktivacije i zaustavqawa pro- i anti- zapaqewskih 
procesa, ~ime se otkqu~ava brava za aktivirawe autoimuniteta kod NOD mi{eva. 
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7-AAD  7 aminoactinomycin
Ag antigen
AICD activation induced cell death
APC antigen-presenting cell
-APC allophycocyanin
AP acid phosphatase
BB-DP  Biobreeding diabetes prone
BSA  bovine serum albumin
BM  bone marrow
CD  cluster of differentiation
DC  dendritic cells
ELISA  enzyme-linked immuno sorbent assay
ER  Erasmus
FACS  fluorescence activated cell sorter
FITC  fluorescein isothiocyanate
Flt3-L  Flt-3 ligand
FCS  fetal calf serum
GM-CSF  granulocyte-macrophage colony stimulating factor
ICAM –  intracellular adhesion molecule
IDDM insulin independent diabetes mellitus
IFN interferon
IL interleukin
IP-10  interferon inducivle protein-10
Lip-CL
2
MDP  clodronate loaded liposomes
LN  lymph node
LPS lipopolysaccharide
MLR mixed leukocyte reaction
Mf  macrophages
M-CSF  macrophage-colony stimulating factor
MACS magnet activated cell sorting
mAb  monoclonal antibody
MHC  major histocompatibility complex
MPS  mononuclear phagocyte system
NK  natural killer cell
NKT  natural killer T cell
NF-kB nuclear factor kB
NOD  non-obese diabetic
Abbreviations210 211Abbreviations
PE  phycoerythrin
PI3K  phosphoinositide-3 kinase
PerCP  peridin chlorophyll protein
PBS  phosphate-buffered saline
RIP-LCMV    rat insulin promoter-lymphocytic choriomeningitis virus
RPMI  Roswell Park Memorial Institute medium
SAV  streptavidine
STAT  Signal Transducers and Activators of Transcription
TNF  tumor necrosis factor
Th  helper T cell
Treg  regulatory T cell
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(weer! ;o), Kam-Wing, Petra, Ester, although we did not spend much time working together, 
it was very nice to share the lab with you.
Pieter, there are only few words that can describe how much I'm thankful for everything 
you have done for me. You introduced me to a real science and gave me a chance to develop. 
You have had the time and patience to help me organize my arrival here, when the situation 
in my country was far from normal. Many brainstorms with you, your hesitation to accept 
new views unless I provide enough experimental evidence for them (and unless they fit in the 
large scheme ;o) and an almost limitless freedom to plan experiments that would lead me to 
the truth, created a healthy and inspirational playground for me. You were also my friend and 
family when the real family was far and have always had "an ear" for my personal problems, 
boyfriends, looking for an apartment, driving exam…thank you.
Marleen, thanks for my first steps in the lab, teaching me to culture DC, to isolate and 
label antibodies. You were also my friend and I hope we will enjoy many more “ladiesnights” 
with the rest of the ladies. 
My dearest paranimf, Berlinda, it was great to work with you but also to go out, chat in the 
coffee/tea breaks, do all the other things we did together and I’m sure we will keep doing.
Thanks for help and good times to my lab-colleagues from “Pieter’s group”, Adri, 
Marcel, and all other former and current members of the Autoimmunity Unit: MarjanV, 
Harm, Wai-Kwan, Vinod, Pieter S., Dariusz, Ester, Patricia, and also to Marjan V. and her 
group: Gerben, Jojaneke, Loneke, Corine, Hui, Rebecca, and all others I forgot to mention 
(not intentionally).
Prof. Drexhage, beste Hemmo, I always admired your firmness. The last few months were 
the most intensive in our communication ;o), I hope you did not find me too stubborn on some 
occasions. I always enjoyed our discussions, but also the nice new-years borrels at your place. 
Thank you very much for all the help during creation of this thesis.
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My students, one for each year, Marjolijn, Anouk, Bernice, Milouda and Samorah, and 
of course Jeremy, it was challenging to take the responsibility to scientifically educate you. I 
hope you have had as much fun working with me as I have with you. 
My AIO life would not be the same without the AIO weekends, which I enjoyed a lot, 
especially with my AIO club from ’99 (Sabine, Lizette, Wai-Kwan) but also Gerben, Rogier 
(third time!!! ;o)), Patricia, Ester, Floor and the “older” AIO’s Saskia, Wim, Martijn, Judith.
Nice memories from my AIO years at the Immunology department also include many other 
people. It seems unfair to miss any name but if I would start naming you all and everything 
each of you ment to me, I would need to write an extra book. So, you won't mind if I simply 
say thanks to you all, for all the help, nice lab-days, borrels and for making me feel like home 
on the 8th floor. I still need to name FC-DJ– Berlinda, Edwin, Marcia, Anja, Wouter with whom 
I improved my organizing skills ;o)). Also Rene, Harm en Edwin, who assisted me in the long 
sorting experiments, without which this thesis would be less interesting. A special thanks to 
Tar, for all the hours you have spend making the figures for me, and not only that, for being 
a friend, for teaching me stuff about graphic design. 
I can’t finish the part related to Erasmus MC without mentioning my new department, 
Longziekten, Prof. Hoogsteden en Dr. Bart Lambrecht, who helped me solve the 
“verblijfsvergunning” problem on time, and gave me the opportunity to spend unlimited amount 
of working hours working on my thesis. Also all the people from Longziekten, Annabrita, 
Danielle, Femke, Harmjan, Hermelijn, Ivette, Joost, Nanda, Monique, Karolina, Alex, Leonie, 
Hamida, Thomas, Hendrik-Jan, Bianca, Mirjam, Brigit and Lous, thanks for these wonderful 
months of laughter and joy that gave me the energy and patience to finish this book.
I also want to mention two special collaborators, Dr. Doug Drevets and Dr. Cord Suderkotter, 
who helped me open the door to the mononuclear phagocyte world. 
Dearest Sacha, my “twin-AIO”; I put you in the middle between the colleagues’ dear to me 
and my dear friends outside the EUR. You belong to both. Every time you would arrive from 
Paris was an intellectual holiday for me. You could challenge my thoughts in a productive 
way. Together, we created pretty nice studies. I hope we will work together one day. In the 
mean time, do not forget Rotterdam ;o)) 
In the remaining few sentences I would like to thank many friends here in The Netherlands, 
my old friends in Belgrade, Bijeljina and those scattered around the Europe or Canada, for 
being my friends ;o) Sometimes is that enough for help. Sanja, Bojana, hvala vam na vašem 
prijateljstvu, za sve što ste uradile za mene i pomogle mi da riješim probleme kojim sam 
obasipana prošle godine. Aleksandra i Bojane, moji drugari sa najduzim stažom ;o)) žao mi 
je što ne možemo češce da budemo zajedno ali vaša energija je prelazila duge kilometere i 
pomagala mi da istrajem. Mom ličnom sponzoru, teta Agneši hvala za potporu i finansijsku i 
moralnu, a naročito putem masaža koje čovjeka ožive i daju mu novu snagu. Aleksandre, riječi 
su izlišne; ipak, hvala ti za najljepše ilustracije na svijetu, za pomoć kad god je bila potrebna, 
za lijepu riječ a najviše za ljubav i strpljenje koje imaš za mene.
 Mojoj široj porodici iz Crvene Crkve i užoj porodici iz Bijeljine ;o) puno hvala za 
bezgraničnu ljubav koja mi daje krila da letim. Mama i tata, vi ste ipak šampioni. Na kraju, 
Dragana, moja najdraža sisterko na svijetu, i moj saborcu u mnogim bitkama pa i ovoj .... 
drži mi fige …. idemo….  
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Quo vadis
Aberrations in the Development of Dendritic Cells in the 
Autoimmunity-prone Non-Obese Diabetic Mouse
Rotterdam, 3 november 2004
Tatjana Nikolic
Stellingen
1. Prototypical macrophages and dendritic cells are the extremes in a continuum of 
functionally and/or developmentally related cells recognized as mononuclear phagocytes. 
(this thesis)
2. The terminal differentiation of monocytes into dendritic cells or macrophages is determined 
by signals in the connective tissue of the organ they populate. (this thesis)
3. Subdivision of monocytes suggests a fixation in states, which is not compatible with the 
inherent property of monocytes to change to adapt to their surroundings. (this thesis)
4. Problems in three major intracellular signaling pathways exist in the NOD mouse.           
(this thesis)
5. A deficient induction and maintenance of tolerance by insufficiently produced high-quality 
DC forms a key to the initiation of autoimmunity in the NOD mouse. (this thesis)
6. Initiation of the autoimmune response is entirely non-specific and depends only on the 
presence of misplaced peripherally activated pro-inflammatory monocytes/macrophages. 
N. S. Stoy Medical Hypotheses (2002) 58(4), 312-326
7. The protective and destructive activities of the immune system are comparable to the 
ambiguous acts of Brutus and his conspirators who assassinated Julius Caesar (15 March 
44 B.C.), the leader they had sworn to protect.
8. Flow cytometry for the purpose of quantitative analysis of cellular properties is an 
invaluable research tool. 
9. In an atomic system there exist a number of so-called stationary states, which possess a 
peculiar, mechanically unexplainable stability, of such a sort that every permanent change 
in the motion of the system must consist in a complete transition from one stationary state 
to another. Niels Bohr
10. All essential knowledge relates to existence; only such knowledge as has an essential 
relationship to existence is essential knowledge. Soren Kierkegaard
11. A researcher that has enough supplies of Cup-a-Soup sachets and Senseo coffee-pads 
does not have to worry about his future.
